Neural Stem Cells in the Adult Brain: From Benchside to Clinic

Guest Editors: Oscar Gonzalez-Perez, Jose M. Garcia-Verdugo, Alfredo Quinones-Hinojosa, Sonia Luquin, Graciela Gudino-Cabrera, and Rocio E. Gonzalez-Castaneda
Neural Stem Cells in the Adult Brain: From Benchside to Clinic
Neural Stem Cells in the Adult Brain: From Benchside to Clinic

Guest Editors: Oscar Gonzalez-Perez, Jose M. Garcia-Verdugo, Alfredo Quinones-Hinojosa, Sonia Luquin, Graciela Gudino-Cabrera, and Rocio E. Gonzalez-Castaneda
Editorial Board

Nadire N. Ali, UK
Anthony Atala, USA
Nissim Benvenisty, Israel
Kenneth Boheler, USA
Dominique Bonnet, UK
B. Bunnell, USA
Kevin D. Bunting, USA
Richard K. Burt, USA
Gerald A. Colvin, USA
Stephen Dalton, USA
Leonard M. Eisenberg, USA
Marina Emborg, USA
Josef Fulka, Czech Republic
Joel C. Glover, Norway
Joseph Itskovitz-Eldor, Israel
Pavla Jendelova, Czech Republic
Arne Jensen, Germany
Sue Kimber, UK
Mark D. Kirk, USA
Gary E. Lyons, USA
Athanasios Mantalaris, UK
Eva Mezey, USA
Karim Nayernia, UK
K. Sue O’Shea, USA
J. Parent, USA
Bruno Péault, USA
Stefan Przyborski, UK
Pranela Rameshwar, USA
Hannele T. Ruohola-Baker, USA
D. S. Sakaguchi, USA
Paul R. Sanberg, USA
Paul T. Sharpe, UK
Ashok K. Shetty, USA
Igor Slukvin, USA
Ann Steele, USA
Alexander Storch, Germany
Marc Turner, UK
Su-Chun Zhang, USA
Weian Zhao, USA
Contents

Neural Stem Cells in the Adult Brain: From Benchside to Clinic, Oscar Gonzalez-Perez, Jose M. Garcia-Verdugo, Alfredo Quinones-Hinojosa, Sonia Luquin, Graciela Gudino-Cabrera, and Rocio E. Gonzalez-Castaneda
Volume 2012, Article ID 378356, 2 pages

Effects of Intravenous Administration of Human Umbilical Cord Blood Stem Cells in 3-Acetylpyridine-Lesioned Rats, Lucía Calatrava-Ferreras, Rafael Gonzalo-Gobernado, Antonio S. Herranz, Diana Reimers, Teresa Montero Vega, Adriano Jiménez-Escrig, Luis Alberto Ríchar López, and Eulalia Bazán
Volume 2012, Article ID 135187, 14 pages

Growth Factors Released from Gelatin Hydrogel Microspheres Increase New Neurons in the Adult Mouse Brain, Kanako Nakaguchi, Hideo Jinnou, Naoko Kaneko, Masato Sawada, Takao Hikita, Shinji Saitoh, Yasuhiro Tabata, and Kazunobu Sawamoto
Volume 2012, Article ID 915160, 7 pages

Adrenomedullin as a Growth and Cell Fate Regulatory Factor for Adult Neural Stem Cells, Sonia Martínez-Herrero, Ignacio M. Larráyoz, Laura Ochoa-Callejero, Josune García-Sanmartín, and Alfredo Martínez
Volume 2012, Article ID 804717, 18 pages

Bench to Bedside of Neural Stem Cell in Traumatic Brain Injury, Solomon O. Ugoya and Jian Tu
Volume 2012, Article ID 141624, 8 pages

Nestin Protein Is Phosphorylated in Adult Neural Stem/Progenitor Cells and Not Endothelial Progenitor Cells, Jun Namiki, Sayuri Suzuki, Takeshi Masuda, Yasushiki Ishihama, and Hideyuki Okano
Volume 2012, Article ID 430138, 5 pages

Regulation of Injury-Induced Neurogenesis by Nitric Oxide, Bruno P. Carreira, Caetana M. Carvalho, and Inês M. Araújo
Volume 2012, Article ID 895659, 15 pages

Ethical Implications in the Use of Embryonic and Adult Neural Stem Cells, Rodrigo Ramos-Zúñiga, Oscar González-Pérez, Ana Macías-Ornelas, Vivian Capilla-Gonzalez, and Alfredo Quiñones-Hinojosa
Volume 2012, Article ID 470949, 7 pages

The Insulin Regulatory Network in Adult Hippocampus and Pancreatic Endocrine System, Masanao Machida, Shin Fujimaki, Ryo Hidaka, Makoto Asashima, and Tomoko Kuwabara
Volume 2012, Article ID 959737, 8 pages
Increasing evidence indicates that neural stem cells (NSCs) play an important role in sustaining cellular homeostasis and brain tissue restoration. The study of all mechanisms that control and modulate the function of NSC is a crucial step for the design of therapies against chronic neurodegenerative processes. In this special issue of the journal, we had the pleasure to edit the topic entitled “Neural Stem Cells in the Adult Brain: From Benchside to Clinic.” This special compilation of paper was aimed to provide a global forum for publications of original peer-reviewed manuscripts that reported original research findings in the field of adult neural stem cell, including short communications, full-length research, and review articles. Below, we briefly discuss the papers you may find in this issue.

K. Nakaguchi et al., in their paper entitled “Growth factors released from gelatin hydrogel microspheres increase new neurons in the adult mouse brain”, suggest that new neurons born in the subventricular zone (SVZ) may be able to replace neurons lost in degenerative disease or injury and improve or repair neurological deficits. In this excellent paper, they tested whether delivering growth factors via gelatin hydrogel microspheres can support neurogenesis in the SVZ. Their findings indicated that hepatocyte growth factor-containing microspheres increased the number of new neurons migrating from the SVZ towards the injured striatum in a stroke model in mouse. Therefore, they propose that gelatin hydrogel microspheres may be a good delivery tool for the sustained release of growth factors to promote neural regeneration of damaged brain tissues.

J. Tu and S. O. Ugoya discuss that traumatic brain injury (TBI) is one of the leading causes of major disability and death worldwide. Neural stem cells (NSCs) have recently been shown to contribute to the cellular remodeling and may represent a possible therapy for TBI. In their work the authors nicely summarized a critical assessment of recent data and developed a view comprising of six points to possible quality translation of NSCs in TBI.

B. P. Carreira et al., in their paper entitled “Regulation of injury-induced neurogenesis by nitric oxide”, sustain that nitric oxide (NO), a pleiotropic signaling molecule in the central nervous system, is able to modulate neurogenesis, acting as a pro- or antineurogenic agent. In their interesting review, they discussed the relevance of the NO system for the treatment of neurodegenerative diseases or several pathological conditions that affect the brain.

J. Namiki et al. analyzed the phosphorylation of nestin, an intermediate filament protein commonly used as a neural stem/progenitor cell marker. Nestin is required for the survival and self-renewal of neural stem cells. In this study, the authors nicely reported CNS-specific phosphorylation sites in nestin that allow distinguishing vascular expression of nestin from other intermediate filament protein subtypes.

Hormonal signals from the pancreatic islets influence the energy homeostasis of the brain and vice versa. In an excellent review, M. Machida and coworkers explain the correlation between the insulin-mediated regulatory system of the CNS and the pancreatic endocrine system. Remarkably, adult neurogenesis from undifferentiated neural stem cells is...
greatly decreased in diabetic patients, and as a result their learning and memory functions decline. In their paper, the authors summarized latest research regarding this endocrinological and neurological relationship.

L. Calatrava-Ferreras et al. explained that cerebellar ataxias, a heterogeneous group of diseases characterized by motor incoordination, may be treated using cell transplantations. Specifically they propose the use of human umbilical cord blood mononuclear cells as a promising approach for restoration of cerebellar function.

S. Martinez-Herrero et al. discuss that adrenomedullin (AM) acts as a growth and cell fate regulatory factor for adult neural stem cells. AM regulates the proliferation rate and the differentiation of stem/progenitor cells into neurons, astrocytes, and oligodendrocytes, probably through the PI3K/Akt pathway. AM gene is also able to regulate the cytoskeleton rearrangements, which is important for cellular morphogenesis. In addition, AM appears to contribute to neural stem cell growth regulation by allowing cells to pass through mitosis. Consequently, AM may contribute to program stem cells for future clinical uses.

Finally, R. Ramos-Zuniga et al. discussed the ethical implications on the use of stem cells. They explain that every clinical project should take that into account, along with potential clinical applications, the principle of "primum non nocere" (first, do no harm). The authors also indicate the importance of keeping a close clinical surveillance to establish the possible risks in the use of stem-cell-based therapies.

With this compendium of cutting-edge review articles and original articles written for experts in the stem-cell field, we hope these in the field of adult neural stem cells will help be helpful and educational for readers.

Oscar Gonzalez-Perez
Jose M. Garcia-Verdugo
Alfredo Quinones-Hinojosa
Sonia Luquin
Graciela Gudino-Cabrera
Rocio E. Gonzalez-Castaneda
Research Article

Effects of Intravenous Administration of Human Umbilical Cord Blood Stem Cells in 3-Acetylpyridine-Lesioned Rats

Lucía Calatrava-Ferreras,1 Rafael Gonzalo-Gobernado,1 Antonio S. Herranz,1 Diana Reimers,1 Teresa Montero Vega,2 Adriano Jiménez-Escrig,3 Luis Alberto Richart López,4 and Eulalia Bazán1,5

1 Servicio de Neurobiología, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain
2 Servicio de Bioquímica, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034 Madrid, Spain
3 Servicio de Neurología, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain
4 Centro de Transfusiones de la Comunidad de Madrid, Valdebernardo, 28030 Madrid, Spain
5 Servicio de Neurobiología-Investigación, Hospital Ramón y Cajal, Carretera de Colmenar Km. 9, 1, 28034 Madrid, Spain

Correspondence should be addressed to Eulalia Bazán, eulalia.bazan@hrc.es

Received 25 June 2012; Accepted 1 August 2012

Copyright © 2012 Lucía Calatrava-Ferreras et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cerebellar ataxias include a heterogeneous group of infrequent diseases characterized by lack of motor coordination caused by disturbances in the cerebellum and its associated circuits. Current therapies are based on the use of drugs that correct some of the molecular processes involved in their pathogenesis. Although these treatments yielded promising results, there is not yet an effective therapy for these diseases. Cell replacement strategies using human umbilical cord blood mononuclear cells (HuUCBMCs) have emerged as a promising approach for restoration of function in neurodegenerative diseases. The aim of this work was to investigate the potential therapeutic activity of HuUCBMCs in the 3-acetylpyridine (3-AP) rat model of cerebellar ataxia. Intravenous administered HuUCBMCs reached the cerebellum and brain stem of 3-AP ataxic rats. Grafted cells reduced 3-AP-induced neuronal loss promoted the activation of microglia in the brain stem, and prevented the overexpression of GFAP elicited by 3-AP in the cerebellum. In addition, HuUCBMCs upregulated the expression of proteins that are critical for cell survival, such as phospho-Akt and Bcl-2, in the cerebellum and brain stem of 3-AP ataxic rats. As all these effects were accompanied by a temporal but significant improvement in motor coordination, HuUCBMCs grafts can be considered as an effective cell replacement therapy for cerebellar disorders.

1. Introduction

Cerebellar ataxias (CAs) include a heterogeneous group of infrequent diseases characterized by lack of motor coordination [1]. According to their etiology, they can be divided into sporadic forms and hereditary diseases. All of them have in common cerebellum and associated neuronal circuits dysfunction, in particular spinocerebellar afferents [2–5]. Current therapeutic approaches are based on the use of drugs that correct some of the molecular processes involved in the pathogenesis of this group of diseases [1, 6–8]. Furthermore, other studies have assayed the potential therapeutic activity of intracerebroventricular, peripheral, or intranasal administration of neurotrophic factors such as insulin-like growth factor (IGF-I), or glial-derived growth factor (GDNF), in different experimental models of cerebellar ataxia in rodents [9–13]. Although the above-mentioned treatments (drugs and trophic factors) yielded promising results, there is not yet an effective therapy for these types of diseases to date [1].

Cell replacement strategies using stem cells (SCs) as donor tissue have emerged as a promising approach for restoration of function in neurodegenerative diseases [14–19]. Hematopoietic stem cells from human umbilical cord blood (HuUCBCs) have been proposed as an excellent source of embryonic SCs in regenerative therapies for
the Central Nervous System [20–23]. HuUCBCs are easily accessible they retain certain properties of embryonic SCs such as the expression of transcription factors specific to embryonic antigens [24] and are well tolerated by the host due to their low immunogenicity [25]. Additionally, in vitro manipulation of HuUCBCs has shown their plasticity. Thus, after exposure to different agents, these cells are able to express antigens of diverse cellular lineages, including the neural type [26–31].

HuUCBCs were used successfully for the first time in 1989, as a bone marrow transplant in a patient with Fanconi’s anemia [32]. Other studies have shown that systemic administration of HuUCBCs to different experimental models of neurodegenerative diseases improved their neurological symptoms and life expectancy [22, 23]. The beneficial effects of HuUCBCs seemed to be due to their ability to synthesize and release trophic factors involved in cell survival, rather than having a role in neuronal replacement [23, 33–36].

Stem cell-reparative approaches have been proposed for cerebellum-related disorders [37–40]. However, the type of stem cells most appropriate for future human cell therapy is not clearly defined at present [37]. Considering the possibility that HuUCBCs could be used as a therapeutic agent in CA, we analyze their potential neuroregenerative and/or neuroprotective activity in the 3-acetylpyridine (3-AP) experimental model of CA in rats. The rationale for using this CA model was because the neurotoxin 3-AP selectively lesions calbindin expressing neurons in the inferior olive [9], and this nucleus plays a key role in the control of the cerebellar function by sending glutamatergic excitatory signals to Purkinje cells [41, 42].

Here, we report that intravenous administration of HuUCB mononuclear cells (HuUCBMCs) reaches the cerebellum and brain stem of 3-AP-lesioned rats. Grafted cells reduce neuronal loss in the brain stem, prevent glial reactivity in the cerebellum, and improve motor coordination in ataxic rats. In this study, we also show that HuUCBMCs upregulate the expression of proteins that are critical for cell survival, such as phospho-Akt and Bcl-2, in the cerebellum and brain stem of 3-AP-lesioned rats. The role of activated microglia in HuUCBMCs-mediated neuronal protection in the brain stem is also discussed.

2. Materials and Methods

2.1. Experimental Model of Cerebellar Ataxia in Rats. A total of 40 female Sprague Dawley rats weighing 220–250 g were used in accordance with the European Union Council Directive (86/609/EEC). Rats received an intraperitoneal (i.p.) injection of the neurotoxin 3-AP (40 mg/kg) that selectively lesioned calbindin expressing neurons in the inferior olive [9]. This nucleus plays a key role in the control of the cerebellar function by sending glutamatergic excitatory signals to Purkinje cells (PCs) [41, 42]. From a histological point of view, PC and granule neurons of the cerebellar cortex are the most commonly affected population of neurons in CA [3].

2.2. Behavioral Testing. Motor performance was analyzed using the rotarod test. Before 3-AP lesions were produced, rats received 9 independent training sessions in the rotarod (PanLab S.L., Mod. LE 8500, Cornellá, Spain), with 4 1-minute evaluations at 40 rpm (fixed speed), and 4 1-minute evaluations at 4 to 40 rpm (accelerating rod). Those animals that withstood more than 1 minute at 40 rpm and at 4 to 40 rpm were selected for 3-AP lesions. Motor coordination was evaluated at 72 hours after lesion. Those animals resulting in mean latencies to fall on the accelerating rod of approximately 19 ± 3 s (n = 16) were selected for HuUCBMCs or vehicle administration. Starting 10 days after 3-AP lesion procedure, animals were monitored once a week until the end of the study period.

2.3. HuUCBMCs Isolation of Blood Cell Concentrate. Assessment, processing, and cryopreservation of HuUCBCs were carried out by the Centro de Transfusiones de la Comunidad de Madrid (Valdebernardo) in accordance with the Spanish Directive for Donors’ Selection (Edition 4/May 2009/PO.CO.01). The donated units met the criteria for minimal cellularity and volume showing the following parameters: mononuclear cells (MCs): 337.8 ± 32.56 × 10^6, total nucleated cells (TNCs): 910.8 ± 86.77 × 10^6, and cells positives for CD34: 0.7620 ± 0.0914 × 10^6. For isolation of HuUCBMCs we followed a methodology previously described [43]. Briefly, HuUCBCs were drawn from the bag and divided into 2 Falcon tubes with half volume of Lymphoprep and centrifuged at 800 g and 20°C for 40 min to create a Ficoll gradient. The band of mononuclear cells located at the interface (2 to 7 mL) was taken and washed 3 times with PBS. An aliquot of 40 μL was used to determine the number of living cells by Trypan Blue using a Neubahuer chamber.

2.4. Cell Transplantation. At 3 days after 3-AP lesion, rats were anesthetized by inhalatory administration of Isoflurane (2%). One group of animals (n = 14) received a single injection of 4.5 × 10^6 HuUCBMCs in 250 μL of sterile PBS into the lateral vein of the tail (3-AP + cells). Another group of 3-AP-lesioned rats (n = 10) received the same volume of sterile PBS (3-AP + vehicle). As controls we used a group of naive rats that did not receive HuUCBMCs grafts (n = 6). All experimental groups received cyclosporine (5 mg/kg i.p.) once a day to avoid rejection of human cells 24 hours before cell transplantation, and until the end of the study. Animals were sacrificed at 1, 7, 21 and 44 days after transplantation (4, 10, 24, and 48 days after lesion, resp.).

2.5. Tissue Processing. At 4, 10, and 21 days after lesion the animals were perfused intracardially under deep anesthesia with 50 mL of isotonic saline, followed by 250 mL of 4% paraformaldehyde. Brains were postfixed in the same solution for 4 hr at 4°C, cryoprotected and frozen, before sectioning on a cryostat. For the inferior olive 20 μm thick coronal sections were performed at three levels separated by a distance of approximately 400 μm. These levels correspond
to the following coordinates of the stereotaxic atlas of Paxinos and Watson [44]: −13.30 mm from Bregma (Zone 1), −12.80 mm (zone 2) and −11.96 mm (zone 3).

For immunohistochemical analysis of the cerebellum, 20 μm thick coronal sections were obtained in the cryostat, and mounted on positively charged slides (Dako REAL Capillary Gap microscope slides).

2.6. Antibodies and Immunochemicals. The primary antibodies used in this study were rabbit antiproliferating cell nuclear antigen (PCNA, 1:75; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), rabbit antiligial fibrillary acidic protein (GFAP, 1:200; DakoCytomation), mouse antineuronal nuclei (NeuN, 1:1000; Chemicon International Inc.), mouse anti-OX6 (1:250; AbD Serotec, Oxford, UK), rabbit antialaminin (1:25; Sigma Chemical Co., St. Louis, MO, USA), mouse anti-Bcl-2 (1:25; Santa Cruz Biotech), rabbit anticalbindin (1:500; Millipore, Temecula, CA, USA), mouse anti-human leucocyte antigen ABC (HLA-ABC 1:500; AbD Serotec, Oxford, UK), mouse anti-human nuclei protein (HuNu, 1:25; Millipore, Temecula, CA, USA), and rabbit anti-Bax (1:250; Santa Cruz Biotech). The secondary antibodies and other immunochemicals used were peroxidase-labeled isocyanate B4 (IB4, 1:20; Sigma Chemical Co., St. Louis, MO, USA), biotinylated goat anti-mouse IgG (Zymed Laboratories; South San Francisco, CA, USA), streptavidin-biotin-peroxidase complex (DakoCytomation), diaminobenzidine (DAB) + substrate-chromogen system (both from DakoCytomation), Alexa Fluor-568 goat anti-mouse IgG, and Alexa Fluor-488 goat anti-rabbit IgG (1:400; all from Molecular Probes; Eugene, OR, USA), fluorescein-conjugated goat anti-mouse IgG (1:25; Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA), Cy3-conjugated donkey anti-guinea pig IgG (1:500, Jackson ImmunoResearch Laboratories Inc.), and rhodamine-conjugated goat anti-rabbit IgG (1:100, Chemicon International Inc.).

2.7. Immunohistochemistry and Morphometric Analysis. Tissue sections were treated with sodium acetate 10 mM, pH 6.0, at 95°C for 4 min, and preincubated with 5% normal goat serum (NGS) in Tris-buffered saline (TBS: 0.15 M NaCl and 0.1 M Tris HCl, pH 7.4)/0.1% Triton X-100 for 30 min. Primary antibodies were applied for 24 hr at 4°C, and most of them were visualized using immunofluorescence procedures. The slides were coverslipped in a medium containing p-phenylenediamine and bisbenzimide (Hoechst 33342; Sigma) for the detection of nuclei. Some series of sections were preincubated with 5% NGS in TBS and then processed for the histochemical detection of IB4, a marker of microglia and macrophages, by incubating for 2 hr with IB4 conjugated to peroxidase. Finally, the reaction product was detected with DAB chromogen.

For quantitative estimation of calbindin immunostaining in the inferior olive, measurements were performed in several coronal sections of the brainstem, at the three levels indicated previously (see tissue processing). The area of the olive was demarcated and measured in each zone, and the number of cells with calbindin staining was assessed using the 20X objective. Immunohistochemical results were expressed as the number of positive cells/section with the aid of the Computer-Assisted Stereology Toolbox (CAST) grid system (Olympus, Ballerup, Denmark). Fluorescence images were acquired and analyzed by confocal microscopy (Nikon C1 plus ECLIPSE Ti-e microscope).

2.8. Western Blotting Protein Analysis. After 44 days of cells transplantation, the brain stem and cerebellum of 3-AP-lesioned rats that received vehicle (n = 8) or cells (n = 9) were removed and dissected following a previously described methodology [45]. Tissue was homogenized (1:8, w/v) with homogenization buffer (20 mM Tris-HCl, pH 7.5: 140 mM potassium chloride; 5 mM magnesium acetate; 1 mM dithiothreitol, 2 mM benzamidine, 1 mM EDTA, 2 mM EGTA, 0.5% Triton X-100, 10 μg/mL pepstatin A, 10 μg/mL leupeptin, and 10 μg/mL antipain; 20 mM sodium β-glycerophosphate; 20 mM sodium molybdate; 200 mM sodium orthovanadate). Homogenates were centrifuged at 11,000 g for 20 min, and proteins were processed for Western blot analysis to determine the relative levels of several proteins. The procedures were performed at 4°C, and samples were kept at −80°C until use. Aliquots of 30 μg of protein were separated by electrophoresis on 10−15% SDS-polyacrylamide minigels and transferred to nitrocellulose filters. Membranes were soaked in blocking solution (0.1 M PBS and 5% dry skimmed milk, pH 7.4) and incubated with the following primary antibodies diluted in 0.1 M PBS and 1% dry skimmed milk, pH 7.4: mouse anti-Bcl-2 (1:400; Santa Cruz Biotechnology Inc., Burlingame, CA, USA), rabbit anti-Bax (1:300; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit antiproliferating cell nuclear antigen (PCNA, 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit antialmigial fibrillary acidic protein (GFAP, 1:5000; DakoCytomation, Denmark), rabbit anti-Glut5 (1:500; Abcam), mouse anti- OX6 (1:1000, AbD Serotec, Oxford, UK), rabbit anti-HuNu protein (1:200, Millipore, Temecula, CA, USA), rabbit anticalbindin (1:5000; Millipore, Temecula, CA, USA), rabbit anti-Akt (Ser473P) (1:2000; Cell Signaling Technology, Beverly, MA, USA), rabbit anti-Akt (1:2000; Cell Signaling Technology). After extensive washing in 0.05% PBS-Tween, membranes were incubated with the peroxidase-conjugated or alkaline-phosphatase-conjugated secondary antibodies diluted 1:2000 in blocking solution. The membranes were developed with enhanced chemiluminescence Western blotting, following the manufacturer’s instructions (Amersham, Buckinghamshire, England), and were exposed to hyperfilm. Membranes were also immunolabeled for loading control using mouse anti-β actin (1:5000; Sigma Aldrich) and anti-mouse IgG alkaline phosphatase-conjugated (1:3000, Sigma Aldrich) and were developed with alkaline phosphatase reagent. The density of stained bands was scanned and quantified with the Image QuantTL software package, and the data were normalized in relation to β actin levels.
2.9. Data Analysis. Results are expressed as mean ± SEM of \(n\) independent animals. Statistical analyses for immunohistochemical and biochemical studies were performed using one-way ANOVA followed by the Newman-Keuls multiple comparison test. For behavioral studies, a two-way ANOVA followed by Student’s \(t\)-test was used. Differences were considered significant when \(P \leq 0.05\).

3. Results

3.1. HuUCBMCs Grafts Ameliorate Motor Coordination in 3-AP-Lesioned Rats. To determine whether HuUCBMCs transplantation was functional in vivo, we have analyzed motor coordination using the rotarod test. Motor performance of naïve rats was relatively stable over repeated tests, resulting in mean latencies to fall on the accelerating rod of approximately 52.31 ± 2.7 s \((n = 16)\). At 3 days after 3-AP lesion, the latency to fall from rotarod was reduced to 19 ± 3 sec \((n = 16)\). As shown in Figure 1(a), 3-AP-lesioned rats showed a progressive impairment that reached a plateau between 15 and 24 days after lesion. By contrast, in the 3-AP + cells group of animals, motor performance was stable between 8 and 32 weeks after lesion (Figure 1(a)). Moreover, 21 days after HuUCBMCs transplantation (24 days after lesion), their motor coordination was significantly
3.2. Detection of HuUCBMCs in Brain Stem and Cerebellum of 3-AP-Lesioned Rats. Immunohistochemical analysis for the human endogenous marker HLA-ABC was performed to determine if intravenous transplanted HuUCBMCs were able to reach the brain stem and cerebellum of 3-AP-lesioned rats. Seven days after HuUCBMCs transplantation, 3-AP-lesioned rats showed HLA-ABC-positive cells in ventral (Figure 2(a)) and dorsal (Figure 2(c)) zones of the brain stem. These cells were associated to laminin-positive blood vessels (Figure 2(b)), or integrated in the parenchyma (Figure 2(c)). Similarly, the cerebellum of 3-AP + cells treated rats showed HLA-ABC immunoreactivity (Figures 2(d)–2(f)). Thus, HLA-ABC-positive cells were observed in the vermis associated to blood vessels (Figure 2(d)), and in the parenchyma of the granular (Figure 2(e)) and molecular (Figure 2(f)) layers of the cerebellar cortex. Under our experimental conditions, HLA-ABC immunoreactivity was not observed at longer periods after transplantation (i.e. 21 days). However, by western blot analysis we found that 45 days after HuUCBMCs grafts were performed (48 days after lesion), the cerebellum and brain stem of 3-AP-lesioned rats showed significant levels of the nuclear antigen expressed by human cells HuNu, compared to 3-AP + vehicle-treated rats, where HuNu protein expression was very low in both structures (Figure 1(b)). We were unable to confirm these results by immunohistochemistry because the antibody used for HuNu detection gave a high background in rat brain slices.

3.3. HuUCBMCs Grafs Partially Prevent Neurotoxin-Induced Neuronal Loss in the Brain Stem. A single injection of 40 mg/kg 3-AP significantly ($P \leq 0.001$, $n = 6$) reduced the number of calbindin-positive neurons in zone 3 (Z3) of the inferior olive from 616 ± 22 to 220 ± 51 calbindin-positive cells/section in naive and 3-AP-lesioned rats, respectively. A similar effect was observed in zone 1 (Z1) where calbindin-positive cells were reduced by 1.7-fold in 3-AP-lesioned rats ($P \leq 0.01$, $n = 4$). As shown in Figure 3, after 48 days after lesion calbindin immunoreactivity was slightly higher in both zones of the inferior olive of 3-AP-lesioned rats that received HuUCBMCs (Figures 3(b) and 3(d)), compared to 3-AP + vehicle-treated rats (Figures 3(a) and 3(c)). We also analyzed the expression of calbindin and NeuN, a nuclear antigen expressed by neurons, by western blot. In the brain stem of 3-AP + vehicle-treated rats calbindin (Figure 4(a)) and NeuN (Figure 4(b)) protein levels were significantly lower than those found in naive and 3-AP + cells treated rats. The neurotoxin 3-AP also reduced calbindin and
NeuN protein expression in the cerebellum, but HuUCBMCs transplantation was unable to recover the levels of both proteins in this structure (Figures 4(a) and 4(b)).

3.4. HuUCBMCs Grafts Modulate Glial Reactivity in 3-AP-Lesioned Rats. Previously, we observed that 3-AP induced a time-dependent invasion of cells expressing the vital marker of microglia IB4 in the inferior olive, that was maintained up to 24 days after lesion [46]. In agreement with those studies, the inferior olive of 3-AP + vehicle-treated rats showed a higher number of IB4-positive cells at 10 days after lesion than 48 hours after 3-AP was injected (Figures 5(a) and 5(b)). Moreover, IB4 labeling was increased in the inferior olive of 3-AP + vehicle-treated rats, as compared with 3-AP lesioned rats that received HuUCBMCs (Figures 5(b) and 5(c)). At 48 days after lesion, western blot analysis for the glucose transporter expressed by microglia GLUT5 gave similar results. Thus, GLUT5 protein expression was significantly raised in the brain stem of 3-AP + vehicle group of animals, compared to naïve and 3-AP + cells-treated rats (Figure 6(a)).

The anti-OX6 antibody recognizes a histocompatibility Class II antigen expressed by activated microglia. As shown in Figure 6(b), OX6 protein levels were raised by 1.76-fold in the brain stem of 3-AP + vehicle group of animals, compared to naïve and 3-AP + cells-treated rats (Figure 6(a)). In the cerebellum, neither GLUT5 (Figure 6(a)), or OX6 (Figure 6(b)), nor PCNA protein levels were affected by HuUCBMCs transplantation, compared to naïve and 3-AP + vehicle-treated rats. However, the intravenous injection of HuUCBMCs prevented the increase in GFAP protein expression induced by 3-AP (Figure 6(c)). Besides, the cerebellum of 3-AP + cell-treated rats showed lower GFAP immunoreactivity than the cerebellum of 3-AP + vehicle rats (Figures 5(h)–5(j)).

3.5. HuUCBMCs Grafts Stimulate Bcl-2 Protein Expression and Phosphorylation of Akt. Several studies have proposed a neuroprotective role for HuUCBMCs [23]. Using western blot analysis, we studied the effects of HuUCBMCs grafts in the expression of proteins involved in cell survival. The Bcl-2 family comprise proteins that have either antiapoptotic (such as Bcl-2), or proapoptotic (such as Bax) effects [47–49]. In the cerebellum of 3-AP + cell-treated rats, the ratio Bcl-2/Bax was significantly raised compared to naïve rats and 3-AP + vehicle-treated rats (Figure 7(a)). This effect was due to the increase by 1.6-fold observed in Bcl-2 protein levels (\(^{*}P \leq 0.05\) and \(^{+}P \leq 0.05\) versus naïve and 3-AP + vehicle rats, resp.). In addition, some of the OX6-positive cells were PCNA positive in the inferior olive of 3-AP + cell-treated rats (Figure 5(g)).

In the cerebellum, neither GLUT5 (Figure 6(a)), or OX6 (Figure 6(b)), nor PCNA protein levels were affected by HuUCBMCs transplantation, compared to naïve and 3-AP + vehicle-treated rats. However, the intravenous injection of HuUCBMCs prevented the increase in GFAP protein expression induced by 3-AP (Figure 6(c)). Besides, the cerebellum of 3-AP + cell-treated rats showed lower GFAP immunoreactivity than the cerebellum of 3-AP + vehicle rats (Figures 5(h)–5(j)).
The protein Akt is a key downstream effector of the PI3K/Akt-signaling pathway which phosphorylation plays a critical role in the regulation of neuronal survival [24, 50–54]. As shown in Figure 7(b), the ratio phospho-Akt/Akt was significantly increased in the cerebellum and brain stem of 3-AP + cells rats. HuUCBMCs grafts did not modify total Akt protein expression in both structures, but upregulated phospho-Akt levels in the cerebellum and brain stem of 3-AP-lesioned rats by 2- and 1.4-fold, respectively (*P < 0.05 versus naïve cerebellum and +P < 0.05 versus 3-AP + vehicle brain stem).

4. Discussion

In the present study we show that intravenous administered HuUCBMCs were able to reach the cerebellum and brain stem of 3-AP-lesioned rats. Implanted cells partially blocked the loss of neurons induced by the neurotoxin in the brain stem, prevented the overexpression of GFAP in cerebellum, and stimulated the expression of proteins involved in cell survival in both structures. All these effects were accompanied by a temporal but significant improvement in motor coordination, suggesting the potentiality of HuUCBMCs grafts as a cell replacement therapy for cerebellar disorders.

HuUCBMCs are considered an excellent source of stem cells that can be used for cell replacement therapies in neurodegeneration [20, 22, 23]. However, to our knowledge there are only two studies using HuUCBCs for the treatment of CA [39, 40]. By using an anti-HLA-ABC antibody, we found that intravenous administered HuUCBMCs reached the cerebellum and brain stem of 3-AP-lesioned rats. Under our experimental conditions, HLA-ABC immunostaining
was only observed during the first three weeks of transplantation. However, western blot analysis showed HuNu protein expression in the cerebellum and brain stem of 3-AP + cell-treated rats two months after the administration of HuUCBMCs. These apparently contradictory results could be explained by a potential reduction in the expression of HLA-ABC at two months of transplantation.

In vitro and in vivo studies have demonstrated that HuUCBMCs are able to differentiate into neurons [31, 34, 43, 55, 56]. In ataxic rats HuUCBMCs implantation slightly recovered calbindin-positive neurons from 3-AP neurotoxicity in the inferior olive and restored calbindin and NeuN levels in brain stem. Although we found HLA-ABC-positive cells in the brain stem of 3-AP + cells-treated rats, none of these cells were located in the inferior olive. For this reason, we may infer that HuUCBMCs did not differentiate in calbindin-positive neurons in this structure. However, from our studies we cannot exclude the possibility that HuUCBMCs are able to differentiate in neurons in the brain stem as we were unable to detect HLA-ABC-positive cells after one month of transplantation.

Increasing evidence strengthens the hypothesis that the beneficial role of transplanted HuUCBMCs is associated with the production of neuroprotective factors [14, 33, 36, 40, 57]. We did not analyze the expression of neurotrophins or cytokines and chemokines with anti-inflammatory properties, but we found that HuUCBMCs grafts potentiated the activation of microglia in the inferior olive and the brain stem of 3-AP-lesioned rats, as analyzed by OX6 and PCNA immunohistochemistry and immunoblot. Although activated microglia have been associated with the pathogenesis of several neurodegenerative diseases [58, 59], these cells could play a key role in neuroprotection through the production and release of neurotrophic factors [60, 61]. A recent study associated the therapeutic benefits of HuUCBMCs transplantation in a rat model of neonatal
Figure 6: HuUCBMCs grafts modulate glial reactivity in 3-AP ataxic rats. (a), (b), and (c) show GLUT5 (a), OX6 (b), and GFAP (c) protein levels in the cerebellum and brain stem of 3-AP-lesioned rats receiving vehicle (3-AP + vehicle rats, white bars) or HuUCBMCs grafts (3-AP + cells rats, black bars). Note how HuUCBMCs transplantation upregulates OX6 protein expression in the brain stem and reduces GFAP protein levels in the cerebellum of 3-AP-lesioned rats. (a1) and (a2) show representative blots for GLUT5, (b1) and (b2) for OX6, and (c1) and (c2) for GFAP in the cerebellum (a1, b1, and c1) and brain stem (a2, b2, and c2). Lane 1: naïve rats (control); lane 2: 3-AP + vehicle; lane 3: 3-AP + cells. Results represent the mean ± SEM of 9 to 15 individual animals. *P ≤ 0.05, **P ≤ 0.01 versus naïve rats, †P ≤ 0.05 versus 3-AP + vehicle rats.
hypoxia with a transient up-regulation of microglial activity [62]. By contrast, the blockage of microglia activation enhanced neuroprotection and functional recovery induced by HuUCBMCs grafts in cortical ischemia [63]. Whether HuUCBMCs-driven activated microglia mediates the up-regulation of neuronal markers in the brain stem of 3-AP-lesioned rats or not, will be analyzed in the near future by blocking microglia activation with agents such as minocycline. 

Up-regulation of GFAP is a feature of reactive astrocytes that was reported in the cerebellum of ataxic rats [64, 65], and patients suffering from progressive ataxia [66]. In agreement with those studies, we found increased GFAP protein levels in the cerebellum of 3-AP ataxic rats. This overexpression of GFAP could be the consequence of glial activation induced by a loss of neurons, as has been reported in several diseases and neuropathologies [67–69]. Although we did not analyze the number of neurons in the cerebellum, we found that 3-AP significantly decreased the expression of the neuronal markers calbindin and NeuN.

Rat umbilical cord stem cells grafts prevented reactive astrogliosis and rendered neuronal protection in the hippocampus of ischemic rats [70]. In our study, HuUCBMCs transplantation reduced GFAP protein levels...
and immunoreactivity, but was unable to prevent the fall in calbindin and NeuN levels due to 3-AP neurotoxicity in the cerebellum. These results suggest that grafted cells could be involved in the modulation of astrogliosis, but they are not enough efficient to prevent neuronal damage in the cerebellum of 3-AP-ataxic rats.

An interesting finding was that HuUCBMCs transplantation modulated the expression of proteins involved in cell survival. As shown here, intravenous administration of HuUCBMCs significantly raised the phospho-Akt/Akt ratio in the cerebellum and brain stem of 3-AP + cell-treated rats. This effect was due to an increase in phospho-Akt levels, while total Akt remained unchanged in both structures. As other studies have shown that phospho-Akt plays a critical role in the regulation of neuronal survival induced by HuUCBMCs [71, 72], we may consider that this protein could mediate the neuroprotective activity of HuUCBMCs grafts observed in the brain stem. Phospho-Akt also contributes to glial cells survival [72–74]. However, there are no reports showing its possible role in preventing astrogliosis to our knowledge. The PI3K/Akt-signaling pathway regulates the expression of the antiapoptotic factor Bcl-2 [69, 75–77]. Here we found that HuUCBMCs grafts upregulated Bcl-2 protein expression in the cerebellum of 3-AP-lesioned rats. Bcl-2 overexpression enhanced the survival of different types of neurons [69, 77, 78], including those of the granular layer of the cerebellum [79]. Additionally, Bcl-2 may contribute to the maintenance of grafted cells in the cerebellum of 3-AP ataxic rats. In fact, Bcl-2 overexpression mediated the survival of human hematopoietic precursors during fetal life [80] and prolonged the survival of myoblasts transplantation in acute myocardial infarction [81] and chronic heart failure [82].

Finally, our results show that HuUCBMCs implantation ameliorates motor coordination in 3-AP-lesioned rats. This beneficial effect was probably due to neuronal protection elicited by the graft in the brain stem. In addition, HuUCBMCs could modulate neuronal activity in ataxic rats. In this respect, our preliminary studies have detected increased levels of glutamate and GABA in the brain stem of 3-AP-lesioned rats that were significantly reduced to basal levels in those animals receiving HuUCBMCs grafts (our unpublished observations). Under our experimental conditions, functional improvement was not maintained up to one month after transplantation. Recent studies have reported that repeated injections of HuUCBGCs improved motor skills in ataxic mice and functional symptoms in patients with hereditary ataxia for longer periods of time [39, 40]. We administered a single intravenous injection of 4.5 × 10⁶ cells/rat, so further experiments are needed to determine the effectiveness of the repeated application of HuUCBMCs in the 3-AP-experimental model of cerebellar ataxia.

5. Conclusions

In summary, our results show that intravenously administered HuUCBMCs reach the cerebellum and brain stem of 3-AP-lesioned rats. Implanted cells stimulate the expression of proteins involved in cell survival in both structures. These proteins could mediate the survival of grafted cells, and the neuroprotective effect observed in the brain stem of ataxic rats. As HuUCBMCs grafts also ameliorate motor coordination in 3-AP-lesioned rats, they can be considered as a potential source of cells useful for cerebellar disorders treatment.

Author Contributions

L. Calatrava-Ferreras, R. Gonzalez-Gobernado, A. S. Herranz, and D. Reimers made the experimental design. L. Calatrava-Ferreras, R. Gonzalez-Gobernado, A. S. Herranz, D. Reimers, T. Montero Vega, L. A. R. López, and E. Bazán contributed in experimental realization. L. Calatrava-Ferreras, R. Gonzalez-Gobernado, A. S. Herranz, D. Reimers, and E. Bazán carried out data analysis. L. Calatrava-Ferreras, R. Gonzalez-Gobernado, A. S. Herranz, D. Reimers, A. Jiménez-Escrig, and E. Bazán wrote the paper.

Acknowledgments

This work was funded by Agencia Pedro Lain Entralgo (NDG7/09) and Fundación Ataxias en Movimiento. L. Calatrava-Ferreras and R. Gonzalez-Gobernado were the recipients of Agencia Pedro Lain Entralgo fellowship and Contrato de Personal de Apoyo a la Investigación (Fondo de Investigaciones Sanitarias), respectively. We are grateful to Maria José Asensio and Judit Muñoz for technical help and Kerry Davis for her paper.

References

[1] D. Marmolino and M. Manto, “Past, present and future therapeutics for cerebellar ataxias,” Current Neuropharmacology, vol. 8, no. 1, pp. 41–61, 2010.
[2] A. M. Fernandez, E. M. Carro, C. Lopez-Lopez, and I. Torres-Aleman, “Insulin-like growth factor I treatment for cerebellar ataxia: addressing a common pathway in the pathological cascade?” Brain Research Reviews, vol. 50, no. 1, pp. 134–141, 2005.
[3] T. Klockgether, “Ataxias,” Parkinsonism & Related Disorders, vol. 13, supplement 3, pp. S391–S394, 2007.
[4] T. Klockgether, “Update on degenerative ataxias,” Current Opinion in Neurology, vol. 24, no. 4, pp. 339–345, 2011.
[5] M. Manto and D. Marmolino, “Cerebellar ataxias,” Current Opinion in Neurology, vol. 22, no. 4, pp. 419–429, 2009.
[6] F. Lim, G. M. Palomo, C. Mauritz et al., “Functional recovery in a Friedreich’s ataxia mouse model by frataxin gene transfer using an HSV-1 ampiclon vector,” Molecular Therapy, vol. 15, no. 6, pp. 1072–1078, 2007.
[7] M. Pandolfo, “Drug Insight: antioxidant therapy in inherited ataxias,” Nature Clinical Practice Neurology, vol. 4, no. 2, pp. 86–96, 2008.
[8] M. Voncken, P. Ioannou, and M. B. Delatycki, “Friedreich ataxia—update on pathogenesis and possible therapies,” Neurogenetics, vol. 5, no. 1, pp. 1–8, 2004.
[9] A. M. Fernandez, A. G. de la Vega, and I. Torres-Aleman, “Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia,” Proceedings of the National
Y. Zhao, H. Wang, and T. Mazzone, "Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics," *Experimental Cell Research*, vol. 312, no. 13, pp. 2454–2464, 2006.

D. T. Harris, "Cord blood stem cells: a review of potential neurological applications," *Stem Cell Reviews*, vol. 4, no. 4, pp. 269–274, 2008.

A. S. Herranz, R. Gonzalo-Gobernado, D. Reimers, M. J. Asensio, M. Rodriguez-Serrano, and E. Bazán, "Applications of human umbilical cord blood cells in central nervous system regeneration," *Current Stem Cell Research & Therapy*, vol. 5, no. 1, pp. 17–22, 2010.

P. R. Sanberg, D. J. Eve, A. E. Willing et al., "The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood-derived stem cells," *Cell Transplantation*, vol. 20, no. 1, pp. 85–94, 2011.

P. Rubinstein, C. Carrier, A. Scaradavou et al., "Outcomes among 562 recipients of placental-blood transplants from unrelated donors," *The New England Journal of Medicine*, vol. 339, no. 22, pp. 1565–1577, 1998.

A. R. Bicknese, H. S. Goodwin, C. O. Quinn, V. C. D. Henderson, S. N. Chien, and D. A. Wall, "Human umbilical cord blood cells can be induced to express markers for neurons and glia," *Cell Transplantation*, vol. 11, no. 3, pp. 261–264, 2002.

L. Buzan'ska, E. K. Machaj, B. Zablocka, Z. Pojda, and K. Domańska-Janik, "Human cord blood-derived cells attain neuronal and glial features in vitro," *Journal of Cell Science*, vol. 115, part 10, pp. 2131–2138, 2002.

N. Chen, J. E. Hudson, P. Walczak et al., "Human umbilical cord blood progenitors: the potential of these hematopoietic cells to become neural," *Stem Cells*, vol. 23, no. 10, pp. 1560–1570, 2005.

A. Habich, M. Jurga, I. Markiewicz, B. Lukomska, U. Bany-Laszewicz, and K. Domańska-Janik, "Early appearance of stem/progenitor cells with neural-like characteristics in human cord blood mononuclear fraction cultured in vitro," *Experimental Hematology*, vol. 34, no. 7, pp. 914–925, 2006.

J. R. Sanchez-Ramos, S. Song, S. G. Kamath et al., "Expression of neural markers in human umbilical cord blood," *Experimental Neurology*, vol. 171, no. 1, pp. 109–115, 2001.

T. Zigova, S. Song, A. E. Willing et al., "Human umbilical cord blood cells express neural antigens after transplantation into the developing rat brain," *Cell Transplantation*, vol. 11, no. 3, pp. 263–274, 2002.

E. Gluckman, H. E. Broxmeyer, A. D. Auerbach et al., "Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling," *The New England Journal of Medicine*, vol. 321, no. 17, pp. 1174–1178, 1989.

H. Arien-Zakay, S. Lecht, M. M. Bercu et al., "Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors," *Experimental Neurology*, vol. 216, no. 1, pp. 83–94, 2009.

N. Chen, S. Kamath, J. Newcomb et al., "Trophic factor induction of human umbilical cord blood cells in vitro and in vivo," *Journal of Neural Engineering*, vol. 4, no. 2, pp. 130–145, 2007.

W. V. Nikolic, H. Hou, T. Town et al., "Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular β-amyloid deposits in Alzheimer mice," *Stem Cells and Development*, vol. 17, no. 3, pp. 423–439, 2008.

I. Zwart, A. J. Hill, F. Al-Allaf et al., "Umbilical cord blood mesenchymal stromal cells are neuroprotective and promote regeneration in a rat optic tract model," *Experimental Neurology*, vol. 216, no. 2, pp. 439–448, 2009.

S. Ercg, V. Moreno-Manzano, M. Garita-Hernandez, M. Stojkovic, and S. S. Bhattacharya, "Concise review: stem cells for the treatment of cerebellar-related disorders," *Stem Cells*, vol. 29, no. 4, pp. 564–569, 2011.

K. Kemp, E. Mallam, K. Hares, J. Witherick, N. Scolding, and A. Wilkins, "Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts," *PLoS ONE*, vol. 6, no. 10, Article ID e26098, 2011.

W. Z. Yang, Y. Zhang, F. Wu et al., "Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with hereditary ataxia," *Journal of Translational Medicine*, vol. 9, article 65, 2011.
[40] M. J. Zhang, J. J. Sun, L. Qian et al., “Human umbilical mesenchymal stem cells enhance the expression of neurotrophic factors and protect ataxic mice,” Brain Research, vol. 1402, pp. 122–131, 2011.

[41] H. Aoki and I. Sugihara, “Morphology of single olivocerebellar axons in the denervation-reinnervation model produced by subtotal lesion of the rat inferior olive,” Brain Research, vol. 1449, pp. 24–37, 2012.

[42] S. Ausim Azizi, “And the olive said to the cerebellum: organization and functional significance of the olivo-cerebellar system,” The Neuroscientist, vol. 13, no. 6, pp. 616–625, 2007.

[43] S. Garbuzova-Davis, A. E. Willing, T. Zigova et al., “Intravenous administration of human umbilical cord blood cells in a mouse model of amyotrophic lateral sclerosis: distribution, migration, and differentiation,” Journal of Hematotherapy and Stem Cell Research, vol. 12, no. 3, pp. 255–270, 2003.

[44] G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, 1997.

[45] A. Carlsson and M. Lindqvist, “Evidence of ERK and cAMP response element-binding protein (CREB) by short chain fatty acids induce TH gene expression via ERK-mediated survival of embryonic retinal ganglion cells: signaling mechanisms,” General and Comparative Endocrinology, vol. 156, no. 3, pp. 613–621, 2008.

[46] W. H. Zheng and R. Quirion, “Insulin-like growth factor-1 (IGF-1) induces the activation/phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells,” BMC Neuroscience, vol. 7, article 51, 2006.

[47] D. Zhang, X. Hu, L. Qian et al., “Modulation of inflammatory responses after global ischemia by transplanted umbilical cord matrix stem cells,” Stem Cells, vol. 26, no. 11, pp. 2893–2901, 2008.

[48] A. C. Hirko, R. DallaS, S. I. Lee, B. G. Kim, D. H. Hwang, H. M. Kim, and S. U. Noshita, A. Lewén, T. Sugawara, and P. H. Chan, “Evidence of ERK and cAMP response element-binding protein (CREB) by short chain fatty acids induce TH gene expression via ERK-dependent phosphorylation of CREB protein,” Brain Research, vol. 1107, no. 1, pp. 13–23, 2006.

[49] M. P. Shah, B. B. Nankova, S. Parab, and E. F. La Gamma, “Short chain fatty acids induce TH gene expression via ERK-dependent phosphorylation of CREB protein,” Brain Research, vol. 1107, no. 1, pp. 13–23, 2006.

[50] W. H. Zheng and R. Quirion, “Insulin-like growth factor-1 (IGF-1) induces the activation/phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells,” BMC Neuroscience, vol. 7, article 51, 2006.

[51] J. Y. Lim, S. I. Park, J. H. Oh et al., “Brain-derived neurotrophic factor stimulates the neural differentiation of human umbilical cord blood-derived mesenchymal stem cells and survival of differentiated cells through MAPK/ERK and PI3K/Akt-dependent signaling pathways,” Journal of Neuroscience Research, vol. 86, no. 10, pp. 2168–2178, 2008.

[52] E. Polazzi and A. Contestabile, “Microglia and cAMP response element-binding protein (CREB) by short chain fatty acids induce TH gene expression via ERK-mediated survival of embryonic retinal ganglion cells: signaling mechanisms,” General and Comparative Endocrinology, vol. 156, no. 3, pp. 613–621, 2008.

[53] M. Mittelbronn, J. Schittenhelm, G. Bakos et al., “CD8+/perforin+/granzyme B+ effector cells infiltrating cerebellum,“ Neurology, vol. 74, no. 1, pp. 10–20, 2012.

[54] J. Shi, Y. Ma, M. Zheng et al., “Effect of periventricular exposure to acrylamide on GABAergic neurons and astrocytes in weaning rat cerebellum,” Toxicology and Industrial Health, vol. 28, no. 1, pp. 33–42, 2012.

[55] A. A. Nasehi, J. Garcia-Estrada, L. M. Garcia-Segura, and I. Torres-Aleman, “Astrogliosis in CNS pathologies: is there a role for microglia?” Journal of Neuroinflammation, vol. 8, no. 12, pp. 318–331, 2012.

[56] A. M. Fernandez, J. Garcia-Estrada, L. M. Garcia-Segura, and I. Torres-Aleman, “Insulin-like growth factor I modulates neuronal survival and differentiation of embryonic retinal ganglion cells: signaling mechanisms,” General and Comparative Endocrinology, vol. 156, no. 3, pp. 613–621, 2008.

[57] W. H. Zheng and R. Quirion, “Insulin-like growth factor-1 (IGF-1) induces the activation/phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells,” BMC Neuroscience, vol. 7, article 51, 2006.
after spinal cord injury,” *Neurochemical Research*, vol. 33, no. 1, pp. 134–149, 2008.

[72] V. R. Dasari, K. K. Veeravalli, K. L. Saving et al., “Neuroprotection by cord blood stem cells against glutamate-induced apoptosis is mediated by Akt pathway,” *Neurobiology of Disease*, vol. 32, no. 3, pp. 486–498, 2008.

[73] B. Gabryel, A. Pudelko, and A. Malecki, “Erk1/2 and Akt kinases are involved in the protective effect of aniracetam in astrocytes subjected to simulated ischemia in vitro,” *European Journal of Pharmacology*, vol. 494, no. 2-3, pp. 111–120, 2004.

[74] D. D. Rowe, C. C. Leonardo, J. A. Recio, L. A. Collier, A. E. Willing, and K. R. Pennypacker, “Human umbilical cord blood cells protect oligodendrocytes from brain ischemia through Akt signal transduction,” *The Journal of Biological Chemistry*, vol. 287, no. 6, pp. 4177–4187, 2012.

[75] T. K. Creson, P. Yuan, H. K. Manji, and G. Chen, “Evidence for involvement of ERK, PI3K, and RSK in induction of Bcl-2 by valproate,” *Journal of Molecular Neuroscience*, vol. 37, no. 2, pp. 123–134, 2009.

[76] M. Tamatani, Y. H. Che, H. Matsuzaki et al., “Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkB activation in primary hippocampal neurons,” *The Journal of Biological Chemistry*, vol. 274, no. 13, pp. 8531–8538, 1999.

[77] H. Matsuzaki, M. Tamatani, N. Mitsuda et al., “Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons,” *Journal of Neurochemistry*, vol. 73, no. 5, pp. 2037–2046, 1999.

[78] T. Sasaki, K. Kitagawa, Y. Yagit et al., “Bcl2 enhances survival of newborn neurons in the normal and ischemic hippocampus,” *Journal of Neuroscience Research*, vol. 84, no. 6, pp. 1187–1196, 2006.

[79] L. Lossi, G. Gambino, F. Ferrini, S. Alasia, and A. Merighi, “Posttranslational regulation of BCL2 levels in cerebellar granule cells: a mechanism of neuronal survival,” *Developmental Neurobiology*, vol. 69, no. 13, pp. 855–870, 2009.

[80] A. Bonati, R. Albertini, D. Garau et al., “BCL2 oncogene protein expression in human hematopoietic precursors during fetal life,” *Experimental Hematology*, vol. 24, no. 3, pp. 459–465, 1996.

[81] K. Kitabayashi, A. Siltanen, T. Päätäälä et al., “Bcl-2 expression enhances myoblast sheet transplantation therapy for acute myocardial infarction,” *Cell Transplantation*, vol. 19, no. 5, pp. 573–588, 2010.

[82] A. Siltanen, K. Kitabayashi, T. Päätäälä et al., “Bcl-2 improves myoblast sheet therapy in rat chronic heart failure,” *Tissue Engineering A*, vol. 17, no. 1-2, pp. 115–125, 2011.
Recent studies have shown that new neurons are continuously generated by endogenous neural stem cells in the subventricular zone (SVZ) of the adult mammalian brain. Some of these new neurons migrate to injured brain tissues and differentiate into mature neurons, suggesting that such new neurons may be able to replace neurons lost to degenerative disease or injury and improve or repair neurological deficits. Here, we tested whether delivering growth factors via gelatin hydrogel microspheres would support neurogenesis in the SVZ. Insulin-like growth factor-1 (IGF-1)-containing microspheres increased the number of new neurons in the SVZ. Hepatocyte growth factor (HGF)-containing microspheres increased the number of new neurons migrating from the SVZ towards the injured striatum in a stroke model in mouse. These results suggest that the strategy of using gelatin hydrogel microspheres to achieve the sustained release of growth factors holds promise for the clinical regeneration of damaged brain tissues from endogenous neural stem cells in the adult SVZ.

1. Introduction

Neural stem cells (NSCs) reside in the brain of adult animals, including humans [1–6]. NSCs residing in the subventricular zone (SVZ) at the lateral walls of the lateral ventricle and in the subgranular zone (SGZ) in the dentate gyrus of the hippocampus produce new neurons and glial cells throughout adult life in mammals [7–11]. The NSCs in the SVZ have the potential to regenerate lost neurons and glia in response to various pathological conditions [12–17]. Neuroregenerative therapy using endogenous NSCs in the SVZ is a highly anticipated emerging strategy for treating human brain diseases because it avoids the risk of immunological incompatibility and the ethical problems inherent in harvesting human cells, and it may reduce the risk of tumorigensis—which are all problems associated with transplanted stem cells [18, 19]. However, the spontaneous regeneration that takes place in the injured brain is insufficient for its structural or functional restoration [12, 17]. For future clinical applications, the ability to regulate each step in neuronal regeneration, including the generation, migration, differentiation, survival, and functional maturation of new neurons to promote efficient regeneration will be crucial for developing novel and reliable neuronal self-repair strategies [9, 20–23].

Various proteins, including neurotrophic factors and paracrine signaling molecules, are reported to enhance neurogenesis in the SVZ [24]. However, one limitation of using these factors in the treatment of brain diseases is the lack of appropriate delivery systems. It is difficult to engineer systemically administered proteins to cross the blood-brain barrier, and such proteins can cause systemic toxicity at high concentrations [25, 26]. On the other hand, a single local injection of liquid drugs into the brain parenchyma...
may not enhance neuronal regeneration effectively, given the limited volume and persistence of substances administered in this way. Therefore, for clinical applications, safe and effective methods for the sustained delivery of neurogenesis-enhancing factors to the SVZ or injured neural tissues must be developed.

Here, we report that growth factors released from biodegradable gelatin hydrogel microspheres increase new neurons in the adult mouse brain. Gelatin hydrogels consist of gelatin polymers, which can be electrically complexed with growth factors [27, 28]. They have been used clinically to deliver growth factors in the treatment of patients with diseases including sudden sensorineural hearing loss, Bell’s palsy, and peripheral artery diseases [29–32]. In this paper, we tested the effects of insulin-like growth factor (IGF) [33, 34] and hepatocyte growth factor (HGF) [35–37] delivered by gelatin hydrogel microspheres on neurogenesis in the SVZ in the normal brain, and then on the recruitment of SVZ-derived new neurons to the injured brain after stroke in a mouse model.

## 2. Materials and Methods

### 2.1. Preparation of Gelatin Hydrogel

Gelatin hydrogel microspheres (MedGel P15; MedGel, Osaka, Japan) with a diameter within 30 μm were prepared as described previously [27, 28]. The microspheres were incubated with phosphate buffered saline (PBS) (control) or PBS containing recombinant human IGF-1 (PeproTech, Rocky Hill, USA; 0.25 μg) or recombinant human HGF (PeproTech, Rocky Hill, USA; 0.5 μg) for 1 hour at room temperature.

### 2.2. Animals

Adult (8 weeks old) male ICR mice were purchased from SLC (Shizuoka, Japan) and maintained on a 12-hour light/dark cycle with unlimited access to food and water. All animal-related procedures were approved by the Laboratory Animal Care and Use Committee of Nagoya City University.

### 2.3. Injection of Gelatin Hydrogel

In intact mice, 3 μL of the gelatin hydrogel suspension or 2 μL of the solutions without gelatin hydrogel were stereotaxically injected using a capillary micropipette (Drummond Scientific Company, Broomall, PA, USA) into the striatum of anaesthetized 8-week-old ICR mice at the following position relative to bregma: 1.0 mm anterior, 1.5 mm lateral, and 3.2 mm deep (n = 5 and 3 animals for groups treated with and without gelatin hydrogel, resp.). In the MCAO model, 11 days after MCAO, 5 μL of gelatin hydrogel suspension or 2 μL of the solutions without gelatin hydrogel were stereotaxically injected using a capillary micropipette into the striatum of anaesthetized 8-week-old ICR mice at the following position relative to bregma: 1.0 mm anterior, 2.0 mm lateral, and 3.2 mm deep (n = 6 and 4 animals for groups treated with and without gelatin hydrogel, resp.). After surgery, the animals were left on a heat mat and constantly monitored until recovery. After 7 days, the mice were killed and their brains were prepared for immunohistochemistry.

### 2.4. Middle Cerebral Artery Occlusion

Middle cerebral artery occlusion (MCAO) was accomplished using the previously described intraluminal filament technique [17, 38, 39]. A laser-Doppler flowmetry probe (model ALF21; Advance, Tokyo, Japan) was attached to the surface of the skull to monitor the regional cerebral blood flow. A silicone-coated 8-0 filament was inserted into the internal carotid artery through an incision in the external carotid artery and then advanced to occlude the middle cerebral artery (MCA). The occlusion of the MCA was confirmed by observing a reduction in the value of laser-Doppler flowmetry of about 30%. The filament was withdrawn 50–60 minutes later, and reperfusion was confirmed by laser-Doppler flowmetry, and the incision was then closed. Gelatin hydrogel microspheres were injected 11 days after MCAO. Seven days after the injection, the mice were killed and their brains were prepared for immunohistochemistry.

### 2.5. Immunohistochemistry and Quantification

Brains were perfusion-fixed with 4% paraformaldehyde, postfixed in the same fixative overnight, and 50 μm sections were cut on a Vibratome sectioning system (VT1200S; Leica, Heidelberg, Germany) as described previously [17, 38, 39]. After three rinses in PBS, the sections were incubated for 40 min in blocking solution (PBS containing 10% donkey serum and 0.2% Triton X-100) and then overnight at 4°C with primary antibodies, which were diluted in the same solution. The next day, the sections were incubated for 2 hours at room temperature with biotinylated secondary antibodies (1:500) (Jackson, West Grove, PA, USA) or Alexa Fluor-conjugated secondary antibodies (1:500) (Invitrogen, Carlsbad, CA, USA), unless otherwise noted. Biotinylated antibodies were visualized using the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) and DAB (diaminobenzidine tetrahydrochloride).

The primary antibodies (final dilution and source) used in this study were goat anti-doublecortin (anti-DCX) (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-Ki67 (1:200; Novocasta, Newcastle, UK), and mouse anti-NeuN (1:100; Merck Millipore, Billerica, MA, USA).

For laser scanning microscopy, we used an LSM700 Microscope (Carl Zeiss, Oberkochen, Germany). For the quantification of immunolabeled cells, the images of stained cells were acquired using a fluorescence microscope, BX51 (Olympus, Tokyo, Japan), and a CCD camera, DP71 (Olympus). The actual number of DCX+ cells was counted in three sections: the one containing the injection site and two sections taken 600 μm and 1200 μm, respectively, anterior to the injection site. For analyses of the brain after MCAO, the section including the injection site and an additional 5 (DCX) and 2 (Ki67) anterior sections spaced 300 μm apart were used. The total cell number was estimated by multiplying the sum of the counted cells by 12 and 6, respectively.

### 2.6. Infarct Volume Evaluation

Brain sections prepared after MCAO (thickness, 50 μm) were immunostained for NeuN.
and visualized with DAB using a standard procedure. The images of the sections including the injection site and two additional anterior sections spaced 600 μm apart were captured using a fluorescence microscope, BX51 (Olympus, Tokyo, Japan), and a CCD camera, DP71 (Olympus).

For this analysis, we used only mice in which the striatal infarction (NeuN negative area) was observed within 1 mm of the SVZ in at least one section. The areas that lacked NeuN immunoreactivity (infarct area) and those of the ipsilateral hemisphere in the three sections were measured using the Photoshop CS 8.0.1 (Adobe Systems, San Jose, CA, USA) image software. The percentage of the infarct area was determined by dividing the infarct area by that of the ipsilateral hemisphere for each mouse and used for the analysis of infarct volume.

2.7. Statistics. All data are presented as the mean ± SEM. Comparisons between experimental groups were analyzed by two-tailed Student’s t-test, and differences were regarded as statistically significant when P < 0.05.

3. Results and Discussion

3.1. Study Design. In this study, we focused on two growth factors, IGF-1 and HGF, incorporated into gelatin hydrogel, which can slowly release proteins after implantation into the body [27, 28]; both IGF-1 and HGF have been approved for clinical applications in the treatment of various diseases [29–32, 40–42]. The gelatin hydrogel microspheres were injected into the striatum of normal brain or close to the injured tissue of a stroke model (Figure 1). Seven days after the injection, the brains were fixed and number of DCX+ new neurons was compared.

3.2. IGF. IGF-1 promotes the proliferation of neural stem or progenitor cells as well as neuronal differentiation and survival [43–46]. It has a neuroprotective effect in animal models of stroke [47]. IGF-1-containing gelatin hydrogel microspheres have been used in a clinical trial for the treatment of patients with glucocorticoid-resistant sudden sensorineural hearing loss [29]. However, it is unknown whether the controlled release of IGF-1 using gelatin hydrogel is useful to stimulate neurogenesis in the SVZ.

We tested the effects of gelatin hydrogel containing IGF-1 on the number of new neurons in the intact adult mouse SVZ. First, we injected PBS containing IGF-1 (0.25 μg) without hydrogel into the striatum close to the SVZ (Figure 2(a)). Seven days later, there was no significant difference in the number of DCX+ new neurons in the SVZ between the IGF-1-injected and PBS-injected control brains (Figure 2(c), PBS: 1469 ± 99 cells, IGF-1: 1633 ± 205 cells, n = 5 animals for each group), indicating that the IGF-1 injection without gelatin hydrogel was not effective in stimulating neurogenesis under these experimental conditions. We then injected a gelatin-hydrogel suspension in PBS, with or without the same amount of IGF-1, into the striatum (Figure 2(b)). Seven days later, significantly increased numbers of DCX+ new neurons were observed in the SVZ of brains that received the IGF-1-containing gelatin hydrogel compared with the control group (Figures 2(b) and 2(c), PBS: 1621 ± 50 cells, IGF-1: 1916 ± 143 cells, n = 3 animals for each group), indicating that the IGF-1 injection without gelatin hydrogel was not effective in stimulating neurogenesis under these experimental conditions. We then injected a gelatin-hydrogel suspension in PBS, with or without the same amount of IGF-1, into the striatum (Figure 2(b)). Seven days later, significantly increased numbers of DCX+ new neurons were observed in the SVZ of brains that received the IGF-1-containing gelatin hydrogel compared with the control group (Figures 2(b) and 2(c), PBS: 1469 ± 99 cells, IGF-1: 1916 ± 143 cells, n = 5 animals for each group). These results indicate that gelatin hydrogel is suitable as a vehicle for the delivery of IGF-1 to the SVZ. In addition, these results are consistent with the sustained release of IGF-1 from gelatin hydrogel efficiently promoting IGF-1’s actions on the proliferation and differentiation of neural stem or progenitor cells [43–46], resulting in increased numbers of new neurons in the SVZ.

Figure 1: Study design. Schematic illustration of experiments performed to test the effects of growth factors released from gelatin hydrogel on neurogenesis in the SVZ. Effects of growth factors injected into normal (a) and injured brains 11 days after MCAO (b) with or without gelatin hydrogel on the number of new neurons in the SVZ and injured striatum, respectively, were compared 7 days after the injections. Blue and pink circles represent gelatin hydrogel microspheres.
3.3. HGF. Previous studies indicated that HGF stimulates the proliferation of neural stem or progenitor cells in the adult SVZ, as well as the migration and differentiation of new neurons [48–52]. Acute injection of HGF into the adult striatum has a neuroprotective effect and promotes neurological recovery in a mouse model of stroke [53]. Topical application of HGF-containing gels on the surface of the cerebral cortex increases the number of new migrating neurons in the striatum of the MCAO model [54]. HGF-containing gelatin hydrogel has been used for the treatment of animal models of several diseases including noise-induced hearing loss [55] and collagen-induced arthritis [56]. These studies strongly suggest that HGF-containing gelatin hydrogel is likely to be useful to enhance neuronal regeneration after stroke.

We first tested the effects of HGF in PBS, with or without gelatin hydrogel, injected into the striatum, on the number of new neurons in the SVZ of the normal adult brain. Seven days after the injection, there was no significant difference in the number of DCX+ cells between the HGF and PBS-control groups regardless of the use of gelatin hydrogel: with gelatin hydrogel, animals treated with PBS showed 1790±102 new cells, and those given HGF generated 1750±106 cells (n = 3 animals for each group); without gelatin hydrogel, animals treated with PBS showed 2111±82 cells; those treated with HGF generated 1992±78 cells (n = 5 animals for each group, t-test).

Next, we tested the effects of injecting the same substances in a mouse model of stroke induced by MCAO. In this model, SVZ-derived new neurons can be found migrating toward the injured striatum 2-3 weeks after the induction of ischemia [17]. Therefore, we injected HGF in PBS, with or without gelatin hydrogel, into the striatum 11 days after MCAO (Figures 3(a) and 3(b)). Eighteen days after MCAO, we quantified the infarct volume and number of new neurons in the striatum. The HGF administration did not affect the infarct volume, regardless of the use of gelatin hydrogel microspheres: with gelatin hydrogel, PBS yielded an infarct volume of 26.3±3.4%, and those treated with HGF had an infarct volume of 25.3±2.0% (n = 6 animals for each group); without gelatin hydrogel, animals treated with PBS showed an infarct volume of 26.6±1.6% and those treated with HGF had an infarct volume of 29.6±3.6% (n = 4 animals, t-test).

The administration of HGF without gelatin hydrogel also did not affect the number of DCX+ cells in the striatum (Figures 3(c) and 3(d)). However, the HGF-containing gelatin hydrogel significantly increased the number of DCX+ cells migrating in the striatum after MCAO (Figures 3(c) and 3(d)). Interestingly, the majority of the DCX+ cells extended...
a long leading process toward the injected gelatin hydrogel, suggesting that these cells were migrating laterally. Because HGF has been reported to stimulate the proliferation of SVZ progenitors [48], we also examined the effects of HGF on cell proliferation in the SVZ after MCAO. There was no significant difference in the number of Ki67+ proliferating cells between the HGF and PBS-control groups, regardless of the use of gelatin hydrogel (with gelatin hydrogel, PBS: 796.5 ± 87.65 cells, HGF: 798.8 ± 96.12 cells, n = 6 and 5 animals, respectively; without gelatin hydrogel, PBS: 837.5 ± 78.77 cells, HGF: 926.0 ± 109.4 cells, n = 4 animals for each group, t-test). These results suggest that the increased number of new neurons in the injured striatum induced by treatment with HGF with gelatin hydrogel was due to an increased efficiency of the new neurons' migration but not to their production in the SVZ (Figure 3(e)).

Since the receptor for HGF, c-Met, is expressed in adult DCX+ migrating neurons [49] as well as GFAP+ astrocytes [50], it is possible that DCX+ cells are attracted by the HGF-releasing gelatin hydrogel. It is also possible that the HGF-induced increase in the number of DCX+ cells in the striatum was caused by angiogenic activity [54], since new neurons use blood vessels for their migration [17, 38].

4. Conclusions

The benefits reported here of using gelatin hydrogel microspheres to deliver growth factors to simulate neurogenesis in the SVZ demonstrate that gelatin hydrogel is a promising vehicle for the local and sustained release of drugs in the brain. Previous studies demonstrated that the epicortical delivery of EPO [57] and HGF [54] enhance neurogenesis in the SVZ in mouse models of stroke. However, considering the longer distance between the brain surface and the SVZ in the human brain, direct injection inside the brain parenchyma may be needed to efficiently stimulate neurogenesis from neural stem cells in the SVZ. The local delivery of drugs using hydrogels should result in a lower total dose of medications and thus in fewer side effects. In addition, this technology should be applicable to any charged protein that can enhance neural regeneration [58]. Further studies are needed to improve the injectability of the gelatin hydrogel, which will result in a less invasive procedure. Finally, how the newly generated neurons produced by this treatment contribute to neurological improvement needs to be elucidated.

Authors’ Contribution

K. Nakaguchi and H. Jinnou contributed equally to this work.

Acknowledgments

The authors are grateful to Hiroshi Funakoshi (Asahikawa Medical University) and members of the Sawamoto...
Laboratory for discussions. M. Sawada is a Research Fellow of the Japan Society for the Promotion of Science. This work was supported by the Project for Realization of Regenerative Medicine (Ministry of Education, Culture, Sports, Science and Technology, Japan) and the Funding Program for Next Generation World-Leading Researchers (Japan Society for the Promotion of Science).

References

[1] A. Bédard and A. Parent, “Evidence of newly generated neurons in the human olfactory bulb,” Developmental Brain Research, vol. 151, no. 1-2, pp. 159–168, 2004.

[2] P. S. Eriksson, E. Perfilieva, T. Björk-Eriksson et al., “Neurogenesis in the adult human hippocampus,” Nature Medicine, vol. 4, no. 11, pp. 1313–1317, 1998.

[3] B. Kirshenbaum, M. Nedergaard, A. Preuss, K. Barami, R. A. Fraser, and S. A. Goldman, “In vitro neuronal production and differentiation by precursor cells derived from the adult human forebrain,” Cerebral Cortex, vol. 4, no. 6, pp. 576–589, 1994.

[4] A. Quiñones-Hinojosa, N. Sanai, M. Soriano-Navarro et al., “Cellular composition and cytoarchitecture of the adult human subventricular zone: a niche of neural stem cells,” Journal of Comparative Neurology, vol. 494, no. 3, pp. 415–434, 2006.

[5] N. S. Roy, S. Wang, L. Jiang et al., “In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus,” Nature Medicine, vol. 6, no. 3, pp. 271–277, 2000.

[6] H. Sanai, A. D. Tramontin, A. Quiñones-Hinojosa et al., “Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration,” Nature, vol. 427, no. 6976, pp. 740–744, 2004.

[7] A. Alvarez-Buyll and J. M. Garcia-Verdugo, “Neurogenesis in adult subventricular zone,” Journal of Neuroscience, vol. 22, no. 3, pp. 629–634, 2002.

[8] R. A. Ihrie and A. Alvarez-Buylla, “Lake-front property: a unique germinial niche by the lateral ventricles of the adult brain,” Neuron, vol. 70, no. 4, pp. 674–686, 2011.

[9] N. Kaneko and K. Sawamoto, “Adult neurogenesis and its alteration under pathological conditions,” Neuroscience Research, vol. 63, no. 3, pp. 155–164, 2009.

[10] P. M. Lledo, M. Alonso, and M. S. Grubb, “Adult neurogenesis and functional plasticity in neuronal circuits,” Nature Reviews Neuroscience, vol. 7, no. 3, pp. 179–193, 2006.

[11] C. Zhao, W. Deng, and F. H. Gage, “Mechanisms and functional implications of adult neurogenesis,” Cell, vol. 132, no. 4, pp. 645–660, 2008.

[12] A. Arvidsson, T. Collin, D. Kirik, Z. Kokaia, and O. Lindvall, “Neuronal replacement from endogenous precursors in the adult brain after stroke,” Nature Medicine, vol. 8, no. 9, pp. 963–970, 2002.

[13] S. W. Levison and J. E. Goldman, “Both oligodendrocytes and astrocytes develop from progenitors in the subventricular zone of postnatal rat forebrain,” Neuron, vol. 10, no. 2, pp. 201–212, 1993.

[14] B. Menn, J. M. Garcia-Verdugo, C. Yaschine, O. Gonzalez-Perez, D. Rowitch, and A. Alvarez-Buylla, “Origin of oligodendrocytes in the subventricular zone of the adult brain,” Journal of Neuroscience, vol. 26, no. 30, pp. 7907–7918, 2006.

[15] J. M. Parent, Z. S. Vexler, C. Gong, N. Derugin, and D. M. Ferriero, “Rat forebrain neurogenesis and striatal neuron replacement after focal stroke,” Annals of Neurology, vol. 52, no. 6, pp. 802–813, 2002.

[16] N. Picard-Riera, L. Decker, C. Delarasse et al., “Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 20, pp. 13211–13216, 2002.

[17] T. Yamashita, M. Ninomiya, P. H. Acosta et al., “Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum,” Journal of Neuroscience, vol. 26, no. 24, pp. 6627–6636, 2006.

[18] L. Grabel, “Prospects for pluripotent stem cell therapies: into the clinic and back to the bench,” Journal of Cellular Biochemistry, vol. 113, no. 2, pp. 381–387, 2012.

[19] K. Pfannkuche, T. Hannes, M. Khalil et al., “Induced pluripotent stem cells: a new approach for physiological research,” Cellular Physiology and Biochemistry, vol. 26, no. 2, pp. 105–124, 2010.

[20] N. Kaneko, E. Kako, and K. Sawamoto, “Prospects and limitations of using endogenous neural stem cells for brain regeneration,” Genes, vol. 2, no. 1, pp. 107–130, 2011.

[21] K. Nakaguchi, H. Masuda, N. Kaneko, and K. Sawamoto, “Strategies for regenerating striatal neurons in the adult brain by using endogenous neural stem cells,” Neurology Research International, vol. 2011, Article ID 898012, 10 pages, 2011.

[22] H. Okano, M. Sakaguchi, K. Ohki, N. Suzuki, and K. Sawamoto, “Regeneration of the central nervous system using endogenous repair mechanisms,” Journal of Neurochemistry, vol. 102, no. 5, pp. 1459–1465, 2007.

[23] H. Okano and K. Sawamoto, “Neural stem cells: Involvement in adult neurogenesis and CNS repair,” Philosophical Transactions of the Royal Society B, vol. 363, no. 1500, pp. 2111–2122, 2008.

[24] G. Kempermann, “Regulation,” in Adult Neurogenesis: Stem Cells and Neuronal Development in the Adult Brain, pp. 325–325, Oxford University Press, New York, NY, USA, 2006.

[25] W. Lösch and H. Potschka, “Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases,” Progress in Neurobiology, vol. 76, no. 1, pp. 22–76, 2005.

[26] A. Misra, S. Ganesh, A. Shaiwala, and S. P. Shah, “Drug delivery to the central nervous system: a review,” Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 2, pp. 252–273, 2003.

[27] Y. Tabata and Y. Ikada, “Protein release from gelatin matrices,” Advanced Drug Delivery Reviews, vol. 31, no. 3, pp. 287–301, 1998.

[28] Y. Tabata and Y. Ikada, “Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities,” Biomaterials, vol. 20, no. 22, pp. 2169–2173, 1999.

[29] T. Nakagawa, T. Sakamoto, H. Hiraumi et al., “Topical insulin-like growth factor 1 treatment using gelatin hydrogels for ischemia by sustained release of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities,” Cell, vol. 132, no. 4, pp. 645–660, 2008.

[30] A. Marui, Y. Tabata, S. Kojima et al., “A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel—an initial report of the phase I-IIa study,” Circulation Journal, vol. 71, no. 8, pp. 1181–1186, 2007.
Y. Arsenijevic, S. Weiss, B. Schneider, and P. Aebischer, “Facial nerve decompression surgery using bFGF-impregnated biodegradable gelatin hydrogel in patients with Bell palsy,” *Otolaryngology*, vol. 146, no. 4, pp. 641–646, 2012.

G. Takagi, M. Miyamoto, S. Tara et al., “Controlled-release basic fibroblast growth factor for peripheral artery disease: comparison with autologous bone marrow-derived stem cell transfer,” *Tissue Engineering A*, vol. 17, no. 21-22, pp. 2787–2794, 2011.

E. Rinderknecht and R. E. Humbel, “Amino terminal sequences of two polypeptides from human serum with nonsuppressible insulin like and cell growth promoting activities: evidence for structural homology with insulin B chain,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 73, no. 12, pp. 4379–4381, 1976.

E. Rinderknecht and R. E. Humbel, “The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin,” *Journal of Biological Chemistry*, vol. 253, no. 8, pp. 2769–2776, 1978.

H. Funakoshi and T. Nakamura, “Hepatocyte growth factor: from diagnosis to clinical applications,” *Clinica Chimica Acta*, vol. 327, no. 1-2, pp. 1–23, 2003.

T. Nakamura, K. Nawa, and A. Ichihara, “Partial formation and characterization of hepatocyte growth factor from serum of heptactomized rats,” *Biochemical and Biophysical Research Communications*, vol. 122, no. 3, pp. 1450–1459, 1984.

T. Nakamura, T. Nishizawa, M. Hagiy et al., “Molecular cloning and expression of human hepatocyte growth factor,” *Nature*, vol. 342, no. 6248, pp. 440–443, 1989.

T. Kojima, Y. Hirota, M. Ema et al., “Subventricular zone-derived neural progenitor cells migrate along a blood vessel scaffold toward the post-stroke striatum,” *Stem Cells*, vol. 28, no. 3, pp. 545–554, 2010.

M. Ninomiya, T. Yamashita, N. Araki, H. Okano, and K. Sawamoto, “Enhanced neurogenesis in the ischemic striatum following EGF-induced expansion of transit-amplifying cells in the subventricular zone,” *Neuroscience Letters*, vol. 403, no. 1-2, pp. 63–67, 2006.

Y. Gu, J. Zhang, L. Guo et al., “A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia,” *The Journal of Gene Medicine*, vol. 13, no. 11, pp. 602–610, 2011.

T. D. Henry, A. T. Hirsch, J. Goldman et al., “Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study,” *Gene Therapy*, vol. 18, no. 8, pp. 788–794, 2011.

H. Shigematsu, K. Yasuda, T. Iwai et al., “Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia,” *Gene Therapy*, vol. 17, no. 9, pp. 1152–1161, 2010.

C. Vicario-Abejon, M. J. Yusta-Boyo, C. Fernandez-Moreno, and F. De Pablo, “Locally born olfactory bulb stem cells proliferate in response to insulin-related factors and require endogenous insulin-like growth factor-1 for differentiation into neurons and glia,” *Journal of Neuroscience*, vol. 23, no. 3, pp. 385–390, 2003.

G. J. Brooker, M. Kalloniatis, V. C. Russo et al., “Endogenous IGF-1 regulates the neuronal differentiation of adult stem cells,” *Journal of Neuroscience Research*, vol. 59, no. 3, pp. 332–341, 2000.

Y. Arsenijevic, S. Weiss, B. Schneider, and P. Aebischer, “Insulin-like growth factor-1 is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2,” *Journal of Neuroscience*, vol. 21, no. 18, pp. 7194–7202, 2001.

R. D. Hodge, A. Joseph D’Ercole, and J. R. O’Kusky, “Insulin-like growth factor-I accelerates the cell cycle by decreasing G1 phase length and increases cell cycle reentry in the embryonic cerebral cortex,” *Journal of Neuroscience*, vol. 24, no. 45, pp. 10201–10210, 2004.

R. Kooijman, S. Sarre, Y. Michotte, and J. D. Keyser, “Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke?” *Stroke*, vol. 40, no. 4, pp. e83–e88, 2009.

D. Garzotto, P. Giacobini, T. Crepaldi, A. Fasolo, and S. Del Marchis, “Hepatocyte growth factor regulates migration of olfactory interneuron precursors in the rostral migratory stream through Met-Grb2 coupling,” *Journal of Neuroscience*, vol. 28, no. 23, pp. 5901–5909, 2008.

C. Nicoleu, O. Benzakour, F. Agasse et al., “Endogenous hepatocyte growth factor is a niche signal for subventricular zone neural stem cell amplification and self-renewal,” *Stem Cells*, vol. 27, no. 2, pp. 408–419, 2009.

T. W. Wang, H. Zhang, M. R. Gyetko, and J. M. Parent, “Hepatocyte growth factor acts as a mitogen and chemoattractant for postnatal subventricular zone-olfactory bulb neurogenesis,” *Molecular and Cellular Neuroscience*, vol. 48, no. 1, pp. 38–50, 2011.

J. Kokuzawa, S. Yoshimura, H. Kitajima et al., “Hepatocyte growth factor promotes proliferation and neuronal differentiation of neural stem cells from mouse embryos,” *Molecular and Cellular Neuroscience*, vol. 24, no. 1, pp. 190–197, 2003.

M. Kato, S. Yoshimura, J. Kokuzawa et al., “Hepatocyte growth factor promotes neuronal differentiation of neural stem cells derived from embryonic stem cells,” *NeuroReport*, vol. 15, no. 1, pp. 5–8, 2004.

T. R. Doepnner, B. Kaltwasser, A. Elali, A. Zechariah, D. M. Herrmann, and M. Bähr, “Acute hepatocyte growth factor treatment induces long-term neuroprotection and stroke recovery via mechanisms involving neural precursor cell proliferation and differentiation,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 31, no. 5, pp. 1251–1262, 2011.

J. Shang, K. Deguchi, Y. Ohta et al., “Strong neurogenesis, angiogenesis, synaptogenesis, and antifibrosis of hepatocyte growth factor in rats brain after transient middle cerebral artery occlusion,” *Journal of Neuroscience Research*, vol. 89, no. 1, pp. 86–95, 2011.

T. Inaoka, T. Nakagawa, Y. S. Kikkawa et al., “Local application of hepatocyte growth factor using gelatin hydrogels attenuates noise-induced hearing loss in guinea pigs,” *Acta Oto-Laryngologica*, vol. 129, no. 4, pp. 443–457, 2009.

K. Okunishi, O. Sasaki, T. Okasora et al., “Intratracheal delivery of hepatocyte growth factor directly attenuates allergic airway inflammation in mice,” *International Archives of Allergy and Immunology*, vol. 149, supplement 1, pp. 14–20, 2009.

Y. Wang, M. J. Cooke, C. M. Morshed, and M. S. Shoichet, “Hydrogel delivery of erythropoietin to the brain for endogenous stem cell stimulation after stroke injury,” *Biomaterials*, vol. 33, no. 9, pp. 2681–2692, 2012.

R. J. Dempsey and H. S. G. Kalluri, “Ischemia-induced neurogenesis: role of growth factors,” *Neurosurgery Clinics of North America*, vol. 18, no. 1, pp. 183–190, 2007.
Review Article

Adrenomedullin as a Growth and Cell Fate Regulatory Factor for Adult Neural Stem Cells

Sonia Martínez-Herrero, Ignacio M. Larráyoz, Laura Ochoa-Callejero, Josune García-Sanmartín, and Alfredo Martínez

Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), 26006 Logroño, Spain

Correspondence should be addressed to Alfredo Martínez, amartinezr@riojasalud.es

Received 25 May 2012; Revised 16 August 2012; Accepted 21 August 2012

Academic Editor: Graciela Gudino-Cabrera

Copyright © 2012 Sonia Martínez-Herrero et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The use of stem cells as a strategy for tissue repair and regeneration is one of the biomedical research areas that has attracted more interest in the past few years. Despite the classic belief that the central nervous system (CNS) was immutable, now it is well known that cell turnover occurs in the mature CNS. Postnatal neurogenesis is subjected to tight regulation by many growth factors, cell signals, and transcription factors. An emerging molecule involved in this process is adrenomedullin (AM). AM, a 52-amino acid peptide which exerts a plethora of physiological functions, acts as a growth and cell fate regulatory factor for adult neural stem and progenitor cells. AM regulates the proliferation rate and the differentiation into neurons, astrocytes, and oligodendrocytes of stem/progenitor cells, probably through the PI3K/Akt pathway. The active peptides derived from the AM gene are able to regulate the cytoskeleton dynamics, which is extremely important for mature neural cell morphogenesis. In addition, a defective cytoskeleton may impair cell cycle and migration, so AM may contribute to neural stem cell growth regulation by allowing cells to pass through mitosis. Regulation of AM levels may contribute to program stem cells for their use in medical therapies.

1. Introduction

A continuously increasing number of research articles reporting new experimental data on stem cells confirm the trend that began in 1999. Due to the prospects for the translation of stem cell biology advancements to treatment of many severe conditions such as Parkinson disease [1, 2], Alzheimer disease [3], Duchenne muscular dystrophy [4], amyotrophic lateral sclerosis [3], diabetes [5], stroke [6], myocardial regeneration [7], cartilage repair [8], or acute fail liver [9], stem cells are common in the popular press and great hopes are stirring in the public about their therapeutic potential.

The dogmatic view of an ever-immutable neural tissue in mammals is now been replaced by the notion that cell turn over does occur in the mature central nervous system thanks to the persistence of precursor cells that possess the functional characteristics of neural stem cells [10]. In modern society, where neurodegenerative diseases are becoming a major public health problem, neural stem cells have become one of the main attention points of the scientific community. Their capacity to self-renew and to produce all cell types of the mature central nervous system leads to hypothesize about their potential use in transplantation therapies for severe neurodegenerative diseases such as Parkinson or Alzheimer disease [4].

All the processes of self-renewal, proliferation, progressive maturation, and differentiation, which are needed for stem cell physiology, are orchestrated by a set of transcription factors, cell-to-cell interactions, niche-to-cell interactions, and many soluble diffusible signals [11]. One of these signals is adrenomedullin (AM), a 52-aminoacid peptide with structural homology to calcitonin gene-related peptide [12, 13]. AM displays a large variety of physiological functions including cell growth and differentiation regulation [14]. In addition, recent studies point to specific roles of this regulatory peptide in the behaviour of several stem cells, including neural stem and progenitor cells. This paper tries to sum up the current knowledge about this topic.
2. Adrenomedullin

This regulatory peptide was isolated from human pheochromocytoma by Kitamura et al. in 1993 [15]. This peptide was able to stimulate cAMP production in human platelets and exerted potent and long-lasting hypotensive activity in rats. AM is synthesized by both tumor cells and normal adrenal medulla as well as by many other tissues. AM is a circulating hormone, although it functions also as a local paracrine and autocrine mediator with multiple biological activities such as vasodilatation, cell growth, regulation of hormone secretion, natriuresis, and antimicrobial effects [16].

2.1. Structure of Adrenomedullin. Human AM consists of 52 amino acids and it belongs to the amylin/calcitonin gene-related peptide (CGRP) family. Intermedin, also named adrenomedullin 2, has also been identified as a novel member of this family [12, 13]. AM contains a 6-amino acid ring formed by a disulfide bond between residues 16 and 21. The C-terminal tyrosine residue is amidated (-CONH2). Both structural features are essential for its biological activity [17].

The three-dimensional structure of AM comprises a central α-helical region, covering approximately one third of its total length, flanked by two disordered segments. The presence of the α-helix at the centre of AM seems to be a general feature of the calcitonin peptide family, which is important for the physiology of these peptides and the recognition of their specific receptors [18].

2.2. Adrenomedullin Gene Expression and Release. AM is encoded by a gene contained in human chromosome 11 and consisting of 4 exons and 3 introns, with TATA, CAAT, and GC boxes in the 5'-flanking region [16]. In mice, the AM gene is localized in chromosome 7.

The mature AM peptide is derived from proadrenomedullin, which contains 185 amino acids in humans. After cleaving of 21-residue N-terminal signaling peptide, proadrenomedullin is converted to proadrenomedullin, which is a precursor of mature AM (amino acids 95–146 of proadrenomedullin) as well as of another active peptide, proadrenomedullin N-terminal 20-peptide or PAMP (amino acids 22–41 of proadrenomedullin) [17].

AM production is mostly regulated by oxidative stress and inflammation-related substances such as lipopolysaccharide and inflammatory cytokines like TNF-α and IL-1, which increase AM secretion rate. There are several binding sites for activator protein-2 (AP-2) and c-AMP-regulated enhancer element. It has also been discovered that there are nuclear factor-KB sites on the promoter of the AM gene [14]. Hypoxia is also a potent inducer of AM expression. This overexpression is mediated by transactivation of the AM promoter by hypoxia inducible factor 1 (HIF-1) transcription factor, as well as by posttranscriptional mRNA stabilization. Hypoxia response elements (HREs) have been found in the promoter of the human AM gene [19].

2.3. Metabolism of Adrenomedullin. AM is a circulating peptide and it can be found in plasma at a concentration of 2–10 pM in humans. AM is also present in other biological fluids such as urine, saliva, sweat, milk, amniotic fluid, and cerebrospinal liquid [16]. In plasma, AM is specifically bound to adrenomedullin binding protein-1 (AMBP-1), which was later identified as complement factor H [20]. AM bound to complement factor H cannot be detected in plasma, so it is thought that total plasma AM could be higher than reported in most studies. Circulating AM is rapidly degraded with a half-life of 16–20 minutes. Matrix metalloprotease 2 seems to be responsible for the initial degradation of AM, which is followed by an aminopeptidase [21, 22].

2.4. Adrenomedullin Receptor Distribution. Specific binding sites for AM are located in many cell types and tissues like the heart, lungs, spleen, liver, vas deferens, kidney glomerulus, skeletal muscle, hypothalamus, spinal cord, and so on [16]. The wide distribution of binding sites for AM has to be related with its great variety of biological functions. In addition, recent studies reveal that AM is able to bind to many areas of the brain, providing the anatomical basis for the involvement of AM in the physiology of the central nervous system (CNS) [23].

The same studies also provide evidence for the possible existence of heterogeneous populations of AM binding sites in the brain and peripheral tissues [23] with different affinities for AM.

The AM receptor belongs to the 7-transmembrane domain G-protein-coupled receptor superfamily and is named calcitonin receptor-like receptor (CLR). However, CLR needs the presence of modulating proteins with a single transmembrane domain known as receptor activity modifying proteins (RAMP) [24]. Three RAMP isoforms have been identified in the human genome: RAMP1, RAMP2 and RAMP3. RAMPs bind to the CLR in the endoplasmic reticulum promoting the plasma membrane localization [25]. RAMP1 transports and present the CLR at the membrane surface as a mature glycoprotein, and this heterodimer functions as a CGRP receptor. The CLR molecules transported by RAMP2 and RAMP3 are core-glycosylated and function as AM receptors (AMR); CLR/RAMP2 is known as AMR1, whereas CLR/RAMP3 is AMR2 [26].

Qi et al. [27] studied the sequence differences between RAMP1, RAMP2, and RAMP3 to identify individual residues that could be able to alter their pharmacology. They hypothesized that residues present in RAMP2 and RAMP3 but not in RAMP1 are responsible for making CLR/RAMP2 and CLR/RAMP3 AM receptors. It was reported that position 74 in RAMP2 and RAMP3 is critical to establish their affinity for AM while Phe93 in RAMP1 contributes in a very important way to αCGRP affinity for CGRP receptors [27].

The expression of RAMP isoforms in a particular cell may change between physiological and pathological conditions, determining the degree of response to AM and CGRP. In physiological conditions the more abundant isoform is RAMP2, suggesting that most CLR molecules bind to RAMP2 to form a functional receptor for AM. Despite this observation, dynamic changes in the expression pattern of RAMP genes may take place during disease and in some
physiological conditions like pregnancy. The most robust changes in RAMP expression levels coincide with those situations in which plasma AM is most elevated, as in pregnancy or diseases like sepsis or heart failure. In those situations in which AM levels are higher, there is an elevation in RAMP3 expression apparently in order to decrease AM responsiveness [28].

2.5. Signal Transduction Mechanisms. The signal transduction pathways activated by AM vary between species, organs, tissues, and cells. However, there are three main signaling pathways whereby AM exerts its actions: cAMP, Akt, and mitogen-activated protein kinase (MAPK) extracellular signal-regulated protein kinase (ERK).

The main signal transduction pathway activated by AM seems to be the adenylyl cyclase/cAMP system. In many cell types, AM and CGRP receptors are coupled to Gs proteins that activate adenylate cyclase and increase intracellular levels of cAMP [17]. In bovine aortic endothelial cells and vascular smooth muscle cells (VSMC), the accumulation of cAMP causes the activation of protein kinase A (PKA) which in turn increases calcium (Ca²⁺) efflux leading to relaxation of the vascular cells [29].

Moreover, AM can induce Ca²⁺ mobilization independently from cAMP levels. This fact suggests that other signalling mechanisms may be responsible for AM-induced positive ionotropic action. This theory was confirmed by Szokodi et al. [30]. AM activated phospholipase C through its specific receptor and accelerated Inositol-1,4,5-P³ formation to stimulate Ca²⁺ release from the endoplasmic reticulum intracellular stores [29, 30]. In addition, the activation of phospholipase C is also involved in ion channel opening. However, other studies have shown that AM administration does not have any effects in intracellular Ca²⁺ concentration and even decreases Ca²⁺ content in cultured HUVECs [31] or in porcine coronary arteries [32]. These results suggest that the regulation of Ca²⁺ mobilization by AM may depend on the cell type and context.

It has been shown that intracellular Ca²⁺ increases, in response to AM, caused activation of nitric oxide (NO) synthase and NO release leading to relaxation of cardiac myocytes [33]. AM activation of NO pathway has a very important role in the regulation of the cardiovascular system by regulating blood flow [34]. The NO pathway and the reactive oxidative species produce an elevation of collateral flow in ischemic tissues having a cytoprotective action against ischaemia/reperfusion injury and against myocardial ischaemia-induced arrhythmias in rats [35]. Furthermore, Sata et al. demonstrated that AM inhibited endothelial cell apoptosis through a NO-dependent pathway [36]. Their results suggest that the antiapoptotic effect of AM mediated by NO is independent of cGMP, whereas the cGMP/cGMP-dependent kinase pathway mediates many biological functions of NO-like vasodilatation [36]. Some authors postulate that NO prevents apoptosis by S-nitrosylating caspases [37–39].

AM has been shown to activate the PI3K/Akt pathway in vascular endothelial cells where it regulates many steps like vasodilation, cell survival, proliferation, migration, and vascular cord-like structure formation [40]. The specific role of AM in the multistep process of angiogenesis is regulated via a mechanism that requires the activation of the CLR/RAMP2 and CLR/RAMP3 receptors [41].

Other findings suggest that AM also acts directly on myocardium by the presence of CLR in myocytes and induces cardioprotective and antiapoptotic effects through the activation of the PI3K/Akt pathway after ischemia/reperfusion and enhances neovascularization in ischemic tissues [42].

The role of AM in growth and mitogenesis has led to investigate the regulation of MAPK by AM. AM signalling directly promotes endothelial cell growth and survival through activation of MAPK/ERK downstream signalling pathways [43]. Interestingly, in glomerular mesangial cells AM causes an opposite effect by increasing apoptosis during serum deprivation [44]. AM activates apoptosis in mesangial cells but protects against it in endothelial cells and tumors; these results suggest a cell type-dependent effect of AM on apoptosis [14]. Activation of MAPK and other kinases such as cAMP-PKA, JNK, and protein phosphatase 2A (PP2A) has been proposed to mediate the proapoptotic effect of AM in mesangial cells. On the other hand, AM protects malignant cells from hypoxia-induced cell death by upregulation of Bcl-2 in an autocrine/paracrine manner [45].

AM appears to either stimulate or inhibit cell proliferation depending on the particular cell type. Cell proliferative response induced by AM is thus mediated via activation of protein tyrosine kinase-MAPK. However, in cells lacking MAPK activation signalling pathways, stimulation of AM receptors results in activation of cAMP, leading to growth inhibition [46].

On vascular smooth muscle cells (VSMCs) there are conflicting results. Initially it was suggested that AM had an antiproliferative effect [47]. But more recent studies suggest that AM exerts a potent mitogenic effect in serum-deprived VSMCs [48, 49]. Under serum deprivation, AM promotes DNA synthesis and cell proliferation in VSMCs. These responses are mediated by p42/p44 MAPK activation. AM stimulates proline-rich tyrosine kinase 2 (PYK2) which, in turn, activates c-Src and induces recruitment of adaptor proteins (Shc/Grb2), thereby leading to activation of the Ras-dependent MAPK cascade in VSMCs.

All signal mechanisms in which AM is involved are the basis of its extensive repertoire of biological functions as vasodilation, cellular proliferation, apoptosis modulation, or inflammatory regulation.

The main role played by AM in mammalian development has become apparent following the generation of different knockout (KO) models. In AM gene KO mice, in which the expression of AM and PAMP are suppressed, the null phenotype is embryonically lethal due to the absence of placental vascularisation, malformation of the basement membrane in the aorta and cervical arteries, detachment of the endothelial cells from the basement structure, and the presence of edema [50]. In addition, other groups have generated a KO mouse model in which only AM expression is affected [51]. AM−/− mice are also embryonic lethal and both genotypes AM/PAMP−/− and AM−/− caused embryonic
To demonstrate the in vivo importance of the CLR, a gene-targeted KO model of its gene (Calcrl) was generated. Mice heterozygous for the targeted Calcrl allele appear normal, survive to adulthood, and reproduce normally. However, Calcrl−/− pups are not viable, the embryos die between E13.5 and E14.5 of gestation and they exhibit a very similar phenotype to AM−/− and AM/PAMP−/− mice [52]. This result demonstrates that Calcrl is essential for embryo survival.

In models of mice lacking RAMP2 the results are similar to the ones shown above. RAMP2−/− embryos die in utero at midgestation due to severely deformation, vascular fragility, severe edema, and hemorrhage. In contrast, RAMP2+/− mice are viable, they reach adulthood but they exhibit a great variety of phenotypes due to vascular hyperpermeability and impaired neovascularization [53]. These data show that RAMP2 is a key determinant of the effects of AM on the vasculature and is essential for angiogenesis and vasculature integrity.

Surprisingly, a complete absence of RAMP3 has no effect on survival. RAMP3-null mice appear normal until old age (9-10 months), at which point they have less weight than their wild-type littermates [54]. These results provide support to the hypothesis that RAMP2 and RAMP3 have distinct physiological functions in embryogenesis, adulthood, and old age.

To continue with the study of the lack of AM in adult tissues and organisms, tissue-specific conditional KO models have been generated using Cre/loxP technology [55]. For example, loss of AM receptor resulted in abnormal jugular lymphatic vessels in association with reduction in lymphatic endothelial cell proliferation [43]. Another report, by Fernández et al., showed that lack of AM in the mouse nervous system results in behavioural changes, anxiety, and lower survival under stress conditions [56]. In addition, AM suppression causes significant infarct size increase following cerebral artery occlusion [57].

2.6. Physiological Activity of Adrenomedullin. In the adult organism, AM has been located in many cell types and in most tissues throughout the body [58]. This distribution suggests that AM has diverse physiological activities and that it needs a tight regulatory system. The locations of AM expression include the nervous system and related structures, cardiovascular system, endocrine organs, digestive tube, excretory system, respiratory system, reproductive tract, and integument, among others.

AM has a variety of biological actions which are of potential importance for cardiovascular homeostasis, growth and development of cardiovascular tissues, and regulation of body fluid. Systemic AM administration has demonstrated that this peptide reduces arterial pressure, decreases peripheral vascular resistance, and increases heart rate and cardiac output [59]. In vitro, AM dilates blood vessels of different vascular beds from different animal species. Regarding the mechanism of the vasodilatory effect of AM, most data indicate that AM may induce endothelium-independent relaxation by acting on CGRP1 receptors and elevating cAMP level in vascular smooth muscle cells [17]. In addition, AM binds to specific receptors in endothelial cells and elicits endothelium-dependent vasorelaxation mediated by nitric oxide [60], endothelium-derived hyperpolarizing factor [61], and/or vasodilatory prostanoids [62]. On the other hand, accumulating evidence supports a compensatory role for AM in heart failure. It has been established that plasma AM levels increase in patients with heart failure in proportion to the severity of the disease. Furthermore, recent studies suggest that plasma AM level is an independent prognostic indicator of heart failure. This peptide may regulate myocardial hypertrophy and remodelling in arterial hypertension or heart failure in a paracrine/autocrine way [63].

AM exerts a tight control on renal function and body fluid volume. First, AM exerts direct control over the kidney, affecting diuresis and natriuresis. Furthermore, AM may regulate the hypothalamic-pituitary-adrenal axis at all levels. It has been demonstrated that intracerebral infusions of AM inhibit salt intake and thirst. In the pituitary, AM is able to inhibit the secretion of vasopressin and ACTH, whereas in the adrenal gland it regulates the secretion of aldosterone [64].

AM regulates hormone secretion in many tissues and organs. Levels of this peptide have effects in the hypothalamic-pituitary-adrenal axis as shown above. In addition, AM is synthesized in pancreatic polypeptide-producing F cells of the pancreatic islets and AM receptors are expressed in insulin-producing β-cells. Incubation with a monoclonal antibody against AM raised five times the basal insulin secretion by islets [65]. This indicates that endogenous AM tonically inhibits insulin secretion.

In the reproductive tract, AM is synthesized by the granulosa cells of the ovarian follicles. Plasma AM level increases during the follicular phase and decreases during the luteal phase of the menstrual cycle [66]. Both AM and its receptors are expressed in the uterus and their expression is higher during pregnancy [67]. AM can also be detected in the placenta and in many fetal tissues suggesting that it may be involved in growth and embryogenesis [68].

In the digestive system AM immunoreactivity is widely distributed in the mucosal and glandular epithelia of the stomach, esophagus, intestine, gallbladder, bile duct, and acini of the pancreas and salivary glands [69]. AM is a potent inhibitor of basal gastrin-stimulated HCl secretion [70].

Finally, AM has been found in all epithelial surfaces which separate the external and internal environment and in all body secretions. This wide distribution suggests the possibility that AM has an immunity-related function. It has been proven that both AM and PAMP display potent antimicrobial action against Gram-positive and Gram-negative bacteria [71]. In septic shock patients, a marked elevation of AM blood levels have been reported, probably as a defensive action [72]. However, excessive AM release during septic shock may provoke adverse effects such as hypotension which may threaten the patient’s life.
3. Adrenomedullin in the Central Nervous System

AM and its receptors are abundantly expressed in the CNS and its cellular components. By a combination of techniques it has been proven that AM appears from day 10 of embryonic development in maturing cells of the ventral horn of the spinal cord and by day 14 mRNA for AM and its receptors could be observed in specific neuron groups [73]. This was followed by the demonstration of the presence of human AM mRNA in the following regions: frontal, temporal and occipital cortex, pons, thalamus, hypothalamus, cerebellum, and in the pituitary gland [74]. With respect to the rat cerebral cortex, AM immunoreactivity was shown to be widely distributed in all areas under basal conditions. In particular, high levels of immunoreactivity were found in the thalamus, hypothalamus, adenohypophysis, and neurohypophysis [75].

Given the wide distribution of AM immunoreactivity in the adult CNS, it has to be admitted that the function of AM at most of these sites is still largely unknown. It is apparent that AM can act as a neurotransmitter, neuromodulator or neurohormone; but in sight of its ample distribution, it could have other functions apart from these. The prominent localization of AM in dendritic structures and the cytoskeleton also argues against an exclusive role as a neurotransmitter [75].

The AM system may be especially important in cerebral circulation. The concentration of AM is about 50% higher in cerebral blood vessels than in other regional circulations due to an astrocyte-derived elevation of AM production by cerebral endothelial cells [76]. However, the biological actions of AM in cerebral blood vessels have only been partially defined.

AM, as an endothelium-derived autocrine/paracrine hormone, plays an important role in the regulation of specific blood-brain barrier properties [77]. AM may be one of the physiological links between astrocyte-derived factors, cAMP and the induction and maintenance of the blood-brain barrier. Moreover, the role of AM in the differentiation and proliferation of peripheral endothelial cells and in angiogenesis suggests a more complex function for AM in the cerebral circulation and in the development of blood-brain barrier [78].

The hypotensive effect of AM in the periphery is not paralleled in the brain. Both, AM and PAMP, given by intracerebroventricular (icv) infusions, exerts significant hypertensive actions in conscious animals by a central action which stimulates α-adrenergic, sympathetic function. In addition to increasing blood pressure after icv administration, both peptides stimulated significant increases in heart rate in these conscious, unrestrained animals [79]. Direct effects of AM centrally administered on sympathetic nerve activity in conscious rats were observed and these data suggest that icv AM induced an increase in preganglionic sympathetic discharge [80]. The temporal aspects of CNS-induced hypertension by AM are similar to those effects seen after the administration of angiotensin II [79, 80]. This suggests a possible common mechanism for the hypertensive action of both peptides in the brain.

Regarding cerebral physiopathology, using the rat focal stroke model of middle cerebral artery occlusion (MCAO), Wang et al. [81] showed increases in AM mRNA expression in the ischemic cortex. Immunohistochemical studies localized AM to ischemic neuronal processes. However, this study reports that AM exacerbates focal brain ischemic damage, in contrast with all other posterior studies. Two years later, Dogan et al. [82] reported in a MCAO model that pre- and postinfusions of AM decreased the volume of ischemic brain injury, partly by increasing regional cerebral blood flow in a dose-dependent manner in rats. More recent studies have definitely proven the protective role of AM in ischemic brain. In transgenic mice that overproduce AM, the infarct area and gliosis after MCAO were reduced, in association with suppression of leukocyte infiltration, oxidative stress and apoptosis in the ischemic core. In addition, vascular regeneration and subsequent neurogenesis were enhanced, preceded by increase in mobilization of CD34+ mononuclear cells (which are endothelial cell precursors). Brain edema was also significantly reduced via suppression of vascular permeability [83]. On the other hand, Hurtado et al. [57] studied the effect of AM and its binding protein, complement factor H, in the physiopathology of stroke using a brain-specific conditional KO for AM and a complete KO for factor H. They found that animals lacking AM had got a significant infarct size increase compared with their WT littermates following middle cerebral artery occlusion. In contrast, lack of complement factor H did not affect infarct volume. They suggest that the neuroprotective action of AM in the brain may be mediated by regulation of iNOS, matrix metalloproteases, and inflammatory mediators [57].

Fos protein and NO-producing neurons of the rat brain, which are involved in cardiovascular regulation, are also induced by central administration of AM. Following icv administration of AM, Fos-like immunoreactive neurons were markedly increased in several brain areas of the rat, including the forebrain, the hypothalamus, and the brainstem [84, 85]. In the same conditions, the number of double-labeled neurons for Fos and NO synthase was increased in the paraventricular and supraoptic nuclei [86].

AM is hypothesized to be a physiologically relevant regulator of fluid and electrolyte homeostasis. Centrally administered AM inhibits water drinking [87] and salt appetite [88]. In addition, inactivation of endogenous AM increases water and sodium intake, suggesting that AM tonically inhibits thirst and salt intake [89]. AM may therefore participate in the central control of fluid balance by a variety of mechanisms. This peptide has direct actions in the hypothalamus to decrease vasopressin secretion and in the pituitary gland to inhibit ACTH release [90]. AM is also able to inhibit water intake after a hypovolemic challenge or a hyperosmotic challenge [87] and could diminish angiotensin II-stimulated water intake in a dose-dependent manner [90]. Another potential target for AM seems to be the area postrema which is involved in many vegetative functions, such as cardiovascular control and eating and drinking behaviour [75].

Icv injection of AM also causes a dose-dependent reduction in feeding in rats [91]. This effect is attenuated
by administration of CGRP$_8$-$37$ showing that AM action is mediated by CGRP receptors. In the same way, Martinez et al. [92] reported that AM inhibits gastric emptying in conscious rats in a dose-dependent manner by acting through adrenal-dependent, β-adrenergic pathways independently of central CRF receptors activation.

Recently, AM has been reported to exert actions at each level of the hypothalamic–pituitary–adrenal (HPA) axis [93]. These data suggest that the peptide plays a role in the organization of the neuroendocrine responses to stress. AM acts within the hypothalamus of unrestrained male rats to increase HPA axis activity. AM given icv stimulates the release of prolactin but does not alter the secretion of GH, thus demonstrating the specificity of AM within the hypothalamus [94]. The role of AM in the modulation of HPA axis activity appears to be quite complex. Icv administration of AM elevated plasma corticosterone levels, which suggests that AM acts within the hypothalamus to stimulate CRH release into the hypophyseal portal vessels, thus increasing activity of the HPA axis [94]. In addition, AM has been shown to induce Fos expression in CRH-positive hypothalamic paraventricular neurons [95] and AM directly caused depolarization of parvocellular paraventricular neurons in brain slices [96]. It can be concluded that AM produced in the brain may be an important neuromodulator of the hormonal stress response.

These results are also supported by the experiments of Fernández et al. [56]. They built a conditional KO mouse model using the Cre/loxP approach, obtaining animals with no AM nor PAMP expression in the CNS but normal levels in other organs. These genetically modified animals appear to have normal lives and do not present any gross morphological defect. Despite the normal appearance, behavioral analysis show that mice with no AM in their brain have impaired motor coordination and are hyperactive when compared to their wild-type (WT) littermates. Interestingly, heterozygous mice behave exactly as WT animals, suggesting that even a partial presence of AM during brain development is enough to prevent damage. Another characteristic of the mice lacking AM in the brain is their excessive anxiety levels. As seen before, icv administration of AM release stress hormones like corticosterone [94]. This clearly suggests that brain AM limits the magnitude of the stress response. Furthermore, KO mice had lower survival rate under hypobaric hypoxia conditions, demonstrating once again the neuroprotective function of AM in the CNS [56].

AM mRNA and protein have been shown to be expressed in dorsal root ganglia which contains nociceptors [97]. This pattern of expression has led researchers to hypothesize that AM could play a role in nociception. Ma et al. [98] demonstrated the presence of AM-like immunoreactivity in both CGRP-containing and lectin IB4-binding nociceptors in dorsal root ganglion and axon terminals in the superficial dorsal horn of the rat spinal cord. Likewise, immunoreactivity for receptor markers such as CLR and the three RAMPs is localized in the superficial dorsal horn. These results supply anatomical evidence that AM may be a pain-related neuropeptide. Moreover, intrathecal injection of AM induces a long-lasting heat hyperalgesia in rats. AM-induced pain response is mediated by a direct activation of AM receptors located on nociceptive neurons in the dorsal horn and through the activation of the PI3K/Akt/GSK3β signalling pathway. They also suggested that AM potentially induces the release of other pain-stimulating substances such as substance P or glutamate.

Following this line of thought, Fernández et al. [99] explored pain sensitivity in a mouse conditional KO model for AM in neurons of the CNS, including the spinal cord and dorsal root ganglia. Elimination of the AM gene in the CNS of the mouse results in expression changes for several sensory neurotransmitters, including CGRP, substance P, and enkephalin, in the dorsal root ganglia and the spinal cord. Furthermore, lack of AM expression has behavioral consequences when pain sensitivity was tested with the tail-flick and the hotplate latency paradigms. The results of the test suggest the possibility that AM acts as a nociceptive modulator in spinal reflexes, whereas it may have an analgesic function at higher cognitive levels [99]. This study confirms the important role of AM in pain sensitivity processing, but presents a more complex function of AM than previously described.

As seen above, AM is involved in many functions in the CNS, and it also exerts some peripheral actions through CNS mechanisms. However, there is still much work to do in the area to fully understand all the roles that AM play in the nervous system.

4. Adrenomedullin and Stem Cells

4.1. General Aspects about Stem and Progenitor Cells. Stem cells are defined by their ability to self-renew and to differentiate into many functional cell types in response to specific signals [100]. In general, stem cells produce one or more intermediate cell types before reaching the fully differentiated state which is characteristic of adult tissues. These intermediate differentiation steps are known as progenitor cells.

During the last years, stem cells have been found in many organs and tissues, such as bone marrow, peripheral blood, umbilical cord, brain, spinal cord, dental pulp, blood vessels, skeletal muscle, gut epithelium, epidermis, cornea, retina, liver, pancreas, adipose tissue, hair follicle, mammary gland, ovary, prostate, and testis [101]. Among the main functions of these cells, the most relevant is the replacement of tissue cells which die naturally as part of tissue’s homeostasis or because of an injury or illness. Stem cells are therefore indispensable for the integrity of complex and long-living organisms.

In mammals, several stem cell niches can be found. The niche microenvironment plays a critical role in cell maintenance and differentiation since it is composed of a specialized group of cells that regulate stem cell survival, self-renewal, and differentiation [102, 103]. Strong evidence suggests now that the niche is indispensable for stem cells regulation [104]. Regulation from the niche includes growth factor signalling, cell-to-cell contact, and cell-to-extracellular-matrix
interactions for homeostatic cell turnover and increased cell production in response to stimulation [105].

Many molecules have been described to regulate stem cell behavior. The main signals are Shh, Wnts, bone morphogenic proteins, transforming growth factor (TGF) beta, angiopoietin-1/Tie2, fibroblast growth factors, SCF/c-kit, Jagged/Notch, insulin/insulin-like growth factors, and leukemia inhibitory factor through the JAK-Stat pathway [11, 101, 106–109].

4.2. AM as a Growth and Development Factor. From the beginning, it was thought that AM was an important tumor growth factor [110]. Nowadays it is well known that AM stimulates proliferation of fibroblasts, keratinocytes, endothelial cells, osteoblasts, and many tumor-derived cells [14].

In Swiss 3T3 cells, AM increases DNA synthesis in a dose-dependent manner by increasing cAMP/PKA [111]. AM also stimulates DNA and cAMP synthesis in human keratinocytes [112]. These data provide evidence for a growth-promoting effect of AM, possibly mediated through cAMP.

However, in some cell types such as VSMC, mesangial cells, glial cells, and glial tumor cells an inhibitory effect was observed for AM on proliferation and growth [14].

Therefore, the role of AM as a growth factor, depends on the cell type.

In addition, AM has also been proposed as an important factor in embryogenesis and differentiation [73, 113] and as an apoptosis survival factor [114]. In conclusion, there is no doubt about the role of AM in cell and tumor growth, and this might be related with a possible role of AM in the growth and differentiation of stem cells.

4.3. Adrenomedullin and Endothelial Progenitor Cells (EPCs). EPCs are precursor cells which are found in circulating blood and/or in the bone marrow. EPCs are mobilized from the bone marrow into the peripheral blood in response to tissue ischemia or traumatic injury, migrating to injured endothelium sites and differentiating into mature endothelial cells in situ.

Because of the main role of AM in endothelial cell biology, the number of investigations studying the role of AM in the physiology of EPCs are increasing.

The first discoveries were that AM increases the number of early EPCs and also suppresses their apoptosis [115, 116]. AM could exert its actions on EPCs because these cells express CLR on their surface [117].

Nagaya et al. [116] studied the effects of AM gene-modified EPCs on the treatment of pulmonary hypertension in rats. Intravenous administration of AM-expressing EPCs significantly decreased pulmonary vascular resistance compared with EPCs alone and the AM-expressing cells ameliorated pulmonary endothelium regeneration. In addition, rats with pulmonary hypertension transplanted with AM-expressing EPCs had a significantly higher survival rate. All these results taken together suggest that AM gene transfer into EPCs inhibits cell apoptosis and induces proliferation and migration so that AM gene transfer strengthens the therapeutic potential of EPCs.

Given that AM inhibits vascular endothelial apoptosis and induces angiogenesis, some studies investigated whether AM enhances bone marrow cell-induced angiogenesis after transplantation in a rat model of hindlimb ischemia [115]. Bone-marrow-derived mononuclear cells (MNCs) also express CLR. In vivo, rats which received AM infusion plus MNC transplantation showed a significantly higher laser Doppler perfusion index than the control groups and had an important improvement in blood perfusion. Also, capillary density was highest in the AM plus MNC transplantation group. The combination of AM infusion and MNC transplantation enhances MNC-induced angiogenesis. Furthermore, AM increased the number of MNC-derived von Willebrand factor-positive cells and generated α-SMA-positive vascular structures. The same group studied the action of AM in cultured MNCs [115]. In vitro, AM inhibits serum starvation-induced MNC apoptosis. The increase in MNC survival achieved by AM depends on the PI3K/Akt pathway. AM also increases MNC adhesiveness to endothelial cells via activation of adhesion molecules such as ICAM-1 and VCAM-1. MNC adhesiveness to endothelial cells is indispensable for MNC differentiation into the endothelial lineage. In addition, AM may accelerate MNC differentiation into endothelial cells since it increases the number of MNC-derived EPCs that express VE cadherin, KDR and CD31.

The same results were obtained after transplantation of mesenchymal stem cells (MSCs) for improving neurological deficits after stroke in rats [6]. The group of animals which received AM plus MSC transplantation had a significant improvement in their health status. They also showed a marked induction of angiogenesis, and AM infusion significantly inhibited apoptosis of transplanted MSCs.

Taken together, these data suggest that AM enhances the therapeutic potency of MNCs and MSCs through inhibition of apoptosis, induction of angiogenesis, and adhesion and differentiation improvement [6, 115].

Direct transplantation of EPCs seems to be a useful strategy for therapeutic neovascularization in ischemic tissue [117]. EPCs have been successfully used in the treatment of renal ischemia after acute kidney injury [118], myocardial regeneration [7, 119–122], and in therapeutic angiogenesis in diabetes [123]. The coadministration of AM enhances the angiogenic effects of EPCs, improves their mobilization, and helps in the development of collateral vessels [115, 116, 119, 124, 125]. In a model of hindlimb ischemia induced by resecting the right femoral artery [126], AM overexpression significantly enhanced the recovery of blood flow and increased capillary density in the ischemic leg. The results of Abe et al. [126] suggest that AM-induced angiogenesis may be associated with mobilization of bone marrow-derived cells. Treatment with AM increased bone-marrow-derived cells in the ischemic tissue, which expressed the endothelial-cell-specific protein CD31. This treatment also increased the number of Sca1 and c-kit double positive cells in peripheral blood and bone marrow. There is a possibility that the mobilization of EPCs is modulated by NO. In eNOS-deficient mice, bone marrow transplantation itself is not enough to recover the ischemic tissue [127]. It would be possible that EPC mobilization promoted by AM
may be related to AM-induced NO release via activation of the PI3K/Akt pathway [126].

Tumors, besides recruiting neighboring blood vessels or epithelial cells, also incorporate EPCs into the developing vasculature. This process is dependent on the mobilization of VEGFR2+ and CD133+ cells into circulation. The use of an AM antagonist in vivo significantly reduces tumor growth and microvessel density. In tumor endothelial cells isolated from renal cell carcinoma xenografts both proliferation and migration were blocked by treatment with an AM antagonist [128]. The antagonist also reduced the number of circulating CD133+ and VEGFR2+ cells which demonstrates the importance of AM in the mobilization of EPCs [128].

AM is also involved in the vascular differentiation from progenitor cells. Yurugi-Kobayashi et al. [129] studied in vitro the acquisition of arterial or venous identity by endothelial cells induced from VEGFR2+ progenitor cells. Whereas VEGF alone mainly induced venous endothelial cells, addition of AM, which elevates cAMP, supported substantial induction of arterial endothelial cells. Stimulation of cAMP pathway induced Notch signal activation in endothelial cells. All these data indicate that coordinated signalling of VEGF, Notch, and cAMP is required to induce arterial endothelial cells from vascular progenitors. However, more research is needed to understand how arterial differentiation is achieved in the living organism.

In the skin, sensory nerves play a main role in the pattern of arterial differentiation [130–132]. Nerves and blood vessels are branched structures. Arteries, but not veins, are specifically aligned with peripheral sensory nerves in embryonic mouse limb skin. Several lines of evidence suggest that this association reflects a requirement for the nerve to induce arterial differentiation. In mutants lacking peripheral sensory axons and/or Schwann cells, arterial differentiation does not occur and remodelling appears abnormal. Furthermore, in vitro, purified peripheral sensory neurons or Schwann cells can induce arterial marker expression in cultured endothelial cells [130]. The fact that this induction can be blocked by a specific VEGF antagonist suggests that nerve-promoted arteriogenesis may be mediated by local secretion of VEGF. It has also been proven that VEGF is necessary for arterial differentiation of a primitive capillary plexus in vivo [131]. Nerves may promote blood vessel association and arterial differentiation shortly after their arrival in the periphery in order to ensure access to a local source of survival factors during their growth. The idea that AM may be related in this process cannot be excluded, since many perivascular nerves in the rat mesenteric artery show AM-like immunoreactivity [132].

Very recently, it has been confirmed that AM could augment the growth and angiogenic properties of late outgrowth EPCs as potently as VEGF [133]. Hermansen et al. [134] confirmed that cultured EPCs possess an endothelial phenotype and express the AM receptor complex CLR/RAMP2. AM stimulation induced proliferation of EPCs and increased the formation of tubular networks in the EPC/fibroblast coculture and matrigel assays. These effects seem to be mediated through the PI3K/Akt signalling pathway.

Considering all this information, it is possible to assume that AM has a main role on growth, mobilization, and differentiation of EPCs, which leads us to propose that AM may be a relevant therapeutic target for the treatment of vascular diseases.

4.4. Adrenomedullin and Mesenchymal Stem Cells (MSCs). Mesenchymal stem cells (MSCs) are adult stem cell with capacity of self-renewal and differentiation into mesoderm- and nonmesoderm-derived tissues. They also play an important role in endogenous maintenance of stem cells niches.

There is a strong interest in searching for potential therapeutic effects of MSCs. Mobilization of endogenous MSCs represents an alternative treatment for the regeneration of injured growth plate cartilage [135]. Different aspects of MSCs render them an appropriate cell type for clinical use to promote bone regeneration [136]. Since 1995 it has been known that under in vitro conditions, MSCs can differentiate into cells exhibiting features of cardiomyocytes. After this seminal work, several preclinical and clinical studies have supported the notion that MSC therapy may be used for cardiac regeneration [128, 137–139]. In vitro works suggest that a great variety of stimuli such as insulin or fibronectin, and direct cell-to-cell contacts induce the differentiation of MSCs into cardiomyocytes. The stem cells which acquired a cardiomyocytes-like phenotype were characterized by the expression of myosin heavy chain, beta-actin, and troponin T [137]. Studies in animal models have demonstrated the ability of transplanted or infused MSCs to engraft and differentiate into cardiomyocytes, VSMCs, and endothelial cells [137, 140] and to secrete factors such as VEGF, FGF, MCP-1, HGF, IGF-1, SDF-1, thrombopoietin, and AM, to reduce tissue injury and/or enhance tissue repair [125, 138]. These factors stimulate cell adhesion, neoangiogenesis, and formation of inflammatory infiltrate without tissue necrosis. The molecular pathways that regulate MSC-mediated regeneration are, however, poorly understood. Recently, Alfaro et al. [139] demonstrated in a murine myocardial infarct model that downregulation of the canonical Wnt pathway, characterized by significant upregulation of specific secreted frizzled-related proteins (sFRPs), was necessary for MSC self-renewal. Using a genetically modified mouse model they found that sFRP2, an inhibitor of Wnt signalling, is a key molecule for the biogenesis of a superior regenerative phenotype in MSCs.

Several studies have investigated the role of AM in MSC transplantation. MSCs are able to secrete large amounts of angiogenic and antiapoptotic factors, including AM [125]. It has been proven that AM enhances the therapeutic potency of MSC transplantation in experimental stroke in rats [6]. AM induces angiogenesis in the ischemic tissue and significantly inhibits the apoptosis of transplanted MSCs. PI3K/Akt is an important cell survival pathway in MSCs that seems to mediate cytoprotective effects in these cells [141]. AM is able to activate the PI3K/Akt pathway, so it is reasonable to think that AM may promote MSC survival and help to cardiac repair through this pathway.

Adipose tissue-derived stem cells (ASCs) are also adult stem cells with capacity for self-renewal and differentiation,
like MSCs. Both have similar characteristics, but ASCs are
closer to the endodermal and/or early hepatic differentiation
stages. As with MSCs, extensive research has been done to
find therapeutic roles for ASCs. Undifferentiated ASCs
have the ability to improve hepatic function in mice with
acute liver injury in a short-time span [142]. After the
transplantation of ASCs into mice with acute liver failure,
markers of liver injury decreased. In addition, injection of
ASCs into the corpus cavernosum seems to be a potential
therapy for the treatment of erectile dysfunction in rats
with hyperlipidemia [143] and with Streptozotocin-induced
diabetes [144]. This functional restoration is associated with
improvements in the histology of the cavernous body, and an
increased expression of VE markers such as VE-cadherin
and endothelial nitric oxide synthase. In a KO model of
AM, the effect of AM-null ASCs on erectile dysfunction was
significantly diminished. Furthermore, an overexpression of
AM in the same cells significantly improved erectile
function in the diabetic rats [144]. These results suggest that
AM secreted by ASCs plays a main role in the restoration
of erectile function. ASCs have also been used for the
regeneration and repair of infarcted heart but its efficiency
is under debate. The major problem is the poor survival rate
of implanted cells. Overcoming this problem may improve
stem cell therapy [145]. As AM is a factor that improves
the survival in most cells, one might think of it as a way
to improve ASC-induced cardiac regeneration. However, the
role of AM in proliferation or apoptosis of ASCs has not been
tested yet.

4.5. Adrenomedullin and Hematopoietic Stem and Progenitor
Cells. Hematopoietic stem cells (HSCs) possess the unique
capacity to undergo self-renewal in vivo throughout the life
of an individual while also providing the complete repertoire
of mature hematopoietic and immune cells.

Previous attempts to identify the soluble factors that
regulate HSC self-renewal have been poorly successful.
Chute et al. [146] demonstrated that primary human brain
endothelial cells (HUBECs) support the ex vivo amplification
of primitive human bone marrow and cord blood cells
and they analyzed the gene expression of HUBEC trying to
find factors with hematopoietic activity. Functional analyses
demonstrated that AM synergizes with stem cell factor
and Flt-3 ligand to induce the proliferation of primitive
human CD34+CD38-lin-cells and promotes the expansion
of CD34+ progenitors in culture.

Apart from bone marrow, cord blood is an important
source of HSCs and an alternative for allogenic transplanta-
tion. AM, which is also expressed by cord hematopoietic
stem cells, has been used in combination with endothelin-
1 to magnify the cord blood hematopoietic cell middle-
term expansion. This effect seems to be mediated by the
CLR/RAMP system [147]. AM may be used for improving
the expansion of the HSC from the cord blood, which is of
great importance for tissue engineering and clinical use.

In an elastase-induced emphysema mouse model, AM
infusion significantly inhibited the increase in lung volume
and static lung compliance. AM also increased the number of
mononuclear cells, stem cell antigen-1-positive cells in circu-
lating blood, and the number of bone-marrow-derived cells
incorporated into the elastase-treated lung [148]. Addition of
AM to cultured alveolar epithelial cells and endothelial cells
also attenuates elastase-induced cell death [148].

4.6. Adrenomedullin and Adrenocortical Stem Cells. The
theory that adrenocortical homeostasis is maintained by
undifferentiated stem or progenitor cells can be traced back
nearly a century. It is thought that these rare stem cells
remain relatively undifferentiated and quiescent until needed
to replenish the organ. Some experiments suggest that the
adrenocortical progenitors reside in the outer periphery of
the adrenal gland [149]. Early microscopic studies of the
adrenal glands of different vertebrates suggest the presence
of peripheral undifferentiated cells containing conspicuously
large euchromatin-rich nuclei. In addition, the restricted
circumferential expression of preadipocyte factor 1 (Pref-
1) in the glomerulosa of the rat supports the hypothesis
that the glomerulosa layer contains cells on different degrees
of differentiation. Moreover, experiments using radioactive
thymidine indicate that subcapsular cells of the rat adrenal
replenish the neighboring steroidogenic zones, suggesting
that this population provides a pool of progenitors that serve
to maintain the functional capacity of the cortex [149].

AM gene expression changes during rat adrenal regen-
eration after enucleation and contralateral adrenalectomy
[150]. AM mRNA expression suffers a marked rise between
days 1 and 5 of the regeneration. During the early stages
of regeneration, local stem cells are exposed to relative hypoxia
and enucleation induces an inflammatory response. Both
hypoxia, via HIF, and inflammation, through NO pathways,
are known to upregulate AM gene expression [62, 151].

The increase in AM gene transcription and translation may
be considered one of the early events in the enucleation-
induced activation of local adrenocortical stem cells. Fur-
thermore, the two AM receptors complex, CLR/RAMP2
and CLR/RAMP3, are upregulated in enucleated adrenals,
perhaps as a response to the increased local production
of AM [152]. The concerted increase in AM and its
receptors expression might improve the autocrine/paracrine
mechanisms by which AM enhances proliferation of zona
glomerulosa stem cells during adrenal regeneration.

5. Adrenomedullin and Neural Stem
Cells (NSCs)

The dogmatic view of an ever-immutable neural tissue in
mammals is now been replaced by the notion that cell
turn over, including neurons, does occur in the mature
CNS throughout the adulthood, thanks to the persistence of
precursor cells that possess the functional characteristics
of neural stem cells (NSCs) within restricted brain areas [10].
The generation of a particular class of neuron or glial cell
from a multipotent progenitor is a complex process that
can be subdivided into a series of sequential steps. First,
progenitor cells acquire unique positional identities through
a process of spatial patterning. Multipotent progenitors
produce daughter progenitor cells that are restricted to produce only one of the primary neural cell types, neurons, oligodendrocytes, or astrocytes [10]. Committed neuronal progenitors also become specialized to produce neurons of a particular kind. Neural progenitors stop dividing, migrate towards more differentiated areas, and then initiate a programme of terminal differentiation [153].

In the adult mammalian brain, neurogenesis occurs in the subgranular zone (SGZ) of the dentate gyrus of the hippocampus and the subventricular zone (SVZ) of the lateral ventricles [10, 154]. The SVZ is the adult brain region with the highest neurogenic rate and it represents a remnant of the embryonic germinal neuroepithelium. From the SVZ, newly generated neurons reach their destination in the olfactory bulb (OB) after a long migration through the rostral migratory stream [10]. Neurons born in the adult SGZ migrate into the granule cell layer of the dentate gyrus and become dentate granule cells [154]. Neurogenesis declines with aging in both the SVZ and the SGZ [154].

Postnatal neurogenesis is subject to tight regulation, confined to isolated microenvironments, and is sensitive to neuronal activity, stress and aging. This control may be required to prevent network instability, maintain memory and behavioral patterns, and prevent tumorigenesis. Numerous researches are trying to find the molecular mechanisms that regulate NSC self-renewal, proliferation, progressive maturation, and terminal differentiation. These studies have identified many growth factors, cell signals, and transcription factors, which regulate neurogenesis [11]. After intracerebral administration of growth factors such as EGF, FGF2, or TGF-α, cell proliferation in the SVZ is dramatically increased and the progeny fate can change depending on the type of factor used [10]. Cultured neurospheres (Figure 1) synthesize FGF2/EGF which regulate endogenous cytokines that participate in the growth and differentiation of the neurosphere cells [155]. Some angiogenic proteins with neurotrophic effects, such as VEGF and AM, have been shown to stimulate proliferation and neuroblast production in the SVZ, while IGF-1 promotes proliferation and migration in the same niche [11]. Neurogenesis also responds to other cell signals such as neurotransmitters. While GABA and glutamate may not control the fate commitment of stem cells or progenitor cells, they could control the synthesis and release of other diffusible molecules such as growth factors. In addition, they can control the expression of transcription factors and other intracellular molecules such as microRNAs [11]. Emerging epigenetic mechanisms are critical for orchestrating nearly every aspect of neural development and homeostasis, including brain patterning, neural stem cell maintenance, neurogenesis and gliogenesis, neural subtype specification, and synaptic and neural network connectivity and plasticity [156]. Recent evidence indicates that combinations of transcription factors of the homeodomain (HD) and basic helix-loop-helix (bHLH) families establish molecular codes that determine, both where and when the different kinds of neurons and glial cells generated [157].

NSCs differentiate into three distinct cell types as seen above: neurons, astrocytes, and oligodendrocytes [10].

The proportion of each lineage varies considerably depending on internal and external cues.

The generation of different cell types depends first on the presence of proneural factors, which integrate spatial and temporal cues and transform this information into neuronal subtype-specific differentiation programmes [157]. A number of progenitor proteins have been shown to select the cell types produced by progenitors of different domains in the neural tube. Among the best studied are the HD proteins Pax6 and Nk2 homeobox 2, as well as the bHLH protein oligodendrocyte transcription factor 2 (Olig2) [158]. Pax6 expression in mouse spinal cord progenitors induces the formation of neurons whereas the loss of Pax6 results in reduced neurogenesis and increased oligodendrocyte and astrocyte formation [158]. Loss of Olig2 in the mouse spinal cord results in the absence of both motor neurons and oligodendrocytes [158]. Once a progenitor cell has acquired a particular neural or glial identity, the next step is to arrest cell division and to initiate a programme of terminal differentiation [157]. Transcription factors of the bHLH family have a main role in the differentiation of neural progenitors into neurons [106]. The expression of proneural bHLH proteins, that in the mouse include Mash1, Ngn1-3, and Math1, is both necessary and sufficient to enhance the generation of differentiated neurons. Ngn2 expression in proliferating neuronal progenitors in the hippocampus support the idea that it plays a significantly role in adult neurogenesis [154]. The expression of Mash1 or Ngn2 in forebrain progenitor cells promotes the generation of GABAergic and glutamatergic neurons respectively [159]. The downstream effectors of proneural genes in the telencephalon include members of the Notch and Wnt pathways, adhesion proteins, and transduction factors [160]. Proneural genes also control later aspects of the neurogenesis process, including the arrest of progenitor division, migration of
progeny of OBSCs [168]. The progeny of stem/progenitor astrocytes or oligodendrocytes [168].

In vitro proportions of oligodendrocytes than cells from WT animals. Lowered oxygen tension enhances dopaminergic differentiation and survival of NSCs in a human ventral mesencephalic stem cell line. AM gene expression may be influenced by HIF-1 during NSCs growth and differentiation suggesting a possible role for AM in this process.

Furthermore, the KO mice for AM in the CNS shows morphological changes in some areas of the brain with tubulin hyperpolymerization and an increase on Glu-tubulin immunoreactivity [56]. These data can be explained because interactions between AM and several microtubule-associated proteins (MAPs) and between PAMP and tubulin have been found [172]. Downregulation of the gene coding for both, AM and PAMP, through small interfering RNA technology results in morphological changes, microtubule stabilization, increase in posttranslational modifications of tubulin, reduction of cell motility, and partial arrest at the G2 phase of the cell cycle [172]. Cell cycle and cell migration, two cell features that require the intervention of the cytoskeleton, are very important events for all stem cells and, therefore, a defective cytoskeleton may endanger the features and functions of stem cells. Moreover, the cytoskeleton is a main point in the formation and maintenance of mature neural cells morphology and dendritic processes, and its defective function may alter both the morphology and physiology of nerve cells [173]. Although membrane receptors activated by AM and/or PAMP cannot be completely excluded, these data suggest that both peptides may have an intracellular contribution to cell growth regulation by allowing cells to pass through mitosis [172]. The AM gene-null cells show important changes in their cytoskeleton, with tubulin hyperpolymerization and changes in the actin cytoskeleton [168]. Modifications in the tubulin and actin cytoskeleton may lead to profound changes in the morphology of the stem/progenitor cells which show modifications in the cell shape and they display abundant filopodia [168].

Surprisingly, there are not apparent morphological changes in neurons or astrocytes derived from neurospheres lacking AM and PAMP, but the oligodendrocytes present serious modifications with shorter and less numerous cell processes. Both microtubules and microfilaments are extremely important for oligodendrocyte morphogenesis, and the differences observed in the cytoskeleton of the stem cells may be responsible for the immature phenotype described for oligodendrocytes lacking the AM gene [168]. The morphological and proliferative characteristics of the AM KO cells do not revert when synthetic AM is added to the culture medium, in contrast with what occurs with the percentage of cells of the three lineages produced by the neurospheres [168]. This suggests the existence of a molecular switch where AM signalling to the culture medium. These data indicate the existence of a molecular switch where AM signalling stimulates neural precursors to generate either neurons and astrocytes or oligodendrocytes [168].

Otaegi et al. [169] found that the PI3K/Akt pathway is involved in OBSC differentiation into neurons and astrocytes. As AM signalling involves the activation of Akt [170], it is possible that AM regulates the proportion of OBSC progeny through this mechanism.

Hypoxia, via HIF-1, is known to upregulate AM gene expression [151] and, recently, it has been described that physiologic hypoxic conditions, which stimulates HIF-1 production, could strongly influence the growth of neural stem cells and their differentiation mechanisms both in vivo and in vitro [171]. Lowered oxygen tension enhances dopaminergic differentiation and survival of NSCs in a human ventral mesencephalic stem cell line. AM gene expression may be influenced by HIF-1 during NSCs growth and differentiation suggesting a possible role for AM in this process.
of distinct mechanisms regulating AM-mediated stem cell differentiation and morphology. Cell fate may be mediated through the membrane receptor and the activation of the PI3K/Akt pathway, whereas morphological features and cell cycle might be more dependent on the intracellular pool of these peptides.

Taken together, these data demonstrate that AM is an important factor in regulating the proliferation and differentiation of adult NSCs or adult neural progenitor cells (Figure 3), and that AM might be used to modulate stem cell renewal and fate in an attempt to produce and control neural stem cells for regenerative therapies.

6. Concluding Remarks

AM and its receptors are widely distributed throughout the CNS. AM regulates some properties of the blood-brain barrier, increases preganglionic sympathetic discharge, exerts neuroprotective actions in the brain against stroke damage, and regulates fluid balance and electrolyte homeostasis when centrally administered. Recently, it has been reported that AM can organize the neuroendocrine response to stress and play a role in nociception.

These facts and the idea that AM acts as a growth factor and as cell fate determinant for a number of stem and progenitor cells lead us to hypothesize that AM may regulate NSC growth and differentiation.

In this paper we have shown that AM can modify the proportion of each lineage of neurons, astrocytes, and oligodendrocytes produced from undifferentiated progenitor cells, probably through the membrane receptors for AM and the activation of the PI3K/Akt pathway. Furthermore, both AM and PAMP may be able to influence NSC proliferation, growth, and maturation through interactions with the cytoskeleton.

AM could be used for the regulation of growth and differentiation of neural cells derived from neural progenitors as a step towards their potential therapeutic applications in the treatment of a number of neurodegenerative diseases.

Acknowledgment

This study was supported by a Grant from Spain’s Ministry of Science and Innovation, SAF-2009-13240-C02-01.

References

[1] M. Kitada and M. Dezawa, “Parkinson’s disease and mesenchymal stem cells: potential for cell-based therapy,” Parkinson’s Disease, vol. 2012, Article ID 873706, 9 pages, 2012.
[2] N. K. Venkataramana, R. Pal, S. A. Rao et al., “Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson’s disease: a pilot clinical study,” Stem Cells International, vol. 2012, Article ID 931902, 12 pages, 2012.
[3] E. Dantuma, S. Merchant, and K. Sugaya, “Stem cells for the treatment of neurodegenerative diseases,” Stem Cell Research & Therapy, vol. 1, article 37, 2010.
[4] S. Geuna, P. Borrione, M. Fornaro, and M. G. Giacobini-Robecchi, “Adult stem cells and neurogenesis: historical roots
and state of the art,” *Anatomical Record*, vol. 265, no. 3, pp. 132–141, 2001.

[5] P. J. Tsai, H. S. Wang, Y. M. Shyr et al., “Transplantation of insulin-producing cells from umbilical cord mesenchymal stem cells for the treatment of streptozotocin-induced diabetic rats,” *Journal of Biomedical Science*, vol. 19, article 47, 2012.

[6] K. Hanabusa, N. Nagaya, T. Iwase et al., “Adrenomedullin enhances therapeutic potency of mesenchymal stem cells after experimental stroke in rats,” *Stroke*, vol. 36, no. 4, pp. 853–858, 2005.

[7] C. Stamm, B. Westphal, H. D. Kleine et al., “Autologous bone-marrow stem-cell transplantation for myocardial regeneration,” *Lancet*, vol. 361, no. 9351, pp. 45–46, 2003.

[8] U. G. Longo, S. Petrillo, E. Franceschetti, A. Berton, N. Maffulli, and V. Denaro, “Stem cells and gene therapy for cartilage repair,” *Stem Cells International*, vol. 2012, Article ID 168385, 9 pages, 2012.

[9] B. Christ and S. Brückner, “Rodent animal models for surrogate analysis of cell therapy in acute liver failure,” *Frontiers in Physiology*, vol. 3, article 78, 2012.

[10] R. Galli, A. Gritti, L. Bonfanti, and A. L. Vescovi, “Neural stem cells: an overview,” *Circulation Research*, vol. 92, no. 6, pp. 598–608, 2003.

[11] M. Pathania, L. D. Yan, and A. Bordey, “A symphony of signals conducts early and late stages of adult neurogenesis,” *Neuropharmacology*, vol. 58, no. 6, pp. 865–876, 2010.

[12] Y. Takei, K. Inoue, M. Ogoshi, T. Kawahara, H. Bannai, and S. Miyano, “Identification of novel adrenomedulin in mammals: a potent cardiovascular and renal regulator,” *FEBS Letters*, vol. 556, no. 1-3, pp. 53–58, 2004.

[13] J. Roh, C. L. Chang, A. Bhalla, C. Klein, and S. Y. T. Hsu, “Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes,” *Journal of Biological Chemistry*, vol. 279, no. 8, pp. 7264–7274, 2004.

[14] J. P. Hinson, S. Kapas, and D. M. Smith, “Adrenomedullin, a multifunctional regulatory peptide,” *Endocrine Reviews*, vol. 21, no. 2, pp. 138–167, 2000.

[15] K. Kitamura, K. Kangawa, M. Kawamoto et al., “Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma,” *Biochemical and Biophysical Research Communications*, vol. 192, no. 2, pp. 553–560, 1993.

[16] J. López and A. Martinez, “Cell and molecular biology of the multifunctional peptide, adrenomedullin,” *International Review of Cytology*, vol. 221, pp. 1–92, 2002.

[17] I. Bełtowski and A. Jamroz, “Adrenomedullin—what do we know 10 years since its discovery?” *Polish Journal of Pharmacology*, vol. 56, no. 1, pp. 5–27, 2004.

[18] I. Pérez-Castells, S. Martin-Santamaria, L. Nieto et al., “Structure of micelle-bound adrenomedullin, a first step towards the analysis of its interactions with receptors and small molecules,” *Biopolymers*, 2011.

[19] M. Garayoa, A. Martinez, S. Lee et al., “Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis,” *Molecular Endocrinology*, vol. 14, no. 6, pp. 848–862, 2000.

[20] R. Pio, A. Martinez, E. J. Unsworth et al., “Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners,” *Journal of Biological Chemistry*, vol. 276, no. 15, pp. 12292–12300, 2001.

[21] J. Dupuis, A. Caron, and N. Ruef, “Biodistribution, plasma kinetics and quantification of single-pass pulmonary clearance of adrenomedullin,” *Clinical Science*, vol. 109, no. 1, pp. 97–102, 2005.

[22] A. Martinez, H. R. Oh, E. J. Unsworth et al., “Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator,” *Biochemical Journal*, vol. 383, no. 3, pp. 413–418, 2004.

[23] C. Juaneda, Y. Dumont, J. G. Chabot, A. Fournier, and R. Quirion, “Adrenomedullin receptor binding sites in rat brain and peripheral tissues,” *European Journal of Pharmacology*, vol. 474, no. 2-3, pp. 165–174, 2003.

[24] I. Kaafarani, S. Fernandez-Sauze, C. Berenguer et al., “Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice,” *FASEB Journal*, vol. 23, no. 10, pp. 3424–3435, 2009.

[25] D. R. Poyner, P. M. Sexton, I. Marshall et al., “International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors,” *Pharmacological Reviews*, vol. 54, no. 2, pp. 233–246, 2002.

[26] L. M. McLatchie, N. J. Fraser, M. J. Main et al., “RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor,” *Nature*, vol. 393, no. 6683, pp. 333–339, 1998.

[27] T. Qi, G. Christopoulos, R. J. Bailey, A. Christopoulos, P. M. Sexton, and D. L. Hay, “Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function,” *Molecular Pharmacology*, vol. 74, no. 4, pp. 1059–1071, 2008.

[28] C. Gibbons, R. Dackor, W. Dunworth, K. Fritz-Six, and K. M. Caron, “Receptor activity-modifying proteins: RAMPing up adrenomedullin signaling,” *Molecular Endocrinology*, vol. 21, no. 4, pp. 783–796, 2007.

[29] Y. Shimokawa, K. Nagata, S. Ohta et al., “Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca2+ mobilization, in bovine aortic endothelial cells,” *Journal of Biological Chemistry*, vol. 270, no. 9, pp. 4412–4417, 1995.

[30] I. Szokodi, P. Kinnunen, P. Tavi, M. Weckström, M. Tóth, and H. Ruskoaho, “Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide,” *Circulation*, vol. 97, no. 11, pp. 1062–1070, 1998.

[31] S. Hippenstiel, M. Wittenraith, B. Schmeck et al., “Adrenomedullin reduces endothelial hyperpermeability,” *Circulation Research*, vol. 91, no. 7, pp. 618–625, 2002.

[32] Y. Kureishi, S. Kobayashi, J. Nishimura, T. Nakano, and H. Kanaide, “Adrenomedullin decreases both cytosolic Ca2+ kinetics and quantification of single-pass pulmonary clearance of adrenomedullin,” *Circulation Research*, vol. 91, no. 7, pp. 618–625, 2002.

[33] T. Shimosawa, H. Matsui, G. Xing, K. Itakura, K. Ando, and T. Fujita, “Organ-protective effects of adrenomedullin,” *Hypertension Research*, vol. 26, pp. S109–S112, 2003.
[35] Y. H. Looi, K. A. Kane, A. R. McPhaden, and C. L. Wainwright, “Adrenomedullin acts via nitric oxide and peroxynitrite to protect against myocardial ischaemia-induced arrhythmias in anaesthetized rats,” British Journal of Pharmacology, vol. 148, no. 5, pp. 599–609, 2006.

[36] M. Sata, M. Kakoki, D. Nagata et al., “Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism,” Hypertension, vol. 36, no. 1, pp. 83–88, 2000.

[37] J. B. Mannick, X. Q. Miao, and J. S. Stamler, “Nitric oxide inhibits Fas-induced apoptosis,” Journal of Biological Chemistry, vol. 272, no. 39, pp. 24125–24128, 1997.

[38] J. B. Mannick, X. Q. Miao, and J. S. Stamler, “Nitric oxide inhibit human endothelial cell apoptosis via a cyclic GMP-independent mechanism,” Hypertension, vol. 36, no. 1, pp. 83–88, 2000.

[39] M. K. Oehler, C. Norbury, S. Hague, M. C. P. Rees, and J. C. Burnett, “Renal localization and actions of adrenomedullin: a natriuretic peptide,” Circulation Research, vol. 89, no. 1, pp. 6823–6826, 1999.

[40] H. Nishimatsu, E. Suzuki, D. Nagata et al., “Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta,” Circulation Research, vol. 89, no. 1, pp. 63–70, 2001.

[41] A. Plück, “Conditional mutagenesis in mice: the Cre/loxP recombination system,” International Journal of Experimental Pathology, vol. 77, no. 6, pp. 269–278, 1996.

[42] A. P. Fernández, J. Serrano, L. Tessarollo, F. Cuttitta, and A. Martinez, “Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 34, pp. 12581–12586, 2008.

[43] A. Plück, “Conditional mutagenesis in mice: the Cre/loxP recombination system,” International Journal of Experimental Pathology, vol. 77, no. 6, pp. 269–278, 1996.

[44] A. P. Fernández, J. Serrano, L. Tessarollo, F. Cuttitta, and A. Martinez, “Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 34, pp. 12581–12586, 2008.

[45] O. Hurtado, J. Serrano, M. Sobrado et al., “Lack of adrenomedullin, but not complement factor H, results in larger infarct size and more extensive brain damage in a focal ischemia model,” Neuroscience, vol. 171, no. 3, pp. 885–892, 2010.

[46] M. Julián, M. Cacho, M. A. García et al., “Adrenomedullin: a new target for the design of small molecule modulators with promising pharmacological activities,” European Journal of Medicinal Chemistry, vol. 40, no. 8, pp. 737–750, 2005.

[47] M. G. Nicholls, “Hemodynamic and hormonal actions of adrenomedullin,” Brazilian Journal of Medical and Biological Research, vol. 37, no. 8, pp. 1247–1253, 2004.

[48] H. Hayakawa, Y. Hirata, M. Kakoki et al., “Role of nitric oxide-cGMP pathway in adrenomedullin-induced vasodilation in the rat,” Hypertension, vol. 33, no. 2, pp. 689–693, 1999.

[49] R. Wangensteen, A. Quesada, J. Sainz, J. Duarte, F. Vargas, and A. Osuna, “Role of endothelium-derived relaxing factors in adrenomedullin-induced vasodilation in the rat kidney,” European Journal of Pharmacology, vol. 444, no. 1-2, pp. 97–102, 2002.

[50] T. Shindo, Y. Kurihara, H. Nishimatsu et al., “Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene,” Circulation, vol. 104, no. 16, pp. 1964–1971, 2001.

[51] T. Shimosawa, Y. Shibagaki, K. Ishibashi et al., “Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage,” Circulation, vol. 105, no. 1, pp. 106–111, 2002.

[52] R. T. Dackor, K. Fritz-Six, W. P. Dunworth, C. L. Gibbons, O. Smithies, and K. M. Caron, “Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene,” Molecular and Cellular Biology, vol. 26, no. 7, pp. 2511–2518, 2006.

[53] Y. Ichikawa-Shindo, T. Sakurai, A. Kamiyoshi et al., “The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity,” Journal of Clinical Investigation, vol. 118, no. 1, pp. 29–39, 2008.

[54] R. Dackor, K. Fritz-Six, O. Smithies, and K. Caron, “Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age,” Journal of Biological Chemistry, vol. 282, no. 25, pp. 18094–18099, 2007.

[55] A. Plück, “Conditional mutagenesis in mice: the Cre/loxP recombination system,” International Journal of Experimental Pathology, vol. 77, no. 6, pp. 269–278, 1996.

[56] A. P. Fernández, J. Serrano, L. Tessarollo, F. Cuttitta, and A. Martinez, “Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 34, pp. 12581–12586, 2008.

[57] A. Plück, “Conditional mutagenesis in mice: the Cre/loxP recombination system,” International Journal of Experimental Pathology, vol. 77, no. 6, pp. 269–278, 1996.

[58] A. P. Fernández, J. Serrano, L. Tessarollo, F. Cuttitta, and A. Martinez, “Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 34, pp. 12581–12586, 2008.

[59] A. Plück, “Conditional mutagenesis in mice: the Cre/loxP recombination system,” International Journal of Experimental Pathology, vol. 77, no. 6, pp. 269–278, 1996.

[60] A. Plück, “Conditional mutagenesis in mice: the Cre/loxP recombination system,” International Journal of Experimental Pathology, vol. 77, no. 6, pp. 269–278, 1996.
protein,” Regulatory Peptides, vol. 112, no. 1-3, pp. 121–130, 2003.

[66] E. Marinoni, R. Di Iorio, B. Villaccio et al., “Follicular fluid adrenomedullin concentrations in spontaneous and stimulated cycles: relationship to ovarian function and endothelin-1 and nitric oxide,” Regulatory Peptides, vol. 107, no. 1-3, pp. 125–128, 2002.

[67] K. Kobayashi, T. Kubota, T. Aso, Y. Hirata, T. Imai, and F. Marumo, “Immunoreactive adrenomedullin (AM) concentration in maternal plasma during human pregnancy and AM expression in placenta,” European Journal of Endocrinology, vol. 142, no. 6, pp. 683–687, 2000.

[68] M. Garayoa, E. Bodegas, F. Cuttitta, and L. M. Montuenga, “Adrenomedullin in mammalian embryogenesis,” Microscopy Research and Technique, vol. 57, no. 1, pp. 40–54, 2002.

[69] K. Marutsuka, K. Hatakeyama, Y. Sato, A. Yamashita, A. Sumiyoshi, and Y. Asada, “Immunohistological localization and possible functions of adrenomedullin,” Hypertension Research, vol. 26, pp. S33–S40, 2003.

[70] W. J. Rossowski, B. L. Cheng, N. Y. Jiang, and D. H. Coy, “Examination of somatostatin involvement in the inhibitory action of GIP, GLP-1, amylin and adrenomedullin on gastric acid release using a new SRIF antagonist analogue,” British Journal of Pharmacology, vol. 125, no. 5, pp. 1081–1087, 1998.

[71] A. Martinez, T. H. Elsasser, C. Muro-Cacho et al., “Expression of adrenomedullin and its receptor in normal and malignant human skin: a potential pluripotent role in the integument,” Endocrinology, vol. 138, no. 12, pp. 5597–5604, 1997.

[72] E. Zudaire, S. Portal-Núñez, and F. Cuttitta, “The central role of adrenomedullin in host defense,” Journal of Leukocyte Biology, vol. 80, no. 2, pp. 237–244, 2006.

[73] L. M. Montuenga, A. Martínez, M. J. Miller, E. J. Unsworth, and F. Cuttitta, “Expression of adrenomedullin and its receptor during embryogenesis suggests autocrine or paracrine modes of action,” Endocrinology, vol. 138, no. 1, pp. 440–451, 1997.

[74] K. Takahashi, F. Satoh, M. Sone et al., “Expression of adrenomedullin mRNA in the human brain and pituitary,” Peptides, vol. 18, no. 7, pp. 1051–1053, 1997.

[75] J. Serrano, D. Alonso, A. P. Fernández et al., “Adrenomedullin in the central nervous system,” Microscopy Research and Technique, vol. 57, no. 2, pp. 76–90, 2002.

[76] B. Kis, H. Kajiya, R. Nishi et al., “Cerebral endothelial cells are a major source of adrenomedullin,” Journal of Neuroendocrinology, vol. 14, no. 4, pp. 283–293, 2002.

[77] B. Kis, M. A. Deli, H. Kobayashi et al., “Adrenomedullin regulates blood-brain barrier functions in vitro,” NeuroReport, vol. 12, no. 18, pp. 4139–4142, 2001.

[78] B. Kis, C. S. Abrahám, M. A. Deli et al., “Adrenomedullin, an autocrine mediator of blood-brain barrier function,” Hypertension Research, vol. 26, pp. S61–S70, 2003.

[79] W. K. Samson, T. C. Murphy, and Z. T. Resch, “Central mechanisms for the hypertensive effects of preproadrenomedullin-derived peptides in conscious rats,” American Journal of Physiology, vol. 274, no. 5, pp. R1505–R1509, 1998.

[80] M. Saita, A. Shimokawa, T. Kunitake et al., “Central actions of adrenomedullin on cardiovascular parameters and sympathetic outflow in conscious rats,” American Journal of Physiology, vol. 274, no. 4, pp. R979–R984, 1998.

[81] X. Wang, T. L. Yue, E. C. Barone et al., “Discovery of adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating focal brain ischemic damage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 25, pp. 11480–11484, 1995.
differentiation of arterial endothelial cells from vascular progenitors,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 9, pp. 1977–1984, 2006.

[130] Y. S. Mukouyama, D. Shin, S. Britsch, M. Taniguchi, and D. J. Anderson, “Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin,” *Cell*, vol. 109, no. 6, pp. 693–705, 2002.

[131] Y. S. Mukouyama, H. P. Gerber, N. Ferrara, C. Gu, and D. J. Anderson, “Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback,” *Development*, vol. 132, no. 5, pp. 941–952, 2005.

[132] C. Emanuelli, P. Schratzberger, R. Kirchmair, and P. Madeddu, “Paracrine control of vascularization and neurogenesis by neurotrophins,” *British Journal of Pharmacology*, vol. 140, no. 4, pp. 614–619, 2003.

[133] N. Hobara, A. Nakamura, M. Goda, and H. Kawasaki, “Malfunction of vascular control in lifestyle-related diseases: distribution of adrenomedullin-containing perivascular nerves and its alteration in hypertension,” *Journal of Pharmacological Sciences*, vol. 96, no. 4, pp. 391–394, 2004.

[134] S. E. Hermansen, T. Lund, T. Kalstad, K. Ytrehus, and T. Myrmel, “Adrenomedullin augments the angiogenic potential of late outgrowth endothelial progenitor cells,” *American Journal of Physiology*, vol. 300, no. 4, pp. C783–C791, 2011.

[135] C. J. Xian, R. Chung, and B. K. Foster, “Preclinical studies on mesenchymal stem cell-based therapy for growth plate cartilage injury repair,” *Stem Cells International*, vol. 2011, Article ID 570125, 10 pages, 2011.

[136] E. Zomorodian and M. Baghaban-Eslaminejad, “Mesenchymal stem cells as a potent cells source for bone regeneration,” *Stem Cells International*, vol. 2012, Article ID 980353, 9 pages, 2012.

[137] J. J. Minguell and A. Erices, “Mesenchymal stem cells and the treatment of cardiac disease,” *Experimental Biology and Medicine*, vol. 231, no. 1, pp. 39–49, 2006.

[138] R. C. Lai, T. S. Chen, and S. K. Lim, “Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease,” *Regenerative Medicine*, vol. 6, no. 4, pp. 481–492, 2011.

[139] M. P. Alfaro, M. Pagnia, A. Vincent et al., “The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 47, pp. 18366–18371, 2008.

[140] V. Volarevic, N. Arsenijevic, M. L. Lukic, and M. Stoijkovic, “Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus,” *Stem Cells*, vol. 29, no. 1, pp. 5–10, 2011.

[141] X. Xie, A. Sun, W. Zhu et al., “Transplantation of mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats,” *Tohoku Journal of Experimental Medicine*, vol. 226, pp. 29–36, 2012.

[142] S. J. Kim, K. C. Park, J. U. Lee, K. J. Kim, and D. G. Kim, “Therapeutic potential of adipose tissue-derived stem cells for liver failure according to the transplantation routes,” *Journal of the Korean Surgical Society*, vol. 81, pp. 176–186, 2011.

[143] Y. C. Huang, H. Ning, A. W. Shindel et al., “The effect of intracavernous injection of adipose tissue-derived stem cells on hyperlipidemia-associated erectile dysfunction in a rat model,” *Journal of Sexual Medicine*, vol. 7, no. 4, pp. 1391–1400, 2010.

[144] H. Nishimatsu, E. Suzuki, S. Kumano et al., “Adrenomedullin mediates adipose tissue-derived stem cell-induced restoration of erectile function in diabetic rats,” *Journal of Sexual Medicine*, vol. 9, no. 2, pp. 482–493, 2012.

[145] J. J. Yang, X. Yang, Z. Q. Liu et al., “Transplantation of adipose tissue-derived stem cells overexpressing heme oxygenase-1 improves functions and remodeling of infiltrated myocardium in rabbits,” *Tohoku Journal of Experimental Medicine*, vol. 226, pp. 231–241, 2012.

[146] J. P. Chute, G. G. Muramoto, H. K. Dressman, G. Wolle, N. J. Chao, and S. Lin, “Molecular profile and partial functional analysis of novel endothelial cell-derived growth factors that regulate hematopoiesis,” *Stem Cells*, vol. 24, no. 5, pp. 1315–1327, 2006.

[147] L. Del Pup, A. S. Belloni, G. Carraro, S. De Angeli, P. P. Parnigotto, and G. G. Nussdorfer, “Adrenomedullin is expressed in cord blood hematopoietic cells and stimulates their clonal growth,” *International Journal of Molecular Medicine*, vol. 11, no. 2, pp. 157–160, 2003.

[148] S. Murakami, N. Nagaya, T. Itoh et al., “Adrenomedullin regenerates alveoli and vasculature in elastase-induced pulmonary emphysema in mice,” *American Journal of Respiratory and Critical Care Medicine*, vol. 172, no. 5, pp. 581–589, 2005.

[149] A. C. Kim, F. M. Barlaskar, J. H. Heaton et al., “In search of adenocortical stem and progenitor cells,” *Endocrine Reviews*, vol. 30, no. 3, pp. 241–243, 2009.

[150] P. Rebuffat, C. Macchi, L. K. Malendowicz, and G. G. Nussdorfer, “Up-regulation of adrenomedullin gene expression in the regenerating rat adrenal cortex,” *International Journal of Molecular Medicine*, vol. 20, no. 4, pp. 551–555, 2007.

[151] S. Frede, P. Freitag, T. Otto, C. Heilmaier, and J. Fandrey, “The proinflammatory cytokine interleukin 1β and hypoxia cooperatively induce the expression of adrenomedullin in ovarian carcinoma cells through hypoxia inducible factor 1α activation,” *Cancer Research*, vol. 65, no. 11, pp. 4690–4697, 2005.

[152] P. Rebuffat, C. Macchi, L. K. Malendowicz, and G. G. Nussdorfer, “Up-regulation of adrenomedullin receptor gene expression in activated local stem cells during rat adrenal regeneration,” *International Journal of Molecular Medicine*, vol. 20, no. 6, pp. 855–858, 2007.

[153] C. Kintner, “Neurogenesis in embryos and in adult neural stem cells,” *Journal of Neuroscience*, vol. 22, no. 3, pp. 639–643, 2002.

[154] C. Zhao, W. Deng, and F. H. Gage, “Mechanisms and functional implications of adult neurogenesis,” *Cell*, vol. 132, no. 4, pp. 645–660, 2008.

[155] L. Deleyrolle, S. Marchal-Victorion, C. Dromard et al., “Exogenous and fibroblast growth factor 2/epidermal growth factor-regulated endogenous cytokines regulate neural precursor cell growth and differentiation,” *Stem Cells*, vol. 24, no. 3, pp. 748–762, 2006.

[156] I. A. Qureshi and M. F. Mehler, “The emerging role of epigenetics in stroke: III. Neural stem cell biology and epigenetics in stroke,” *Tohoku Journal of Experimental Medicine*, vol. 132, no. 5, pp. 941–952, 2005.

[157] M. Sugimori, M. Nagao, N. Bertrand, C. M. Parras, F. Guillemot, and M. Nakafuku, “Combinatorial actions of patterning
and HLH transcription factors in the spatiotemporal control of neurogenesis and gliogenesis in the developing spinal cord,” *Development*, vol. 134, no. 8, pp. 1617–1629, 2007.

[159] B. Berninger, E. Guillemot, and M. Götz, “Directing neurotransmitter identity of neurons derived from expanded adult neural stem cells,” *European Journal of Neuroscience*, vol. 25, no. 9, pp. 2581–2590, 2007.

[160] J. M. Gohlke, O. Armant, F. M. Parham et al., “Characterization of the proneural gene regulatory network during mouse telencephalon development,” *BMC Biology*, vol. 6, article 15, 2008.

[161] C. Dromard, S. Bartolami, L. Deleyrolle et al., “NG2 and olig2 expression provides evidence for phenotypic deregulation of cultured central nervous system and peripheral nervous system neural precursor cells,” *Stem Cells*, vol. 25, no. 2, pp. 340–353, 2007.

[162] C. M. Parras, C. Hunt, M. Sugimori, M. Nakafuku, D. Rowitch, and E. Guillemot, “The proneural gene Mash1 specifies an early population of telencephalic oligodendrocytes,” *Journal of Neuroscience*, vol. 27, no. 16, pp. 4233–4242, 2007.

[163] Y. Muroyama, Y. Fujiwara, S. H. Orkin, and D. H. Rowitch, “Specification of astrocytes by bHLH protein SCL in a restricted region of the neural tube,” *Nature*, vol. 438, no. 7066, pp. 360–363, 2005.

[164] T. Kuwabara and M. Asashima, “Regenerative medicine using adult neural stem cells: the potential for diabetes therapy and other pharmaceutical applications,” *Journal of Molecular Cell Biology*, vol. 4, no. 3, pp. 133–139, 2012.

[165] T. Kuwabara, M. N. Kagalwala, Y. Onuma et al., “Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb,” *EMBO Molecular Medicine*, vol. 3, no. 12, pp. 742–754, 2011.

[166] C. Vicario-Abejón, M. J. Yusta-Boyo, C. Fernández-Moreno, and F. De Pablo, “Locally born olfactory bulb stem cells proliferate in response to insulin-related factors and require endogenous insulin-like growth factor-I for differentiation into neurons and glia,” *Journal of Neuroscience*, vol. 23, no. 3, pp. 895–906, 2003.

[167] E. Vergaño-Vera, H. R. Méndez-Gómez, A. Hurtado-Chong, J. C. Cigudosa, and C. Vicario-Abejón, “Fibroblast growth factor-2 increases the expression of neurogenic genes and promotes the migration and differentiation of neurons derived from transplanted neural stem/progenitor cells,” *Neuroscience*, vol. 162, no. 1, pp. 39–54, 2009.

[168] E. Vergaño-Vera, A. P. Fernández, A. Hurtado-Chong, C. Vicario-Abejón, and A. Martinez, “Lack of adrenomedullin affects growth and differentiation of adult neural stem/progenitor cells,” *Cell and Tissue Research*, vol. 340, no. 1, pp. 1–11, 2010.

[169] G. Otaegi, M. J. Yusta-Boyo, E. Vergaño-Vera et al., “Modulation of the PI 3-kinase-Akt signalling pathway by IGF-I and PTEN regulates the differentiation of neural stem/precursor cells,” *Journal of Cell Science*, vol. 119, no. 13, pp. 2739–2748, 2006.

[170] W. Kim, S. O. Moon, M. J. Sung et al., “Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells,” *FASEB J.*, vol. 17, pp. 1937–1939, 2003.

[171] F. Mannello, V. Medda, and G. A. Tonti, “Hypoxia and neural stem cells: from invertebrates to brain cancer stem cells,” vol. 55, no. 6, pp. 569–581, 2011.

[172] D. L. Sackett, L. Ozbun, E. Zudaire et al., “Intracellular proadrenomedullin-derived peptides decorate the microtubules and contribute to cytoskeleton function,” *Endocrinology*, vol. 149, no. 6, pp. 2888–2898, 2008.

[173] O. Demir, S. Singh, L. Klimaschewski, and I. A. Kurnaz, “From birth till death: neurogenesis, cell cycle, and neurodegeneration,” *The Anatomical Record*, vol. 292, no. 12, pp. 1953–1961, 2009.
Review Article
Bench to Bedside of Neural Stem Cell in Traumatic Brain Injury

Solomon O. Ugoya and Jian Tu
Australian School of Advanced Medicine, Macquarie University, 2 Technology Place, North Ryde, Sydney, NSW 2109, Australia

Correspondence should be addressed to Jian Tu, james.tu@mq.edu.au

Received 1 June 2012; Revised 10 August 2012; Accepted 21 August 2012

Academic Editor: Rocio E. Gonzalez-Castaneda

Copyright © 2012 S. O. Ugoya and J. Tu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Traumatic brain injury (TBI) is one of the leading causes of major disability and death worldwide. Neural stem cells (NSCs) have recently been shown to contribute to the cellular remodelling that occurs following TBI and attention has been drawn to the area of neural stem cell as possible therapy for TBI. The NSCs may play an important role in the treatment of TBI by replacing the damaged cells and eventual remyelination. This paper summarized a critical assessment of recent data and developed a view comprising of six points to possible quality translation of NSCs in TBI.

1. Introduction

Traumatic brain injury (TBI) has remained a major cause of mortality, morbidity and leading cause of large-scale disabilities worldwide. TBI results in a large number of deaths and a cause of permanent disabilities with enormous losses to individuals, families, and communities [1]. World Health Organization (WHO), in 2004, has estimated that 25% of road traffic collisions requiring admission to a hospital suffered TBI [1–3].

Moreover, WHO has introduced the new metric tool, the disability-adjusted life year (DALY), which quantifies the burden of diseases, injuries and risk factors. The worldwide leading causes of TBI include road traffic accidents that were estimated being 41.2 million DALYs in 2008, violence being responsible for 21.7 million DALYs, and self-inflicted injuries being 19.6 million DALYs, respectively. All these will leave disability associated with TBI in survivors [2, 3].

However, WHO has introduced the new metric tool, the disability-adjusted life year (DALY), which quantifies the burden of diseases, injuries and risk factors. The worldwide leading causes of TBI include road traffic accidents that were estimated being 41.2 million DALYs in 2008, violence being responsible for 21.7 million DALYs, and self-inflicted injuries being 19.6 million DALYs, respectively. All these will leave disability associated with TBI in survivors [2, 3].

Moreover, WHO has introduced the new metric tool, the disability-adjusted life year (DALY), which quantifies the burden of diseases, injuries and risk factors. The worldwide leading causes of TBI include road traffic accidents that were estimated being 41.2 million DALYs in 2008, violence being responsible for 21.7 million DALYs, and self-inflicted injuries being 19.6 million DALYs, respectively. All these will leave disability associated with TBI in survivors [2, 3].

However, no effective therapy or program is available for treatment of individuals with TBI; nonetheless, researchers had tried some therapeutic agents like levodopa/carbidopa and some neurotrophic factors in brain injury with persistent vegetative state into some degree of consciousness. This still needs experimentation to confirm if these dopamine precursors and other neurotrophic factors have any role in TBI. Several other therapeutic agents like cannabinoid dexamabinol, erythropoietin, and gamma-gluatamylcysteine ethyl ester have all shown to have neuroprotective effect in human at experimental stage with remarkable improvement in post-TBI outcome [4–8].

Recently, more attention has been drawn to the area of stem cell therapy, largely due to advanced knowledge about stem cells. The stem cells may play an important role in the treatment of TBI by replacing damaged cells, and helping functional recovery. The search for stem cell therapy for TBI is progressing. Since the pathophysiology of TBI is largely unknown, it makes a search for an effective stem cell therapy difficult. This is because multiple cell types like neuronal cells, glial, and endothelial cells are usually involved in TBI. Furthermore, cerebral vasculature, especially the blood brain barrier (BBB), may be affected in TBI; this injury may be focal or diffuse axonal injury (DAI). Taming these burgeoning effects of TBI will require NSCs which can differentiate into neurons and glial cells. It has been reported that progenitor cells differentiated into neurons and glial in adult brain, and an increase in astrocytic progeny is forming reactive astocytes to primarily limit cyst enlargement in posttraumatic syringomyelia [9–12].

This review is an optional extra to see if we can achieve the translation of basic knowledge of neural stem cells into therapeutic options in persons with TBI by enhancing and integrating these neural progenitor cells (NPCs) unto neurogenesis and directing these cells to the specified targets.
or through multipotency where the transplanted cells can differentiate into glial cells, neurons, and endothelial cells, as the injuries are not always selective but diffuse and we may need to induce these transplanted cells into appropriate phenotype. This is a critical review of existing current literature on neural stem cell research and proposing an approach for quality clinical translation in TBI. We will look at the pathophysiology of TBI and proposing the “six-point schematic approach” to achieve standard and quality bench to bedside in neural stem cell of TBI. We also highlighted the need for suitable clinical translation, coordination, and administration of research in the field of neural stem cell therapy of TBI.

2. Pathophysiology of TBI

Pathophysiology of TBI involves two main phases: these are primary injury following the trauma, and the secondary injury which is mediated by inflammatory response to trauma.

2.1. Primary Injury. Pathophysiology of initial injury has been postulated to include acceleration, deceleration, and rotational forces which may or may not be as a result of the trauma. This flow of events leads to initiation of inertia which is both acceleration and rotational head movements. This impact on the cortical and subcortical brain structures causes focal or diffuse axonal injury (DAI) and these inertial forces will disrupt the BBB [13]. The primary events also involve massive ionic influx referred to as traumatic depolarization. The major inflammatory neurotransmitters released are excitatory amino acids. This may explain the pathophysiology of DAI in TBI. This is followed by cerebral edema with associated increase in intracranial pressure, which usually forms the major immediate consequences of TBI. Brain edema may come from astrocyte swelling and disruption of the BBB [14, 15]. The BBB is disrupted in acute phase of severe TBI. The expression of high levels of glucose transporter 1 (GLUT 1) was observed in capillaries from acutely injured brain, which occurs in association with compromised BBB function. Vascular endothelial growth factor also plays a role in neuronal tissue disruption and increases the permeability of the BBB via the synthesis and release of nitric oxide [16]. Figure 1 depicts the pathophysiology of the primary injury.

2.2. Secondary Injury. The secondary events are a complex association of the inflammatory response initiated by the trauma leading to diffuse neuronal degeneration of neurons, glial, axonal tearing, and genetic predisposition (Figure 2). Furthermore, excitatory amino acid release, oxygen radical reactions, and nitric oxide production will lead to activation of N-Methyl-D-aspartate (NMDA), 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid (AMPA), alpha-7 nicotinic receptor (α7), and nicotinic acetylcholine receptor (nAChR) [17–19] and subsequent calcium influx. All these cascades of events will cause mitochondrial disruption and free radical release with eventual tissue peroxidation. One theory is that excitatory amino acid release leads to calcium influx into neurons and other brain cells which promote oxygen-free radical reactions. High calcium and the presence of free-radical molecules create an unstable environment in the cell that may lead to increased production and release of nitric oxide and excitatory amino acids (e.g., glutamate). Nitric oxide may participate in oxygen radical reactions and lipid peroxidation in neighboring cells [20]. A summary is shown in Figure 2. The secondary injury plays a major role in the outcome of TBI. Therapeutic interventions should target this phase as it is the major determinant of morbidity and mortality in TBI [16]. Genes implicated to influence the outcome of TBI include apoe. APOE multifactorially affects the clinico-pathological consequences of TBI [21]. Apoe is associated with increased amyloid deposition, amyloid angiopathy, larger intracranial hematomas, and more severe contusional injury. Comt and drd2 are genes which may influence dopamine-dependent cognitive processes, such as executive or frontal lobe functions. The ace gene may affect TBI outcome via alteration of cerebral blood flow and/or autoregulation and the caumal1 gene may exert an influence via the calcium channel pathways and its effect on delayed cerebral edema [22]. Increased signal transducers and activator of transcription (STAT) 3 signaling has been reported in a rat model of TBI [23]. Although several potential genes that may influence the outcomes following TBI have been identified, future investigations are needed to validate these genetic studies and identify new genes that might contribute to the outcomes following TBI.

![Figure 1: Sequential events of primary injury in TBI. Initial impact is usually by directing trauma to the head either open or closed head injury. This trauma will cause mechanical damage to neurons, axons, glia, and blood vessels by shearing, tearing, or stretching. Blood vessel ruptures cause hemorrhage. Even in unruptured blood vessels, BBB permeability increases resulting in edema. Hemorrhage and edema often lead to intracranial hypertension. Following hemorrhage, ischemia could occur in brain tissue. TBI-caused cell damage induces macrophage and lymphocytes migrant to the injury site releasing inflammatory mediators that triggers a cascade of events towards necrosis and/or apoptosis. Necrosis and/or apoptosis also can be a consequence of hemorrhage and ischemia.](image-url)
3. Application of NSCs in TBI

There are at least two possible strategies involving neural stem cells (NSCs) to repair injured brain. They are transplantation of exogenous NSCs and stimulation of endogenous NSCs.

3.1. Transplantation of Exogenous NSCs. There have been attempts to transplant various types of cells, such as neurons and neural stem cells to repair damaged brain. The main objectives of these transplantation experiments are (1) growth facilitation: the transplant fills the lesion site and serves as a cellular bridge; (2) new neurons: the transplant can provide new neurons, which in turn provide new targets and sources of innervations and thus repair the damaged neural circuits; (3) factor secretion: the transplant can produce a variety of substances, such as neurotrophic factors, that may aid in the repair process [24]. Several characteristics of NSCs make them potentially suitable for repair after TBI. Firstly, they can serve as a renewable supply of transplantable cells by clonally expansion in culture. Secondly, they are of CNS origin and the cells generated from the grafts have neural characteristics. Thirdly, NSCs can be manipulated by genetic engineering methods to produce specific proteins, such as neurotrophins, neurotransmitters, and enzymes [25].

It has been reported that autologous-cultured cells harvested at time of emergency surgery from patients with TBI and subsequently engrafted into damaged part of the brain can be detected using MRI [26]. The efficacy of transplantation largely depends on a grafting method that optimizes the survival of the transplanted cells and minimizes the graft-induced lesion. Most transplantation studies involved intraparenchymal injection into the CNS, in which cells were grafted directly into or adjacent to the lesion [27–29]. The optimal time for transplantation may not be immediately after injury. The levels of various inflammatory cytokines (TNFα, IL-1α, IL-1β, and IL-6) in the injured brain peak 6–12 hours after injury remain elevated until the 4th day. Although these inflammatory cytokines are known to have both neurotoxic and neurotrophic actions, they are believed to be neurotoxic within a week after injury, which causes the microenvironment to be unsuitable for survival of the grafted cells [30]. However, if too much time passes after the injury, glial scar forms a barrier around the lesion site and inhibits local blood circulation which is needed for graft survival. Thus, it is considered that those 7 to 14 days after injury are the optimal time for transplantation [31, 32].

3.2. Stimulation of Endogenous NPCs. Since the description of endogenous neurogenesis in adult brain by Luskin in 1997 [33] and Alvarez-Buylla and co-workers in 2000 [34], several publications have confirmed their findings. They demonstrated the presence of NSCs in adult rodent ventricular zone (VZ) that migrated to the olfactory bulb and integrated into the neuronal network called the rostral migratory stream (RMS).

However, the potential success of stimulating endogenous NPCs is hinged on delivery of various growth factors. More so, this seems to be the most common way...
to stimulate NPCs. The following growth factors have been reported: EGF, FGF-2 [35–37], bFGF [38], aFGF [39], BDNF [40], NGF, NT-3 [40, 41], VEGF [42], GDNF [43], IGF-1 [42], and SDF-1 alpha [44]. They were administrated by intraventricular [35], intraparenchymal [40, 42, 45] or intrathecal [36–38, 43] injection. They were reported not only to enhance the proliferation, migration, and gliogenesis of NPCs [35–37, 44] but also to protect the spinal cord from further damage [41, 42]. In addition, these growth factors facilitated the regrowth of axons and remyelination [39, 40, 46]. Functional recovery was also reported after they were delivered into injured spinal cord [35–37, 39]. However, the details of functional recovery are still not clear.

Not only growth factors, other molecules, were shown to stimulate endogenous NPCs. Proliferation of endogenous NPCs was demonstrated when the sodium channel blocker tetrodotoxin and the glycoprotein molecule sonic hedgehog were injected into the parenchyma [47, 48]. Imitola and colleagues reported that cognate chemokine receptor type 4 (CXCR4) expressed by NSCs can regulate their proliferation and direct their migration towards the injury site [44]. In addition, antibodies blocking IL-6 receptors were reported to not only inhibit differentiation of endogenous NSCs into astroglia in vivo and in vitro, but also to promote functionary recovery [49, 50]. Okano and colleagues assumed that the functionary recovery is probably due to blocking IL-6 and consequently inhibiting the formation of glial scars and promoting axonal regeneration [49, 51]. Notably, studies of ATP-binding cassette (ABC) transporters have emerged as a new field of investigation. ABC transporters (especially ABCA2, ABCA3, ABCB1, and ABCG2) are found to play an important role in proliferation and differentiation of NSCs [45, 52–56].

In contrast to transplantation of exogenous NPCs, stimulation of endogenous NPCs to repair damaged spinal cord has three main advantages: (1) there is no ethical issue of embryonic and foetal cells, (2) it is usually less invasive, and (3) no immunogenicity; it avoids immunorejection that observed in transplantation of exogenous NPCs [57].

Like adult NPCs transplantation studies in SCI, no neurogenesis has been reported from the stimulation of endogenous NPCs. Yamamoto and colleagues reported that lack of neuronal differentiation is related to upregulation of the Notch signal pathways [58]. The increased level of various cytokines within the microenvironment surrounding the area of injury may also cause a lack of trophic support for differentiation into neuronal lineage [59–62].

Recently, more attention has been drawn to CBP/p300-phosphorylated Smad complex. It was found that CBP/p300-phosphorylated Smad complex can be bound in NSCs, which may decide the differentiation of NSCs. If the complex is bound with phosphorylated STAT 3, the NSCs differentiate into astroglia lineage cells. On the other hand, if the complex is bound with proneural-type of the basic helix-loop-helix (bHLH) factor, such as neurogenin 1 and 2, they differentiate into the neuronal lineage [51, 63, 64]. Apart from that, Peveny and Placzek reported that SOX gene may also play an important role in neural differentiation [65].

Once NSCs decide to differentiate into neuronal lineage, a cascade of hundreds of genes is regulated over time to lead the immature neuron into its mature phenotype. Many of these neural genes are controlled by RE1-silencing transcription factor (REST). REST acts as a repressor of neural genes in nonneural cells, while regulation of REST activates large networks of genes required for neural differentiation [66–68].

4. Bench to Bedside Translation of Stem Cell Therapy

The main purpose of scientific studies is to put our discoveries into daily clinical practice. The basic science laboratory takes its observations obtained at cellular or molecular levels in a cutting edge condition and implements this into acceptable practice clinically to the benefit of the public. However, this is always met with a lot of challenges, such as ethics, governmental regulations, funding constraints, paucity of adequate collaboration among clinical and basic science, and the challenges of conducting a clinical study.

The authors, nonetheless, propose six-point schema for improving bench to bedside translation of stem cell therapy (Figure 3(a)) involving a rigorous network of six stakeholders: basic researchers, pharmaceutical companies, patient or general public participating in clinical trials, regulatory bodies or agencies for grant approval, collaborative research between basic and clinical scientist with the plan of developing biomarkers for potential drug targets, and creating a concerted network of groups that identifies some of the medical problems relating to TBI. We are still faced with the need to formulate hypothesis both at experimental and clinical epidemiologic levels and implementing these into clinical practice while the translational researcher serves to collaborate and coordinate all these strategies.

Indeed, communication and dissemination (Figure 3(b)) which are patient centeredness will not only impact on the public, but will also help to tame the ethical problems in this field. Communication will involve both patients and other clinicians involved in conducting randomized clinical trials (RCTs). With strong feedback on outcomes, pharmacovigilance, and health promotion, education of the populace in form of scientific advocacy is so paramount as this will impact on improved scientific collaboration, quality public control, and increased transparency among researchers and may improve funding of research work [69].

Research in neural stem cell is still a grey area and much knowledge needs to be gained, to actually close the gaps. There is inadequate understanding of secondary injury process, insufficient preclinical testing in diffuse axonal injury models, species differences, and lack of understanding of the mechanism of drug-receptor interactions. Smith and colleagues had suggested the need to use gyrencephalic models for proper translation of TBI [70]. There is need for increased linkages and networking between academician, researchers, and clinicians for greater reward of what is being generated.

Methodological disparities between experimental models of TBI and clinical studies cannot be overemphasized.
The intent to treat models, differences in statistical analysis as a result of differences in sample size, and different behaviours between human and animals. Injury severities in animals differ from humans; while they are well defined in animals, they could take any direction in human. The need to improve study quality score has recently being called for by stroke therapy academic industry roundtable (STAIR), which was recently updated and this includes the following recommendations: (1) elimination of randomizations and assessment bias, (2) use of a priori definitions of inclusion/exclusion criteria, (3) inclusion of appropriate power and sample size calculations, (4) full disclosure of potential conflict of interest, (5) evaluation of therapies in male and female animals across the spectrum of ages, and with comorbid conditions such as hypertension and/or diabetes. Furthermore, some researchers had also expanded on these proposed recommendations for improved clinical trials in brain injury with special focus on neuroprotective therapies in TBI [70, 71]. Nonadherence was the single most important determinant of trial failure in the past.

Finally, the International Mission on Prognosis and Clinical Trial Design in TBI (IMPACT) proposed ways of overcoming the above disparities and challenges. The recommendations include a robust inclusion criteria and recommendations for general research in TBI [70]. The six-point schema is an overview recommendation with the public, patient, or the society as the core and the fulcrum of all activities of research and if implemented may yield quality research outcome in neural stem cells translation in TBI.

5. Conclusions
Mortality and disability from TBI are projected to rise globally. Neural stem cell therapy is a strategy that offers hope in the future for treatment of brain injury. In addition, we are now able to monitor autologous neural stem cells in vivo, cell migration and clearly demonstrate that neural stem cells could selectively target injured brain or spinal cord tissue and undergo neurogenesis. Finally, the proposed six-points cyclical schema should be implemented with determined effort of all stakeholders for effective bench to bedside translation of neural stem cell therapy in TBI.

Conflict of Interests
The authors declare that they have no conflict of interests.

Acknowledgments
S. O. Ugoya is a recipient of International Macquarie University Research Excellence Scholarship.

References
[1] J. D. Corrigan, A. W. Selassie, and J. A. Orman, “The epidemiology of traumatic brain injury,” Journal of Head Trauma Rehabilitation, vol. 25, no. 2, pp. 72–80, 2010.
[2] Atlas, “country resources for neurological disorders home page,” http://www.who.int/mental_health/neurology/epidemiology/en/index.html, 2012.
[3] Global burden of disease estimates, http://www.who.int/healthinfo/bodestimates/en/index.html, 2012.
[4] S. Nori, O. Tsuji, Y. Okada, Y. Toyama, H. Okano, and M. Nakamura, “Therapeutic potential of induced pluripotent stem cells for spinal cord injury,” Brain Nerve, vol. 64, no. 1, pp. 17–27, 2012.
[5] S. O. Ugoya and R. O. Akinyemi, “The place of L-dopa/carbidopa in persistent vegetative state,” Clinical Neuropharmacology, vol. 33, no. 6, pp. 279–284, 2010.

[6] A. Biegon, “Cannabinoids as neuroprotective agents in traumatic brain injury,” Current Pharmaceutical Design, vol. 10, no. 18, pp. 2177–2183, 2004.

[7] J. Lok, W. Leung, S. Zhao et al., “Gamma-glutamylcysteine ethyl ester protects cerebral endothelial cells during injury and decreases blood-brain barrier permeability after experimental brain trauma,” Journal of Neurochemistry, vol. 118, no. 2, pp. 248–255, 2011.

[8] A. I. R. Maas, “Neuroprotective agents in traumatic brain injury,” Expert Opinion on Investigational Drugs, vol. 10, no. 4, pp. 753–767, 2001.

[9] A. Mannmis, T. K. McIntosh, and A. H. Maniker, “Erythropoietin as a neuroprotective agent in traumatic brain injury,” Surgical Neurology, vol. 71, no. 5, pp. 527–531, 2009.

[10] B. Stoica, K. Byrnes, and A. I. Faden, “Multifunctional drug treatment in neurotrauma,” Neurotherapeutics, vol. 6, no. 1, pp. 14–27, 2009.

[11] J. Tu, J. Liao, M. A. Stoodley, and A. M. Cunningham, “Differentiation of endogenous progenitors in an animal model of post-traumatic Syringomyelia,” Spine, vol. 35, no. 11, pp. 1116–1121, 2010.

[12] J. Tu, J. Liao, M. A. Stoodley, and A. M. Cunningham, “Reaction of endogenous progenitor cells in a rat model of post-traumatic syringomyelia: laboratory investigation,” Journal of Neurosurgery, vol. 14, no. 5, pp. 573–582, 2011.

[13] C. Albert-Weissenberger, C. Varrallyay, F. Raslan, C. Klinessnitz, and A. L. Siren, “An experimental protocol for mimicking pathomechanisms of traumatic brain injury in mice,” Experimental & Translational Stroke Medicine, vol. 4, no. 1, 2012.

[14] J. T. Povlishock, “Traumatically induced axonal injury: pathogenesis and pathobiological implications,” Brain Pathology, vol. 2, no. 1, pp. 1–12, 1992.

[15] M. W. Greve and B. J. Zink, “Pathophysiology of traumatic brain injury,” Mount Sinai Journal of Medicine, vol. 76, no. 2, pp. 97–104, 2009.

[16] H. Nawashiro, K. Shima, and H. Chigasaki, “Blood-brain barrier, cerebral blood flow, and cerebral plasma volume immediately after head injury in the rat,” Acta Neurochirurgica, Supplement, vol. 60, pp. 440–442, 1994.

[17] J. M. Hin zincman, T. C. Thomas, J. E. Quintero, G. A. Gerhardt, and J. Lifshitz, “Disruptions in the regulation of extracellular glutamate by neurons and glia in the rat striatum two days after diffuse brain injury,” Journal of Neurotrauma, vol. 29, no. 6, pp. 1197–1208, 2012.

[18] P. B. Goforth, E. F. Ellis, and L. S. Satin, “Enhancement of AMPA-mediated current after traumatic injury in cortical neurons,” Journal of Neuroscience, vol. 19, no. 17, pp. 7367–7374, 1999.

[19] M. L. Kelso and J. H. Oestreich, “Traumatic brain injury: Central and peripheral role of α7 nicotinic acetylcholine receptors,” Current Drug Targets, vol. 13, no. 5, pp. 631–636, 2012.

[20] M. Stoffel, M. Rinecker, N. Plesnila, J. Eriskat, and A. Baethmann, “Role of nitric oxide in the secondary expansion of a cortical brain lesion from cold injury,” Journal of Neurotrauma, vol. 18, no. 4, pp. 425–434, 2001.

[21] A. A. Potapov, M. M. Iusupova, V. D. Tendieva, A. G. Nikitin, and V. V. Nosikov, “Clinical and prognostic significance of genetic markers of ApoE gene in traumatic brain injury,” Zhurnal voprosy neirokhirurgii imeni N N Burdenko, no. 3, pp. 54–62, 2010.

[22] B. D. Jordan, “Genetic influences on outcome following traumatic brain injury,” Neurochemical Research, vol. 32, no. 4–5, pp. 905–915, 2007.

[23] A. A. Oliva, Y. Kang, J. Sanchez-Molano, C. Furones, and C. M. Atkins, “STAT3 signaling after traumatic brain injury,” Journal of Neurochemistry, vol. 120, no. 5, pp. 710–720, 2012.

[24] K. Barami and F. G. Diaz, “Cellular transplantation and spinal cord injury,” Neurosurgery, vol. 47, no. 3, pp. 691–700, 2000.

[25] D. W. Pincus, R. R. Goodman, R. A. Fraser, M. Nedergaard, and S. A. Goldman, “Neural stem and progenitor cells: a strategy for gene therapy and brain repair,” Neurosurgery, vol. 42, no. 4, pp. 858–868, 1998.

[26] M. Nakamura, R. A. Houghtling, L. MacArthur, B. M. Bayer, and B. S. Bregman, “Differences in cytokine gene expression profile between acute and secondary injury in adult rat spinal cord,” Experimental Neurology, vol. 184, no. 1, pp. 313–325, 2003.

[27] S. Y. Chow, J. Moul, C. A. Tobias et al., “Characterization and intraspinal grafting of EGF/bFGF-dependent neurospheres derived from embryonic rat spinal cord,” Brain Research, vol. 874, no. 2, pp. 87–106, 2000.

[28] Q. L. Cao, Y. P. Zhang, R. M. Howard, W. M. Walters, P. Tsoulfas, and S. R. Whitemore, “Pluripotent stem cells engrafted into the normal or lesioned adult rat spinal cord are restricted to a glial lineage,” Experimental Neurology, vol. 167, no. 1, pp. 48–58, 2001.

[29] P. Jendelová, V. Herynek, L. Urbzdiková et al., “Magnetic resonance tracking of transplanted bone marrow and embryonic stem cells labeled by iron oxide nanoparticles in rat brain and spinal cord,” Journal of Neuroscience Research, vol. 76, no. 2, pp. 232–243, 2004.

[30] J. Zhu, L. Zhou, and F. XingWu, “Tracking neural stem cells in patients with brain trauma,” The New England Journal of Medicine, vol. 355, no. 22, pp. 2376–2378, 2006.

[31] Y. Ogawa, K. Sawamoto, T. Miyata et al., “Transplantation of in vitro-expanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats,” Journal of Neuroscience Research, vol. 69, no. 6, pp. 925–933, 2002.

[32] H. Okano, Y. Ogawa, M. Nakamura, S. Kaneko, A. Iwanami, and Y. Toyama, “Transplantation of neural stem cells into the spinal cord after injury,” Seminars in Cell and Developmental Biology, vol. 14, no. 3, pp. 191–198, 2003.

[33] M. B. Luskin, T. Zigova, B. J. Soteres, and R. R. Stewart, “Neuronal progenitor cells derived from the anterior subventricular zone of the neonatal rat forebrain continue to proliferate in vitro and express a neuronal phenotype,” Molecular and Cellular Neurosciences, vol. 8, no. 5, pp. 351–366, 1996.

[34] A. Alvarez-Buylla, D. G. Herrera, and H. Wichterle, “The subventricular zone: Source of neuronal precursors for brain repair,” Progress in Brain Research, vol. 127, pp. 1–11, 2000.

[35] D. J. Martens, R. M. Seaberg, and D. Van der Kooy, “In vivo infusions of exogenous growth factors into the fourth ventricle of the adult mouse brain increase the proliferation of neural progenitors around the fourth ventricle and the central canal of the spinal cord,” European Journal of Neuroscience, vol. 16, no. 6, pp. 1045–1057, 2002.

[36] A. Koijima and C. H. Tator, “Epidermal growth factor and fibroblast growth factor 2 cause proliferation of ependymal precursor cells in the adult rat spinal cord in vivo,” Journal of Neuropathology and Experimental Neurology, vol. 59, no. 8, pp. 687–697, 2000.
[37] A. Kojima and C. H. Tator, “Intrathecal administration of epidermal growth factor and fibroblast growth factor 2 promotes ependymal proliferation and functional recovery after spinal cord injury in adult rats,” Journal of Neurotrauma, vol. 19, no. 2, pp. 223–238, 2002.

[38] A. G. Rabchevsky, I. Fugaccia, A. F. Turner, D. A. Blades, M. P. Mattson, and S. W. Scheff, “Basic fibroblast growth factor (bFGF) enhances functional recovery following severe spinal cord injury to the rat,” Experimental Neurology, vol. 164, no. 2, pp. 280–291, 2000.

[39] Y. S. Lee, C. Y. Lin, R. T. Robertson, I. Hsiao, and V. W. Lin, “Motor recovery and anatomical evidence of axonal regrowth in spinal cord-repaired adult rats,” Journal of Neuropathology and Experimental Neurology, vol. 63, no. 3, pp. 233–245, 2004.

[40] J. Namiki, A. Kojima, and C. H. Tator, “Effect of brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 on functional recovery and regeneration after spinal cord injury in adult rats,” Journal of Neurotrauma, vol. 17, no. 12, pp. 1219–1231, 2000.

[41] J. Widenfalk, A. Lipson, M. Jubran et al., “Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury,” Neurosurgery, vol. 120, no. 4, pp. 951–960, 2003.

[42] H. S. Sharma, “Neurotrophic factors attenuate microvascular permeability disturbances and axonal injury following trauma to the rat spinal cord,” Acta Neurochirurgica, no. 86, pp. 383–388, 2003.

[43] C. Iannotti, Y. Ping Zhang, C. B. Shields, Y. Han, D. A. Burke, and X. M. Xu, “A neuroprotective role of glial cell line-derived neurotrophic factor following moderate spinal cord contusion injury,” Experimental Neurology, vol. 189, no. 2, pp. 317–332, 2004.

[44] J. Imitola, K. Raddassi, K. I. Park et al., “Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1α/CXC chemokine receptor 4 pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 52, pp. 18117–18122, 2004.

[45] G. Li, P. Shi, and Y. Wang, “Evolutionary dynamics of the ABCA chromosome 17q24 cluster genes in vertebrates,” Genomics, vol. 89, no. 3, pp. 385–391, 2007.

[46] J. M. Gensert and J. E. Goldman, “Endogenous progenitors remyelinate demyelinated axons in the adult CNS,” Neuron, vol. 19, no. 1, pp. 197–203, 1997.

[47] L. J. Rosenberg, L. J. Zai, and J. R. Wrathall, “Chronic alterations in the cellular composition of spinal cord white matter following contusion injury,” GLIA, vol. 49, no. 1, pp. 107–120, 2005.

[48] N. C. Bambakidis, R. Z. Wang, L. Franic, and R. H. Miller, “Sonic hedgehog-induced neural precursor proliferation after adult rodent spinal cord injury,” Journal of Neurosurgery, vol. 99, no. 1, pp. 70–75, 2003.

[49] S. Okada, M. Nakamura, Y. Mikami et al., “Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury,” Journal of Neuroscience Research, vol. 76, no. 2, pp. 265–276, 2004.

[50] M. Nakamura, S. Okada, Y. Toyama, and H. Okano, “Role of IL-6 in spinal cord injury in a mouse model,” Clinical Reviews in Allergy and Immunology, vol. 28, no. 3, pp. 197–203, 2005.

[51] H. Okano, S. Okada, M. Nakamura, and Y. Toyama, “Neural stem cells and regeneration of injured spinal cord,” Kidney International, vol. 68, no. 5, pp. 1927–1931, 2005.
[68] N. Ballas and G. Mandel, “The many faces of REST oversee epigenetic programming of neuronal genes,” *Current Opinion in Neurobiology*, vol. 15, no. 5, pp. 500–506, 2005.

[69] N. C. Keramaris, N. K. Kanakaris, C. Tzioupis, G. Kontakis, and P. V. Giannoudis, “Translational research: from benchside to bedside,” *Injury*, vol. 39, no. 6, pp. 643–650, 2008.

[70] D. J. Loane and A. I. Faden, “Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies,” *Trends in Pharmacological Sciences*, vol. 31, no. 12, pp. 596–604, 2010.

[71] M. Fisher, G. Feuerstein, D. W. Howells et al., “Update of the stroke therapy academic industry roundtable preclinical recommendations,” *Stroke*, vol. 40, no. 6, pp. 2244–2250, 2009.
Research Article

Nestin Protein Is Phosphorylated in Adult Neural Stem/Progenitor Cells and Not Endothelial Progenitor Cells

Jun Namiki,1 Sayuri Suzuki,1 Takeshi Masuda,2 Yasushi Ishihama,2,3 and Hideyuki Okano4

1 Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Shinanomachi 35, Shinjuku, Tokyo 160-8582, Japan
2 Institute for Advanced Biosciences, Keio University, 403-1 Daihiji, Tsuruoka, Yamagata 997-0017, Japan
3 Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan
4 Department of Physiology, Keio University School of Medicine, Shinanomachi 35, Shinjuku, Tokyo 160-8582, Japan

Correspondence should be addressed to Jun Namiki, namikijun@a8.keio.jp

Received 1 July 2012; Accepted 3 August 2012

Academic Editor: Oscar Gonzalez-Perez

Copyright © 2012 Jun Namiki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

An intermediate filament protein, Nestin, is known as a neural stem/progenitor cell marker. It was shown to be required for the survival and self-renewal of neural stem cells according to the phenotypes of Nestin knockout mice. Nestin expression has also been reported in vascular endothelial cells, and we recently reported Nestin expression in proliferating endothelial progenitor cells, but not in mature endothelial cells. We utilized E/nestin:EGFP transgenic mice using its second intronic enhancer element to study neural-specific nestin gene expression [9, 10] and demonstrated that vascular nestin expression is not activated by the CNS-specific enhancer of the nestin gene [8]. This finding indicated that the Nestin expressed in EPCs is cytochemically similar to the protein expressed in CNS stem/progenitor cells, but the regulatory mechanism of gene expression is different.

The reversible phosphorylation of proteins results in a conformational change that alters their function. Many proteins, including cellular receptors, enzymes, and intracellular signaling molecules, are activated/deactivated by phosphorylation/dephosphorylation. Thus, reversible phosphorylation plays a significant role in the regulation of cellular processes. Nestin protein in the cytoplasm of CNS stem/progenitor cells is thought to play a role in distributing Vimentin from copolymerized intermediate filaments to daughter cells during cell division [11]. Elevated phosphorylation of Nestin

1. Introduction

Nestin is a class VI intermediate filament protein expressed in undifferentiated central nervous system (CNS) cells during development. The protein is known as a neural stem/progenitor cell marker and required for the survival and self-renewal of neural stem cells (NSCs) [1]. Nestin expression is downregulated when CNS stem/progenitor cells differentiate into neurons or glial cells [2, 3], and the expression is kept in adult CNS stem/progenitor cells that reside in the forebrain neurogenic regions [4, 5]. Nestin expression has also been reported in vascular endothelial cells (ECs) from a variety of adult human non-CNS tissues [6, 7]. We recently reported Nestin expression in proliferating endothelial progenitor cells (EPCs), but not in mature ECs [8]. We utilized E/nestin:EGFP transgenic mice using its second intronic enhancer element to study neural-specific nestin gene expression [9, 10] and demonstrated that vascular nestin expression is not activated by the CNS-specific enhancer of the nestin gene [8]. This finding indicated that the Nestin expressed in EPCs is cytochemically similar to the protein expressed in CNS stem/progenitor cells, but the regulatory mechanism of gene expression is different.

The reversible phosphorylation of proteins results in a conformational change that alters their function. Many proteins, including cellular receptors, enzymes, and intracellular signaling molecules, are activated/deactivated by phosphorylation/dephosphorylation. Thus, reversible phosphorylation plays a significant role in the regulation of cellular processes. Nestin protein in the cytoplasm of CNS stem/progenitor cells is thought to play a role in distributing Vimentin from copolymerized intermediate filaments to daughter cells during cell division [11]. Elevated phosphorylation of Nestin
has been observed to accompany the mitotic reorganization of Nestin in an immortalized CNS precursor rat cell line [12]. Concerning the developing mouse brain, more than 500 phosphorylation sites on proteins, including Nestin, have been identified by phosphoproteomic analysis [13]. However, Nestin phosphorylation has not been investigated in adult NSCs. Using quantitative phosphoproteome analysis, we demonstrate in the present study that different phosphorylation levels are found among CNS Nestin in adult NSCs and vascular Nestin in adult bone-marrow-derived EPCs.

2. Materials and Methods

2.1. Animals. Adult (8 to 10 weeks old) wild-type C57BL/6j mice were purchased from SLC (Shizuoka, Japan). All animal-related procedures were approved by the Laboratory Animal Care and Use Committee of Keio University and conducted in accordance with the guidelines of the National Institutes of Health, USA.

2.2. Primary Neural Stem/Progenitor Cell Culture. Neurospheres were generated from adult mouse forebrain as described previously [8, 10, 14, 15]. Briefly, the striata from adult mice were dissected, incubated with trypsin solution for 15 min at 37°C, triturated, and then trypsin inhibitor solution added. Dissociated cells (5000 cells/mL) were seeded in neurosphere culture medium composed of DMEM-F12 (1:1), glucose (0.6%), glutamine (2 mM), sodium bicarbonate (13.4 mM), HEPES (5 mM), insulin (25 μg/mL), transferrin (100 μg/mL), progesterone (20 nM), sodium selenate (30 nM), and putrescine (60 nM) supplemented with recombinant human epidermal growth factor (EGF, 20 ng/mL) and recombinant human basic fibroblast growth factor (bFGF, 20 ng/mL). Cells were cultured for 7 days in vitro (DIV) and formed floating cell clusters of neural stem/progenitor cells (neurospheres). Primary neurospheres were collected and mechanically triturated. Dissociated cells were counted and stored at −20°C.

2.3. EPC Culture. EPCs were cultured from mononuclear cells (MNCs) under previously reported culture conditions [8]. The femurs and tibias of adult mice were crushed, suspended in 100 mL of DMEM (#12699, Gibco Invitrogen) supplemented with 10% FBS and 1% penicillin G (10,000 units/mL) streptomycin (1% PS). The medium was renewed every 3 to 4 days. Cells were harvested by incubation with 0.25% trypsin and 1 mM EDTA and stored at −20°C.

2.4. EC Line. To compare phosphorylation between CNS Nestin and vascular endothelial Nestin in proliferative cells further, we prepared neoplastic ECs. Cells from a mouse brain endothelioma cell line (bEnd.3 cells CRL-2299, ATCC, Manassas, VA) were characterized as proliferative endothelial cells expressing vascular Nestin similar to EPCs and positive for mature EC marker vWF [8].

2.5. Quantitative Phosphoproteome Analysis. Cells were processed for phosphoproteome analysis based on mass spectrometry (MS) coupled with miniaturized on-line liquid chromatography (LC). Proteins were extracted from cells (100,000 cells from adult neurospheres; 1,000,000 cells from EPCs and the neoplastic ECs) using 12 mM sodium deoxycholate and 12 mM sodium lauryl sarcosinate, and digested with Lys-C and trypsin [17]. Phosphopeptides were enriched by aliphatic hydroxy acid-modified metal oxide chromatography with titania [18] and analyzed by nanoLC-MS/MS using an LTQ-Orbitrap instrument (Thermo Fisher Scientific, Bremen, Germany). Peptides and proteins were identified using Mascot version 2.3 (Matrix Science, London) with the SwissProt database. Label-free quantitation was performed based on the peak areas of extracted ion chromatograms for identified phosphopeptides using Mass Navigator (Mitsui Knowledge Industry, Tokyo, Japan).

3. Results

3.1. Protein Phosphorylation of CNS Stem/Progenitor Cells, EPCs, and Neoplastic ECs. CNS stem/progenitor cells were obtained from striata of the lateral wall of the lateral ventricles in the adult mouse brain and grown as neurospheres in vitro. Phosphoproteome analysis detected 495 phosphopeptides in the cell lysates (Table 1). Approximately 90% of the peptides detected in neurosphere cells were phosphorylated. A similar percentage of phosphopeptides was measured in neoplastic ECs. However, approximately 60% of peptides in nonneoplastic proliferative endothelial cells,
Table 1: Protein phosphorylation of adult CNS stem/progenitor cells, EPCs, and neoplastic ECs.

|                  | pPeptides (pPeptides/total peptides) | pSites (pSite/total pSites) | Multi-pPeptides (single or multi-pSite peptides/total pPeptides) |
|------------------|--------------------------------------|-----------------------------|---------------------------------------------------------------|
|                  | Serine                               | Threonine                   | Tyrosine                                                    |
| Neurospheres     | 495 (91.2%)                          | 443 (84.2%)                 | 71 (13.5%)                                                  |
| EPCs             | 250 ± 5 (59.7%)                      | 194 ± 8 (87.4%)             | 20 ± 3 (9.0%)                                               |
| Neoplastic ECs   | 980 (97.8%)                          | 896 (88.1%)                 | 103 (10.1%)                                                 |

pPeptides, phosphopeptides; pSites, phosphorylation sites; multi-pPeptides, multi-phosphorylated peptides; 1p, single-phosphorylated site; 2p, two phosphorylated sites. Data are mean ± standard deviation.

EPCs, were phosphorylated, indicating that intracellular and cell membrane proteins were activated overall in neurosphere cells compared to EPCs. Generally, phosphorylation occurs most commonly on serine, followed by threonine. More than 80% of phosphorylated sites were serine residues in our samples, and the ratio of phosphorylated amino acids was not different between neurosphere cells, EPCs, and neoplastic ECs (Table 1). We tabulated phosphorylated proteins and their phosphorylated amino acid residues in Figure 1 in Supplementary Material (available online at doi:10.1155/2012/430138).

3.2. Nestin Phosphorylation of CNS Stem/Progenitor Cells, EPCs, and Neoplastic ECs. Quantitative phosphoproteome analysis identified 10 phosphopeptides and 11 significant phosphorylated amino acid residues (a peak area >1.0E+04) in the Nestin protein from adult neurosphere cells (Figure 1). In contrast, EPCs derived from adult mouse bone marrow showed no significant phosphorylation of Nestin (n = 2). In neoplastic ECs, 13 significant phosphorylated amino acid residues were identified. Thus, the finding that Nestin is not phosphorylated in EPCs is not likely due to the tissue specificity of ECs. All phosphorylated amino acid residues found in neurosphere cells and neoplastic ECs were serine. Although phosphothreonine was reported in samples of Nestin from an immortalized rat cell line [12] and human HeLa cells (cervical carcinoma) [19, 20], we did not detect the phosphorylation of threonine residues in the Nestin proteins from our samples. Five of the phosphorylated amino acid residues (S565, S570, S819, S883, and S886) were detected in neurosphere cells only, eight (S575, S688, S813, S816, S1216, S1562, S1860, and S1861) were detected...
in neoplastic ECs only, and six (S169, S728, S731, S1010, S1565, and S1837) were detected in both neurosphere cells and neoplastic ECs (Figure 1).

In CNS stem/progenitor cells, Nestin protein preferentially forms heterodimers and heterotetramers with a variety of intermediate filament proteins, particularly type III Vimentin and type IV α-Internexin [21, 22]. Phosphoproteome analysis detected phosphorylation of Vimentin but not α-Internexin from the samples of adult neurospheres, EPCs, and neoplastic ECs (Figure 1 in Supplementary Material).

4. Discussion

Recent investigations of nestin-knockout mice have reported that Nestin deficiency results in embryonic lethality with the neuroepithelium of the developing neural tube exhibiting low numbers of NSCs and high levels of apoptosis [1]. The downregulation of nestin in the embryonic cerebral cortex using small interference RNAs against nestin mRNA results in G1 cell-cycle arrest and a severe reduction in the generation of neurons [23]. However, no data have been reported on the in vivo function of adult Nestin. Transient transfection of nestin-non-expressing cells with an expression vector carrying rat nestin cDNA has been shown to promote the disassembly of phosphorylated Vimentin intermediate filaments in the cytoplasm during mitosis [11]. Our phosphoproteome analysis detected phosphorylated Vimentin in the adult neurosphere sample. Thus, Nestin in adult NSCs is likely to mediate the distribution of Vimentin protein to daughter cells during self-renewal and neurogenesis.

In a rat neuronal progenitor cell line, the mitotic reorganization of Nestin was accompanied by the elevated phosphorylation of Nestin, and T316 was identified as a Nestin phosphorylation site [12]. Phosphorylated threonine was not detected in Nestin from adult CNS stem/progenitor cells, EPCs, or neoplastic ECs in the present study. However, we identified 11 significant phosphorylation sites at serine residues in Nestin protein from adult CNS stem/progenitor cells using quantitative phosphoproteome analysis. The difference in phosphorylated amino acids and the number of phosphorylated sites may be due to technological advances in phosphoproteome analysis and/or the difference in cell sources. Phosphorylated serine residues have been reported in Nestin protein from the brain of mouse embryos [13] and mouse skin melanoma [24] and have been assumed by similar data in human HeLa cells [19, 20]. Among the 11 phosphorylated serine residues we identified in Nestin protein, only two (S565 and S1010) were reported previously; the other nine (S169, S570, S728, S731, S819, S883, S886, S1565, and S1837) were newly identified in the present study.

Nestin protein is expressed not only in NSCs, but also in tissue stem/progenitor cells beyond the germ layers, including mesenchymal stem cells [25], vascular endothelium [6–8], muscle [26–28], testes [29], and teeth [30]. Nestin is also abundant in progenitor cells derived from embryonic stem cells that have the potential to develop into neuroectodermal, endodermal, and mesodermal lineages [31]. We recently reported that Nestin is expressed in proliferating ECs and may be useful as a marker of neovascularization [8]. Nestin expression has been reported in the angiogenic endothelium of cancers [32, 33]. Independent cell-type-specific elements of the nestin gene are identified in transgenic mice; the first intron directs reporter gene expression to the mesodermal somite, and the second intron contains enhancer that functions in NSCs [28]. Although the regulatory mechanisms underlying nestin gene expression in proliferative vascular cells are different from those in NSCs, the protein expression of vascular Nestin is cytochemically similar to CNS Nestin [8]. The phosphorylation of Nestin protein from adult neurospheres can allow it to be distinguished from Nestin in EPCs. Although Nestin phosphorylation was also observed in neoplastic ECs, our phosphoproteome analysis identified CNS-specific phosphorylation sites, suggesting that a phospho-specific Nestin antibody may distinguish between the expression of CNS and vascular Nestin proteins.

5. Conclusions

Quantitative phosphoproteome analysis identified phosphorylated serine residues in Nestin from adult mouse CNS stem/progenitor cells. Phosphorylation was not observed in Nestin from EPCs. Detection of the CNS-specific phosphorylation sites in Nestin, for example, by a phospho-specific Nestin antibody, may allow the expression of CNS Nestin to be distinguished from vascular Nestin.

Acknowledgment

This study was supported by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Science, Sports, and Technology to J.N.

References

[1] D. Park, A. P. Xiang, F. F. Mao et al., “Nestin is required for the proper self-renewal of neural stem cells,” Stem Cells, vol. 28, no. 12, pp. 2162–2171, 2010.
[2] J. Dahlstrand, M. Lardelli, and U. Lendahl, “Nestin mRNA expression correlates with the central nervous system progenitor cell state in many, but not all, regions of developing central nervous system,” Developmental Brain Research, vol. 84, no. 1, pp. 109–129, 1995.
[3] K. Frederikson and R. D. G. McKay, “Proliferation and differentiation of rat neuroepithelial precursor cells in vivo,” Journal of Neuroscience, vol. 8, no. 4, pp. 1144–1151, 1988.
[4] C. M. Morshhead, B. A. Reynolds, C. G. Craig et al., “Nestin expression in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells,” Neuron, vol. 13, no. 5, pp. 1071–1082, 1994.
[5] B. A. Reynolds and S. Weiss, “Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system,” Science, vol. 255, no. 5052, pp. 1707–1710, 1992.
[6] T. Klein, Z. Ling, H. Heimberg, O. D. Madsen, R. S. Heller, and P. Serup, “Nestin is expressed in vascular endothelial cells...
in the adult human pancreas,” *Journal of Histochemistry and Cytochemistry*, vol. 51, no. 6, pp. 697–706, 2003.

[7] J. Mokry, D. Cizkova, S. Filip et al., “Nestin expression by newly formed human blood vessels,” *Stem Cells and Development*, vol. 13, no. 6, pp. 658–664, 2004.

[8] S. Suzuki, J. Namiki, S. Shibata, Y. Mastuzaki, and H. Okano, “The neural stem/progenitor cell marker nestin is expressed in proliferative endothelial cells, but not in mature vasculature,” *Journal of Histochemistry and Cytochemistry*, vol. 58, no. 8, pp. 721–730, 2010.

[9] C. B. Johansson, C. Lothian, M. Molin, H. Okano, and U. Lendahl, “Nestin enhancer requirements for expression in normal and injured adult CNS,” *Journal of Neuroscience Research*, vol. 69, no. 6, pp. 784–794, 2002.

[10] A. Kawaguchi, T. Miyata, K. Sawamoto et al., “Nestin-EGFP transgenic mice: visualization of the self-renewal and multipotency of CNS stem cells,” *Molecular and Cellular Neuroscience*, vol. 17, no. 2, pp. 259–273, 2001.

[11] Y. H. Chou, S. Khuon, H. Herrmann, and R. D. Goldman, “Nestin promotes the phosphorylation-dependent disassembly of vimentin intermediate filaments during mitosis,” *Molecular Biology of the Cell*, vol. 14, no. 4, pp. 1468–1478, 2003.

[12] C. M. Sahlgren, A. Mikhailov, J. Hellman et al., “Mitotic reorganization of the intermediate filament protein nestin involves phosphorylation by cdc2 kinase,” *The Journal of Biological Chemistry*, vol. 276, no. 19, pp. 16456–16463, 2001.

[13] B. A. Ballif, J. Villén, S. A. Beausoleil, D. Schwartz, and S. P. Gygi, “Phosphoproteomic analysis of the developing mouse brain,” *Molecular and Cellular Proteomics*, vol. 3, no. 11, pp. 1093–1101, 2004.

[14] A. Murayama, Y. Matsuzaki, A. Kawaguchi, T. Shimazaki, and H. Okano, “Flow cytometric analysis of neural stem cells in the developing and adult mouse brain,” *Journal of Neuroscience Research*, vol. 69, no. 6, pp. 837–847, 2002.

[15] T. Shimazaki, T. Shingo, and S. Weiss, “The ciliary neurotrophic factor/leukemia inhibitory factor/gp130 receptor complex operates in the maintenance of mammalian forebrain neural stem cells,” *Journal of Neuroscience*, vol. 21, no. 19, pp. 7642–7653, 2001.

[16] F. Timmermans, J. Plum, M. C. Yöder, D. A. Ingram, B. Vandekerckhove, and J. Case, “Endothelial progenitor cells: identity defined?” *Journal of Cellular and Molecular Medicine*, vol. 13, no. 1, pp. 87–102, 2009.

[17] T. Masuda, N. Saito, M. Tomita, and Y. Ishihama, “Unbiased quantitation of Escherichia coli membrane proteome using phase transfer surfactants,” *Molecular and Cellular Proteomics*, vol. 8, no. 12, pp. 2770–2777, 2009.

[18] N. Sugiyama, T. Masuda, K. Shinoda, A. Nakamura, M. Tomita, and Y. Ishihama, “Phosphopeptide enrichment by aliphatic hydroxy acid-modified metal oxide chromatography for nano-LC-MS/MS in proteomics applications,” *Molecular and Cellular Proteomics*, vol. 6, no. 6, pp. 1103–1109, 2007.

[19] J. V. Olsen, B. Blagoev, F. Gnadt et al., “Global, in vivo, and site-specific phosphorylation dynamics in signaling networks,” *Cell*, vol. 127, no. 3, pp. 635–648, 2006.

[20] N. Dephoure, C. Zhou, J. Villén et al., “A quantitative atlas of mitotic phosphorylation,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 31, pp. 10762–10767, 2008.

[21] K. Michalczyczyk and M. Ziman, “Nestin structure and predicted function in cellular cytoskeletal organisation,” *Histology and Histochemistry*, vol. 20, no. 2, pp. 665–671, 2005.

[22] C. Eliasson, C. Sahlgren, C. H. Berthold et al., “Intermediate filament protein partnership in astrocytes,” *The Journal of Biological Chemistry*, vol. 274, no. 34, pp. 23996–24006, 1999.

[23] X. J. Xue and X. B. Yuan, “Nestin is essential for mitogen-stimulated proliferation of neural progenitor cells,” *Molecular and Cellular Neuroscience*, vol. 45, no. 1, pp. 26–36, 2010.

[24] S. Zanivan, F. Gnadt, S. A. Wickström et al., “Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry,” *Journal of Proteome Research*, vol. 7, no. 12, pp. 5314–5326, 2008.

[25] S. Méndez-Ferrer, T. V. Michurina, F. Ferraro et al., “Mesenchymal and haematopoietic stem cells form a unique bone marrow niche,” *Nature*, vol. 466, no. 7308, pp. 829–834, 2010.

[26] A. M. Kachinsky, J. A. Dominov, and J. B. Miller, “Intermediate filaments in cardiac myogenesis: nestin in the developing mouse heart,” *Journal of Histochemistry and Cytochemistry*, vol. 43, no. 8, pp. 843–847, 1995.

[27] T. Sejersen and U. Lendahl, “Transient expression of the intermediate filament nestin during skeletal muscle development,” *Journal of Cell Science*, vol. 106, part 4, pp. 1291–1300, 1993.

[28] L. Zimmerman, B. Parr, U. Lendahl et al., “Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or muscle precursors,” *Neuron*, vol. 12, no. 1, pp. 11–24, 1994.

[29] K. Fröjdman, L. J. Pelliniemi, U. Lendahl, I. Virtanen, and J. E. Eriksson, “The intermediate filament protein nestin occurs transiently in differentiating testis of rat and mouse,” *Differentiation*, vol. 61, no. 4, pp. 243–249, 1997.

[30] C. Terling, A. Rass, T. A. Mitsiadis, K. Fried, U. Lendahl, and J. Wroblewski, “Expression of the intermediate filament nestin during rodent tooth development,” *International Journal of Developmental Biology*, vol. 39, no. 6, pp. 947–956, 1995.

[31] C. Wiese, A. Rolletschek, G. Kania et al., “Nestin expression—a property of multi-lineage progenitor cells?” *Cellular and Molecular Life Sciences*, vol. 61, no. 19–20, pp. 2510–2522, 2004.

[32] M. Aihara, K. I. Sugawara, S. Torii et al., “Angiogenic endothelium-specific nestin expression is enhanced by the first intron of the nestin gene,” *Laboratory Investigation*, vol. 84, no. 12, pp. 1581–1592, 2004.

[33] N. Teranishi, Z. Naito, T. Ishiwata et al., “Identification of neovasculature using nestin in colorectal cancer,” *International Journal of Oncology*, vol. 30, no. 3, pp. 593–603, 2007.
Review Article

Regulation of Injury-Induced Neurogenesis by Nitric Oxide

Bruno P. Carreira,1 Caetana M. Carvalho,1 and Inês M. Araújo2,3

1 Centre for Neuroscience and Cell Biology, Neuroendocrinology and Neurogenesis Group, University of Coimbra, Coimbra, Portugal
2 Regenerative Medicine Program, Department of Biomedical Sciences and Medicine, Gambelas Campus, University of Algarve, 8005-139 Faro, Portugal
3 IBB-Institute for Biotechnology and Biotechnology, Centre of Molecular and Structural Biomedicine, Gambelas Campus, University of Algarve, 8005-139 Faro, Portugal

Correspondence should be addressed to Inês M. Araújo, imaraujo@ualg.pt

Received 1 June 2012; Accepted 19 July 2012

Academic Editor: Oscar Gonzalez-Perez

Copyright © 2012 Bruno P. Carreira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The finding that neural stem cells (NSCs) are able to divide, migrate, and differentiate into several cellular types in the adult brain raised a new hope for restorative neurology. Nitric oxide (NO), a pleiotropic signaling molecule in the central nervous system (CNS), has been described to be able to modulate neurogenesis, acting as a pro- or antineurogenic agent. Some authors suggest that NO is a physiological inhibitor of neurogenesis, while others described NO to favor neurogenesis, particularly under inflammatory conditions. Thus, targeting the NO system may be a powerful strategy to control the formation of new neurons. However, the exact mechanisms by which NO regulates neural proliferation and differentiation are not yet completely clarified.

In this paper we will discuss the potential interest of the modulation of the NO system for the treatment of neurodegenerative diseases or other pathological conditions that may affect the CNS.

1. Introduction

Neurogenesis is not limited to embryonic development as previously thought and occurs throughout the entire adult life of mammals, including humans. New neurons are continuously added to neural circuits and originate at two principal brain regions: the subventricular zone (SVZ) of the lateral ventricles, which generates olfactory bulb (OB) neurons, and the subgranular zone (SGZ) of the dentate gyrus (DG) of the hippocampus. Both regions harbor neural stem cells (NSCs) that can be isolated and cultured in vitro in the presence of growth factors, such as basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), or both. The absence of growth factors results in the differentiation of cells into neurons, astrocytes, or oligodendrocytes as discussed in [1]. Neurogenesis has been exhaustively studied over the past years, and despite the great progress that has been achieved, the knowledge of the multiple aspects controlling proliferation, differentiation, or survival of NSCs is far from being known or understood. It was shown that neurogenesis decreases with aging and is impaired in several pathological conditions affecting the brain. Whether the insult is acute, such as ischemic brain stroke, traumatic brain injury, or epileptic seizures, or is a slow-progressing disease like Alzheimer’s disease, Huntington’s disease, or Parkinson’s disease, all these conditions are accompanied by an inflammatory response in the brain [2]. Furthermore, the blockade of neuroinflammation restores adult neurogenesis [3, 4]. When an inflammatory response in the brain appears following an injury, activation of the brain immune cells takes place, particularly microglial cells. In inflammatory conditions, microglial cells become “activated”, and among a plethora of morphological and immunological alterations, they are able to express the inducible nitric oxide synthase (iNOS), producing high levels of nitric oxide (NO).

NO is a multifaceted gaseous signaling molecule with several distinct functions in the central nervous system (CNS) [5]. This molecule is simultaneously involved in neuroprotection and in neurotoxicity, being also involved in inflammatory mechanisms in the CNS [6, 7]. NO was shown to modulate neurogenesis in the adult CNS as reviewed in [8]. In physiological conditions, NO tonically inhibits neurogenesis in the brain, while in pathophysiological conditions...
it exerts a proneurogenic effect on the dividing population of neuronal precursors. Moreover, the physiological effect of NO is mostly mediated by the neuronal nitric oxide synthase (nNOS), which is constitutively expressed, while pathophysiological levels of NO are attained following expression of iNOS [9–12]. Depending on the insult and on its source, NO can act as an antiproliferative agent [9–11] or stimulate neuronal precursor proliferation and differentiation [12]. However, the exact mechanisms by which NO regulates neuronal proliferation and differentiation are not yet clarified, and further investigation on this matter is needed. Since neuroinflammation is detrimental for adult neurogenesis, it would be of great interest to elucidate the role of inflammatory NO on the ongoing neurogenesis in these conditions. Therefore, the main goal of this paper is to elucidate the potential of the NO system modulation for the treatment of neurodegenerative diseases or other pathological conditions that may affect the CNS.

2. Neurogenesis following Brain Injury

Adult neurogenesis is implicated in many forms of plasticity in the CNS. The neurogenic process can be summarized in five main stages: (a) precursor cell proliferation, (b) fate determination, (c) migration, (d) differentiation and integration, and (e) survival.

Various models of injury in the rodent brain have been used to demonstrate that proliferation of stem cells is particularly enhanced in the SVZ and DG after an insult, which has been suggested to be a repair attempt from the lesioned brain, as reviewed in [13]. It has been observed that injury and pathological conditions affect adult neurogenesis, having a particular impact in neurogenic regions, but also in areas that are not normally considered as classical neurogenic regions, as discussed in [14, 15].

Regarding the type of insult to the brain, this may be acute, as ischemic brain stroke, traumatic brain injury or prolonged seizures, or a slow-progressing neurodegenerative disease. Neurogenesis decreases with aging and is impaired in several neurodegenerative disorders, such as Huntington’s disease [16, 17] or Alzheimer’s disease [18]. All these conditions are accompanied by an inflammatory response in the brain. However, the factors that attract neural progenitors to the lesioned areas are still under investigation. Another matter of hot debate is whether these new neurons are functionally integrated and survive in the existing neuronal circuitry.

3. Injury and Neuroinflammation

Inflammation is, by definition, a complex biological response to certain noxious stimuli such as stress, injury, or infection by external agents [19, 20]. After injury or exposure to pathogens, an inflammatory response takes place, with the involvement of two major groups of immune cells: (a) CNS resident microglial cells and astrocytes and (b) infiltrating lymphocytes, monocytes, and macrophages from the hematopoietic system [21, 22]. Therefore, the neuroinflammatory response attempts to protect the affected organism by removing harmful stimuli or removing dead and damaged cells, thereby initiating the healing process and return the tissue to homeostasis. When activated, immune cells release different regulating substances, such as complement molecules, cytokines-like interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-18 and IL-6, chemokines such as stromal-derived factor (SDF)-1alpha and monocytes chemoattractant protein-1 (MCP-1), glutamate, reactive oxygen species (ROSs), and reactive nitrogen species (RNSs) like NO, as extensively reviewed in [23]. These inflammatory mediators are responsible for the recruitment of resident microglia, stimulation of astrogliosis, but also for the disruption of the blood-brain barrier (BBB) and further recruitment of monocytes and lymphocytes from the hematopoietic system to the site of inflammation [24–26].

Although inflammation in the CNS should be considered as a process that seeks to protect, we also must take into account its harmful properties as reported in [27]. The activation of recruited cells to the site of inflammation leads to the release of inflammatory factors that contribute to create a positive feedback loop of inflammatory activation, resulting ultimately in neuronal loss and/or neuronal damage. Thus, the inflammatory response may have a dual effect on the cellular environment, beneficial and/or detrimental. The severity of neuroinflammation can range from mild acute to uncontrolled chronic inflammation, resulting in different activation states of inflammatory cells and distinct biological outcomes [28]. It is believed that neuroinflammation may be involved in the mechanisms that lead to various CNS diseases, also affecting the process by which new neurons are generated in the brain [29].

3.1. Neurodegeneration. Neurodegeneration is characterized by the slow progressive dysfunction and loss of neurons in the CNS. Immune activation within the CNS is a classical event following infections, ischemia, trauma, and neurodegenerative diseases. The inflammatory response often contributes to collateral CNS injury, which is characterized essentially by neuronal loss and atrophy in different brain regions. Neuronal susceptibility to cell death [30, 31] and concomitant failure in self-repair mechanisms [32], combined with inhibition of axonal growth and limited repopulation by neuronal precursor cells are singled out as the main causes for neurodegenerative events that follow brain inflammation [33, 34]. However, not all immune response in the CNS should be considered harmful, and in many cases they actually are an important aid for cell repair and regeneration. Particularly, microglial cells seem to play an important role in facilitating the reorganization of neuronal circuits and in triggering repair [35]. Thus, like inflammation, microglial activation also appears to play a dual role in neurodegeneration, acting either as detrimental or beneficial, as reported in [36].

The relationship between neuroinflammation and neurodegeneration is being studied in numerous models of CNS disorders such as Alzheimer’s and Parkinson’s disease, suggesting neuroinflammation as a critical process, if not the primary cause, for CNS lesions seen in these diseases, as
extensively reviewed in [23, 37]. However, these studies also revealed complex neuroimmune interactions, both at cellular and molecular levels, thus demonstrating that immune cells secrete both neurotoxic and neuroprotective molecules [2]. Although different triggering events could occur, a common feature for the neurodegenerative event seems to be the chronic activation of microglial cells.

3.2. Neuroinflammation and Production of New Neurons. As mentioned in previous sections, neuroinflammation is a complex process with different outcomes in neurogenesis, which can be enhanced or suppressed [38]. Besides differences between mild acute and uncontrolled chronic inflammation, the shift from pro- to anti-neurogenic inflammatory status appears to be dependent on (a) the mechanism by which microglia, macrophages, and/or astrocytes are activated, (b) the type of inflammatory mediators released, and (c) for how long inflammatory cells, particularly microglia, are activated [36].

3.2.1. Impaired Formation of New Neurons. Inflammation and microglia activation were initially thought to inhibit adult neurogenesis [3, 4], while recent studies indicate that microglia can also support neurogenic events, as described in [39]. It was shown that lipopolysaccharide-(LPS-) induced activation of microglia impairs neurogenesis in rats [4], apparently through the increased production of TNF-alpha [40]. Additional evidences corroborating the detrimental effect of LPS-activated microglia was provided by another study, which showed that acute activation of microglia with LPS reduces NSC survival and neuronal differentiation [41]. Furthermore, suppression of microglial activation with an antibiotic, such as minocycline, was also used to demonstrate increased neurogenesis in the hippocampus, thus indicating that the severity of impaired neurogenesis correlates with the number of activated microglial cells [4].

Several other authors reported that the mechanism by which microglia exert these effects involves the release of proinflammatory mediators, such as IL-1, IL-6, IFN-gamma, and TNF-alpha, which seem to play an essential role in suppressing neurogenesis [42–45] (Table 1). It has also been suggested that ROS and RNS, particularly NO, can inhibit adult neurogenesis in inflammatory conditions [3, 46, 47]. In addition, several studies demonstrated that neurogenesis could be restored following treatment with anti-inflammatory drugs [3, 4, 48, 49]. Neurogenesis was restored after treatment with indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), after irradiation-induced inflammation [3] or focal cerebral ischemia [49]. Other studies also reported an increased survival of newly generated neuroblasts in the striatum after stroke [49], or in the DG after middle cerebral artery occlusion (MCAO) [50] when the activation of microglia is inhibited by indomethacin or minocycline, respectively.

3.2.2. Enhancement of Neurogenesis. Contrary to what was initially thought that neuroinflammation is detrimental to adult neurogenesis, recent evidence indicates that under certain circumstances inflammation can also benefit the neurogenic process (Table 1). Apparently, neural stem cells become “activated” following brain injury and migrate into the lesioned areas, thus suggesting the inflammatory microenvironment as an important trigger for the migration of newborn cells [64, 65]. Microglia was reported to play a dual role on neurogenesis, suggesting neurogenesis inhibition to be caused by microglial activation under inflammatory conditions [53]. Other studies showed a persistent production of neurons from adult NSC, even after the inhibition of acute microglial activation, during recovery after stroke [66, 67]. Moreover, it was demonstrated that long-term survival of newborn neurons after status epilepticus (SE), with concomitant chronic activation of microglia [68]. In vitro studies have also showed an important role for microglia in directing the replacement of damaged or lost cells [52, 69–71]. LPS-activated microglia and inflammation increase the integration of newly generated neurons into the adult rat hippocampus [72]. More recently, long-term accumulation of activated microglia, although with

### Table 1: Regulation of adult neurogenesis by inflammatory mediators.

| Inflammatory factor | Proliferation of NSC | Differentiation of NCS | Survival of NSC | References |
|---------------------|----------------------|------------------------|----------------|------------|
| IL-1                | ↑ or ↓               | ↑ neuronal             | ↑ or ↓         | [41]       |
| IL-6                | ↓                    | ↑ neuronal             | ↑              | [4, 46, 52]|
| IFN-gamma           | ↑                    | ↑ neuronal             | ↑              | [42, 53–56]|
|                     | ↑ or ↓ or ↓         | ↑ neuronal (TNF-R1)    | ↑ or ↓         | [40]       |
| TNF-alpha           | ↑                    | ↑ neuronal (TNF-R2)    | ↑              | [43, 54]   |
|                     | ↑ or ↓               | ↑ neuronal (TNF-R1)    | ↑ or ↓         | [40]       |
|                     | ↑ or ↓               | ↑ neuronal (TNF-R2)    | ↑ or ↓         | [36, 44]   |
| SDF-1alpha          | ↑ or ↓               | ↑ neuronal             | ↑              | [62, 63]   |

The effects listed here may not be direct. ↑: increase; ↓: decrease; =: no change; —: no report.
a downregulated inflammatory profile, was shown to be concomitant with persistent neurogenesis in the adult SVZ after stroke [73]. Other inflammatory mediators have also been implicated in the improvement of migration and proliferation of new neurons following brain damage, such as SDF-1 alpha and its receptor CXCR4 [62, 66] or trophic factors such as GDNF and BDNF, who are involved in the removal of damaged synapses [73]. In summary, all these studies suggest a neuroprotective role of microglia for newborns. Although microglia may have a detrimental action in early stages of the inflammatory response that follows acute insults, it could be converted into a protective state during chronic activation.

3.2.3. Dual Role of Inflammation in Neurogenesis. It is now widely accepted that microglia have a dual role in neurogenesis by favoring it or, alternatively, hindering neurogenesis. Apparently, microglial cells and the inflammatory factors they release, like NO (to be discussed below), seem to have opposite roles in neurogenesis under inflammatory conditions [38, 74]. However, it is important to reinforce the idea that inflammation, essentially characterized by activation of microglia, has distinct roles in various stages of neurogenesis, this effect being dependent on the degree of activation of immune cells, type of inflammatory mediator released, and duration of the inflammatory response [38]. Nevertheless, there are lines of evidence for some of the most important inflammatory mediators in the regulation of neurogenesis and/or neuroprotection [23, 75, 76].

As noted, further studies should be conducted to assess the interaction between neuroinflammation and neurogenesis, particularly how neuroinflammation modulates self-renewal, proliferation, migration, differentiation, integration in the neuronal network, and, more importantly, survival of newborn cells. As different authors have reported that chronic inflammation can stimulate one or more stages of neurogenesis, such as migration, proliferation, or differentiation, the problem remains in the reduced long-term survival of newborn neurons [23]. Moreover, since different microglial phenotypes and morphologies can be identified during inflammation, an extensive genetic and proteomic characterization will be of great interest to understand more accurately this complex crosstalk.

4. Nitric Oxide

Nitric oxide, a short-lived gaseous-free radical, is synthesized by the nitric oxide synthase (NOS) family of enzymes present in most of the cells of the body. NO is implicated in a wide range of physiological processes within the cardiovascular, immune, and nervous system, where it can act as a non-canonical neurotransmitter [77], but it can also be an important player in pathophysiological events. Different members of the NOS family control different functions of NO. The discovery of NO in the CNS was a breakthrough in the concept of neuronal communication. NO was characterized in the CNS for the first time as an intracellular messenger to increase cyclic guanosine 3′,5′-monophosphate (cGMP) levels, after the activation of glutamate receptors [78]. Later, the same authors also described NO as a neuromodulator, particularly due to its diffusible properties [79], thus acting not only in cells that release NO, but also in neighboring cells where it can therefore trigger its autocrine and/or paracrine functions. Unlike other neurotransmitters, NO is synthesized on demand, diffusing from nerve terminals since it is not stored in vesicles nor released by exocytosis [5]. In the CNS, NO is also associated with cognitive function, having an important role in synaptic plasticity, and controls biological functions, including body temperature, sleep-wake cycle, appetite, and modulation of hormone release, as reviewed in [7]. Another distinctive feature from classical neurotransmitters is that, unlike them, NO ends its action after reacting with a substrate and not by enzymatic degradation or reuptake. In addition, the key mechanism to regulate the activity of NO is the control of its synthesis.

Physiologically, NO interacts with several intracellular targets activating different signaling pathways with a stimulatory or inhibitory response. However, NO can also be toxic to cells, in a mechanism dependent on the formation of RNS [80, 81]. Oxidative stress and nitrosative stress, a consequence of high levels of NO and RNS, have been implicated in the pathogenesis of several neurodegenerative disorders [80, 82, 83], which will be explored in Section 4.2.

4.1. NO as an Inflammatory Mediator. The NOS family of enzymes is responsible for the synthesis of NO. Three different enzyme isoforms have been identified in mammalian cells: (a) neuronal NOS (nNOS, type I), which is constitutively expressed in brain neurons and is activated by calcium/calmodulin, particularly following stimulation of NMDA-type glutamate receptors; (b) endothelial NOS (eNOS, type III), constitutively expressed in endothelial cells and astrocytes and is regulated by calcium/calmodulin and phosphorylation/dephosphorylation; (c) inducible NOS (iNOS, type II) which is calcium-independent and its regulation depends on de novo synthesis [80, 84, 85]. iNOS is not normally expressed in the “healthy” brain but is induced in glial and endothelial cells by proinflammatory stimuli such as cytokines, bacterial/viral agents, and/or hypoxia [80]. iNOS is mainly expressed in macrophages, astrocytes, and microglial cells, upon neurotoxic, traumatic, and inflammatory damage [7, 84, 86, 87], but it could also be found in neurons [88, 89]. Once expressed, iNOS continuously produces high amounts of NO, even for several days [31, 87, 90–92]. The massive production of NO by iNOS is toxic, since it activates the mitochondrial respiratory chain enzymes that ultimately induce apoptosis in target cells. Moreover, NO has been described as an important activator of cyclooxygenase-II (COX-2) in glial cells, also regulating leukocyte adhesion in vessels [80]. The concentration achieved by NO seems to be a determining factor for the effects observed locally in the brain. Thus, in physiological concentrations, which are believed to range from 0.1 to 100 nM, NO is relatively nonreactive, and its actions are mainly mediated by binding to the heme group
of soluble guanylate cyclase (sGC), leading to its activation and subsequent production of cGMP [93].

NO can also be converted into more reactive species commonly referred as RNS. In high concentrations, NO reacts directly with oxygen (O2) to produce nitrogen dioxide (NO2), which in turn further reacts with NO originating dinitrogen trioxide (N2O3). In addition, NO2 may oxidize or nitrate, by adding a nitro (NO2+) group to a great variety of molecules, being a classic example the nitration of tyrosine to 3-nitrotyrosine [94]. Moreover, NO reacts with superoxide (O2−) to produce peroxynitrite (ONOO−), an extremely reactive molecule which can oxidize or nitrate other molecules or, instead, decay forming other damaging species, such as NO2 and/or the hydroxyl radical (OH·). On the other hand, N2O3 can add a nitrosonium ion (NO+) to thiols or amines, an event also designated as nitrosation/nitrosylation, being a good example of protein dysfunction due to nitration or s-nitrosylation [100]. Both S-nitrosylation and nitration typically lead to alterations in protein function [94].

4.2. Neuronal Death. According to the literature, the role of NO in the brain could be summed up in two radically different outcomes: (a) as an intracellular signaling messenger, regulating a wide variety of physiological events, such as synaptic plasticity, blood flow, and neuronal development [95] and (b) as a cytotoxic agent killing indiscriminately both pathogenic and “healthy” host cells in disease [96, 97]. Strong evidence has been reported in the literature supporting a role of NO in the pathogenesis of neurodegenerative disorders, including autoimmune and chronic neurodegenerative diseases. As stated in previous sections, the role of NO seems to be dependent on the concentration attained locally in tissues. When produced in excess, NO shifts from a physiological to a neurotoxic effector. NO overproduction may be due to nNOS activation following persistent glutamatergic excitatory input and/or iNOS expression, upon an inflammatory response. Activated inflammatory cells generate increased levels of ROS such as superoxide, hydrogen peroxide, and hydroxyl radical. Moreover, NO can also induce the production of superoxide by mitochondria [7]. NO and superoxide readily react to form ONOO−, an extremely reactive molecule [81].

Likewise, the excessive release of both glutamate and NO, coupled to oxidative stress and mitochondrial dysfunction, appears to be involved in the majority of neurodegenerative diseases. NO from inflammatory origin has been reported as an important contributing factor to the vulnerability of neurons, causing neuronal death both in vivo and in vitro in rodents [98, 99]. Some authors have suggested this neurotoxic effect as a consequence of enzymatic inhibition of the respiratory chain, resulting in hypoxia, excitotoxicity, and elevated levels of ONOO−, as reviewed in [81]. Furthermore, the excessive NO release by glial cells leads to the formation of ONOO−, which appears to be involved in the mechanisms of neuronal death, some of them linked to protein dysfunction due to nitration or s-nitrosylation [100]. Protein nitration is an irreversible chemical modification affecting tyrosine phosphorylation or dephosphorylation, which seriously affects several signaling pathways involved in the control of cell survival, proliferation, or programmed cell death, as reviewed in [101].

Although it has been implicated in acute injury events, particularly due to a massive release during an inflammatory response, NO has also been associated to slow progressive disorders that can be genetically inherited or sporadic. Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, multiple sclerosis, and amyotrophic lateral sclerosis are all neurodegenerative disorders in which NO has been suggested to be involved, since all of them show evidence of oxidative and nitrative stress [80, 102]. ROS and RNS are important factors in neuroinflammation-mediated neurotoxicity [103]. Furthermore, the presence of 3-nitrotyrosine has been reported in several neurodegenerative diseases linked to oxidative stress such as Alzheimer’s [104] or Parkinson’s disease [105]. Thus, understanding the involvement of NO in the etiology of these disorders may highlight an eventual beneficial potential role of selective NOS inhibitors.

4.3. Nitric Oxide and Neurogenesis. The role of NO as a modulator of neurogenesis is a matter of strong debate. Depending on the source, NO has a dual influence in the neurogenic process both by inhibiting or stimulating neurogenesis (Table 2).

The role of NO in neurogenesis has not been identified until recently [9, 10, 110]. The authors of these contributions had also described a cytostatic function of NO in the CNS, demonstrating that nNOS-derived NO is involved in the regulation of neurogenesis, particularly neural stem cell function [9, 10, 110]. Since blood vessels are part of the SVZ and dentate gyrus SGZ niches, which are also surrounded by differentiated neurons expressing nNOS, NO is produced in close proximity to NSCs. Several authors have described another function for NO in the rostral migratory stream (RMS), where SVZ-derived progenitor cells migrate into the olfactory bulb and differentiate into neurons [119]. These authors demonstrated that nitrergic neurons are in close

| Condition          | Proliferation of NSC | Differentiation of NSC | Survival of NSC | References               |
|--------------------|----------------------|------------------------|-----------------|--------------------------|
| Physiological      | ↑↑                   | =                      | ↓↑              | [8, 9, 106, 107]          |
| Inflammation       | ↑                    | ↑↑                     | =              | [8, 10, 11, 110–112]      |
|                    | ↓↑                   | ↓                      | ⇑              | [8, 113, 114]            |
|                    | ↑                    | ↓                      | =              | [23, 115]                |
|                    | ↑↑                   | =                      | =              | [12, 23, 74, 116, 117]    |

The effects listed here may not be direct. ↑: increase; ↓, decrease; =, no change or no report.
This antiproliferative effect on SVZ, RMS, and OB, but not in the DG, in adult mice. Nitroindazole (7-NI) greatly increased cell proliferation in SVZ and DG neurogenesis. Indeed, the selective inhibition of nNOS with 7-NI was shown that chronic nNOS inhibition enhances neurogenesis. Moreover, the inhibitory role of nNOS-derived NO on SVZ and DG neurogenesis has also been demonstrated in the context of cerebral ischemia. Other authors suggested NO to be a negative regulator of SVZ neurogenesis by modulating the activity of the EGF receptor [107], via nitrosylation of specific cysteine residues [127] (Table 3). Accordingly to these studies, the antiproliferative effect can be partially explained by the inhibition of the EGF receptor and the phosphoinositide-3-kinase (PI3-K)/Akt signaling pathway [107, 127]. Moreover, these authors described the antimitotic effect of NO to correlate with the nuclear presence of the cyclin-dependent kinase inhibitor p27Kip1 [127].

On the contrary, by using pharmacological or genetic approaches, an opposite role has been found for NO synthesized by eNOS in the SVZ and iNOS in the DG following focal ischemia, which seems to stimulate neurogenesis [12, 128]. Moreover, increased immunoreactivity against iNOS following transient ischemia was shown to correlate with a decrease of nNOS in the hippocampus, which is concomitant with an increased neurogenesis [116, 129]. Numerous works showed that ischemia-induced neurogenesis in DG involves the activation of NMDA receptors [130], which is simultaneous to increased iNOS expression [131, 132] (Table 3). However, in a study regarding the effects of NO in cell proliferation, both nNOS- and iNOS-derived NO increases neurogenesis following seizures in the DG of adult rats [133]. Other authors reported that NO released under inflammatory conditions is involved in NSC differentiation into astrocytes by a mechanism dependent on the activation of the JAK/STAT-1 signal transduction pathway [112]. Recently we showed that supraphysiological levels of NO induce the proliferation of SVZ-derived neural stem cells through the activation of two signaling pathways, in a biphasic manner. Thus, the mitotic effect of NO is initially mediated by the direct activation of signaling pathway downstream of the EGF receptor, but bypassing the EGF receptor [74]. Downstream of the EGF receptor, there is an increased activation of the mitogen-activated protein (MAP) kinase ERK pathway following exposure to NO, which activates several downstream targets, namely p90RSK, and further decreases nuclear levels of p27Kip1, thus allowing cell cycle progression [74]. Furthermore, the proliferative effect of supraphysiological levels of NO, following longer periods of exposure (24 h), is mediated by increased signaling through the cGMP/cGMP-dependent kinase (PKG) pathway [115]. In addition, we also showed that NO from iNOS origin promotes proliferation of NSC in the hippocampus of adult mice following SE [74].

Altogether these findings illustrate that NO is a modulator of neurogenesis in diverse ways, and the different NO

| NO source | Effect | Signaling pathway | References |
|----------|--------|-------------------|------------|
| nNOS     | ↓ proliferation (SVZ) | Nitrosylation of EGF receptor (PI3-K)/Akt pathway | [127] |
|          | ↓ neurogenesis (DG) | PSA-NCAM and CREB | [134] |
| eNOS     | ↑ proliferation (SVZ) | ↓ VEGF | [128] |
|          | ↑ neurogenesis (DG and SVZ) | ↑ BDNF and VEGF | [135] |
| iNOS     | ↑ migration (NT2 cell line) | cGMP/PKG pathway | [136] |
|          | ↑ neurogenesis (DG) | ERK 1/2 pathway | [74] |
|          | ↑ neurogenesis (DG and SVZ) | PSA-NCAM and CREB | [137] |
|          | ↑ astrogliogenesis | L-VGCC | [138] |

↑: Increase; ↓: decrease; Brain-derived neurotrophic factor, BDNF; Vascular endothelial growth factor, VEGF; L-type voltage-gated Ca2+ channel, L-VGCC.

Table 3: NO-dependent signal pathways in neurogenesis.
synthases are important players in this effect on neurogenesis [11, 139, 140]. NO effects on neurogenesis are dependent on the developmental period and source of NO (Table 3). Furthermore, NO can have concentration-dependent effects, depending on the local concentration and surrounding molecular environment. Apparently, under physiological conditions NO acts as a negative regulator of neurogenesis [9, 10, 110], while in inflammatory conditions a decrease in nNOS and increase in iNOS may act as a mechanism to enhance neurogenesis [12, 74, 107, 141, 142]. However, the exact molecular mechanisms underlying this dual effect of NO on neurogenesis, are not fully clarified and more studies need to be conducted.

5. Potential Neurogenic Targets in Nitrergic Pathways

Repair of damaged tissues and organs is essential for the survival of organisms. Although the CNS has pools of neural stem cells, these have a limited ability for repair and endogenous cell replacement. Some strategies have been studied over the past years to promote brain repair, particularly: (a) neural precursor or stem cell transplantation or (b) stimulation of endogenous neurogenesis. Moreover, excessive proliferation of NSCs associated with tumor formation is a major concern in the clinical application of both these strategies. Since most brain disorders that could benefit from enhanced neurogenesis are normally accompanied by neuroinflammation, understanding how the inflammatory response affects the neurogenic process is of major importance for the design of safe and efficient therapeutic strategies.

As discussed previously, NO was described to have a dual role on the regulation of adult neurogenesis. NO synthesized from nNOS appears to decrease neurogenesis or to act as an antiproliferative agent [9, 10, 107, 108, 110, 113, 127], whereas NO from iNOS and eNOS origin seems to stimulate neurogenesis [12, 74, 128, 142]. Taking this evidence into account, the modulation of the NO system may be a good target for the development of strategies to improve brain repair. Next, some of the most relevant therapeutic strategies for brain repair using the modulation of the nitrergic system will be discussed.

5.1. Nitric Oxide-Releasing Drugs. Nitric oxide-releasing drugs are pharmacologically active substances that release NO in vivo or in vitro. Two large groups of NO-releasing drugs can be found today: (a) NO donors and (b) NO-releasing nonsteroidal anti-inflammatory drugs. Although the clinical application of these drugs to improve brain repair seems remote, their potential application in the treatment of CNS disorders is a matter of great interest. Several studies have been carried out in order to understand how these drugs control neurogenesis. In fact, there seem to exist good reasons to believe that the use of these drugs may be advantageous in the treatment of brain disorders.

5.1.1. Nitric Oxide Donors. Nitric oxide-releasing compounds are clinically used for the treatment of patients with coronary heart disease [143]. Different types of NO-releasing agents have been developed and are commercially available, such as sodium nitroprusside (SNP), firstly described as a vasodilator, which is used to manage acute hypertensive crisis; or molsidomine, used in the therapy of angina pectoris and heart failure. SIN-1, another NO donor, is known as both NO and ONOO- donor mainly because during NO release from SIN-1 superoxide is also generated [144, 145]. A wide range of NO-releasing drug classes have been developed recently. Among them are diazeniumdilates, also known as NONOates (such as DEA/NO, SPER/NO, or DETA/NO) that release NO spontaneously under physiological conditions. Preclinical studies have shown a potential application for NONOate in cardiovascular disease, but further studies need to be carried out for their use in the clinic [145]. Chemically distinct NO donors differ in their half-life time and amounts of NO released in vitro. Moreover, depending on pH value, temperature, presence of cofactors, and light, the amount of NO released could be altered [144–146].

These compounds have also been useful to study physiological processes and molecular mechanisms in which NO is involved. NO was described to act as an antiproliferative agent in the CNS under physiological conditions, thus affecting neurogenesis [127]. Interestingly, in this work the authors described NO to be antiproliferative through the inhibition of the EGF receptor by S-nitrosylation [127]. Moreover, other authors have also described NO physiological levels to be antiproliferative in the brain [11, 107].

Numerous studies have used NO donors to investigate the effect of high concentrations of NO on neurogenesis, thus mimicking NO concentrations that can be achieved locally in the brain following an inflammatory response. Several groups reported nitric oxide-releasing drugs to enhance recovery after brain injury, partly by increasing neurogenesis in the DG and SVZ [147–150], following ischemic stroke [147, 151] and traumatic brain injury [148]. One study found that exogenous administration of NO using DETA/NO increases cell proliferation and survival in mice hippocampus [117]. We have shown that high concentrations of NO, which could be attained locally in the brain following an inflammatory response, have a dual effect on the proliferation of SVZ-derived NSCs [74, 115]. In fact, the effect of NO on the proliferation appears to be dependent on the period of exposure and concentration of NO achieved. Thus, a slight elevation on NO levels above the physiological range has a proliferative effect in an initial stage (1 day). On the contrary, continuous release of NO overtime (for 2 days) had an antiproliferative effect in SVZ-derived NSCs [74, 115]. This evidence is important to realize that controlling neuroinflammation, thus controlling NO production, will improve the outcome from the neurogenic process following brain injury. Other groups have shown that high concentrations of NO could also modulate other neurogenic stages, such as migration [136, 152] or differentiation [112].

In fact, the studies published in the literature about the effect of high levels of NO in neurogenesis, using NO donors, seem to bring contradictory evidence. However, it should be noted that in most of these works the NO donors
used are chemically distinct and/or have distinct kinetics on NO release. Therefore, the evidence should be carefully interpreted to prevent misleading conclusions. Nevertheless, all these studies appear to be consensual on the following: NO is an important modulator of neurogenesis.

5.1.2. Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drugs. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NO-NSAIDs) are a group of compounds with potential therapeutic applications in several clinical conditions. These drugs are synthesized by grafting a NO-donating moiety to classical NSAID, such as aspirin (NO-aspirin), flurbiprofen (NO-flurbiprofen), naproxen (NO-naproxen), diclofenac (NO-diclofenac), and ibuprofen (NO-ibuprofen) [143, 153, 154]. At present, NSAIDs are used for the treatment of a variety of inflammatory conditions. However, NSAIDs have a limited therapeutic application in chronic conditions, mainly due to their significant side effects in the gastrointestinal (GI) tract and kidneys. In the last decades, a great effort has been done to improve NSAID safety. Therefore, NO-NSAID may be considered as an important therapeutic attempt to overcome the side effects by NSAID. The release of NO from these drugs mimics the physiological production of NO by constitutive NOS, which appears to reduce the toxicity when compared to the parent NSAID [153, 155]. Moreover, this modification strongly reduces the side effects of NSAID, without affecting the anti-inflammatory effectiveness [153].

Since NSAIDs are primarily used as anti-inflammatory drugs, many of the studies with NO-NSAID have been essentially about its anti-inflammatory effects. Numerous studies in the literature have reported the anti-inflammatory effect of NO-NSAID in animal models of acute or chronic inflammation. More recently, there has been increasing concern about the potential application of these drugs in CNS disorders, particularly in neurodegenerative diseases, such as Alzheimer’s disease. Numerous reports suggested NO-NSAID to be a suitable approach for the treatment of Alzheimer’s disease, since they are less toxic to the GI tract than NSAID following chronic ingestion. Moreover, NO-NSAID also inhibit caspase activity thus protecting neurons against cytokine-induced apoptosis during Alzheimer’s disease [153]. As reported by Hauss-Wegrzyniak and coworkers, chronic ingestion of NO-flurbiprofen reduced the activity state of microglial cells in a rat model of Alzheimer’s disease, when comparing to animals treated with aspirin [156]. Other authors also described NO-flurbiprofen to reduce brain beta-amyloid in a mice model of Alzheimer’s disease, which was associated with activation of microglial cells, the presumed responsible for clearing beta-amyloid deposits [157]. Interestingly, these authors reported NO-aspirin to be more efficacious than ibuprofen or celecoxib, a selective COX-2 inhibitor [157]. The neuroprotective effect of different NO-NSAID has additionally been described in other animal models of brain damage. Treatment with NO-aspirin was shown to be more neuroprotective than aspirin, following MCAO [158]. In fact, the results from these experiments are of great interest since they strongly suggest that NO release is determinant for the protective action of NO-aspirin in this animal model. Although the mechanism underlying this effect is still unclear, NO improved blood flow to the ischemic region, thereby reducing the lesioned area. Moreover, the ability of NO-NSAID to inhibit caspase activity is also important for this effect [159].

Given the ability of NSAID in crossing the BBB [160], the use of NO-NSAID in the treatment of CNS disorders can be a very useful tool, in particular for the control of neuroinflammation that, as noted above, may affect neurogenesis [155]. Therefore, it is important to conduct more studies to understand the mechanisms and levels within which NO released by NO-NSAID may promote neurogenesis.

5.2. PDE Inhibitors. The main cellular signaling pathway stimulated by NO is the activation of sGC, subsequent production of cGMP, and further activation of protein kinases that regulate various physiological events [161]. Neurons synthesize cGMP in response to NO by activation of sGC, a heterodimeric heme-containing enzyme. NO reacts with the heme group of the sGC, which undergoes a conformational change, converting GTP into the second messenger cGMP [93, 162]. Some studies suggest that NO can also downregulate sGC activity, particularly in neuroinflammatory conditions [163]. cGMP-dependent kinases, which are serine/threonine kinases, are activated by cGMP and are involved in several physiological phenomena including long-term potentiation in the hippocampus and long-term depression in the cerebellum [93, 162]. In physiological conditions, intracellular cGMP levels are controlled by cyclic nucleotide phosphodiesterases (PDEs) [94]. PDEs are enzymes that hydrolyze the 3′-phosphodiester bound of cyclic adenosine monophosphate (cAMP) or cGMP, originating their corresponding monophosphates, 5′-AMP or 5′-GMP, respectively. cGMP-related physiological functions can be regulated by controlling the levels of PDE type 5 (PDE5) enzymes, which specifically hydrolyze cGMP. Moreover, cGMP also modulates the activity of PDE [164].

The use of selective PDE inhibitors has been proven to be useful in the clinic, particularly PDE5 inhibitors, which are drugs used to treat erectile dysfunction and pulmonary arterial hypertension [164–166]. Sildenafil, commercially available as Viagra, is classically considered as a PDE5 inhibitor; however, it also inhibits PDE1 and PDE6 [166–168]. Similarly to sildenafil, two other inhibitors with higher selectivity for PDE5 were developed for the treatment of erectile dysfunction: tadalafil (Cialis) and vardenafil (Levitra). More recently, a new compound was developed, T0156, which potently inhibits PDE5 [169]. In fact, T0156 inhibits PDE5 with higher potency than sildenafil also presenting higher selectivity for PDE5 in comparison to PDE6 [169]. In erectile dysfunction, PDE5 inhibition enhances relaxation of the cavernosal smooth muscle by NO and cGMP, thus allowing blood flow and stimulating penile erection [170, 171]. In the lung, PDE5 inhibitors act as vasodilators, increasing blood supply, antagonizing the vasoconstriction of smooth muscle, and decreasing pulmonary arterial resistance, thus treating pulmonary hypertension (for comprehensive review see [172–174]).
In the CNS, neurogenesis generally declines with aging and is correlated with the emergence of neurodegenerative diseases. Moreover, the levels of NO gradually decrease in aging, which is concomitant with a decrease in cGMP levels. As demonstrated in aged rats, cGMP levels are decreased as a consequence of the increasing phosphodiesterase activity when compared to young adult rats [175]. Several authors described NO and cGMP to be important effectors in the regulation of different events related with the neurogenic process, particularly proliferation, migration, differentiation, growth, axon guidance, and cell survival [115, 136, 152, 176, 177]. Furthermore, brain PDE5 was reported to have a role in learning and memory, physiological events that are closely dependent on neurogenesis. Therefore, targeting PDE5 activity as a strategy to reverse the deleterious effects on neurogenesis, and thus enhancing it, seems to be a promising strategy to be applied in clinic. However it should be noted that the use of PDE5 inhibitors as an effective therapy for neurodegenerative diseases is dependent on their permeability to the BBB. For instance, sildenafil is known to cross the BBB and can be easily administered.

The administration of PDE5 inhibitors as a possible therapy for Alzheimer’s disease has been studied, due to their ability to reverse deficits in long-term memory caused by pharmacological agents or aging. Different authors have described that the administration of sildenafil enhances memory and restores learning ability in animal models [178–184]. Beyond this important role, PDE5 inhibitors appear to stimulate neuronal plasticity, particularly through the enhancement of endogenous neurogenesis in the adult brain. In addition, the administration of PDE5 inhibitors, such as sildenafil, but also tadalafl, positively affected neurogenesis in the OB, SVZ, and the DG of rats by a mechanism involving the intracellular increase of cGMP levels [185–187]. Moreover, the administration of PDE5 inhibitors has also been associated to neuronal function recovery in rats following a stroke [188] or after ischemic injury either in young adult rats as in aged rats [187, 189]. Furthermore, PDE5 inhibition by sildenafil stimulated cell proliferation in rat SVZ cultures [190]. In a recent report, it was shown that sildenafil has a neuroprotective role, improving the clinical symptoms and neuropathology in a mouse model of multiple sclerosis, thus suggesting PDE5 as an important target for the therapy of this disease [151].

In summary, this evidence supports the idea that the use of PDE5 inhibitors merits further investigation in order to clarify their involvement on neurogenesis, but also to understand the mechanisms underlying these effects.

6. Future Prospects

Stimulation of endogenous adult neurogenesis and modulation of injury-induced neurogenesis is presently being considered as a potential therapeutic approach for neuronal repair in neurodegenerative disorders, as opposed to the more invasive approach of transplantation of exogenous stem cells. Understanding how the inflammatory response affects neurogenesis is fundamental to better design therapeutic strategies for safe and efficient regulation of endogenous neurogenesis. Therefore, the knowledge of the inflammatory agents that modulate proliferation and/or differentiation of NSCs is of great usefulness if its action could be correctly targeted and controlled, for instance, with selective drugs for the agent of interest.

Nitric oxide, which acts as a nonspecific cytotoxic mediator and a biological messenger, in immunological response, has been attracting increasing importance from pharmaceutical companies. Indeed, several nonsteroidal anti-inflammatory NO-releasing drugs (NO-NSAID) are currently under investigation and were shown to be beneficial in models of several neurodegenerative conditions accompanied by inflammation [153, 191]. As an alternative to conventional NSAIDs with significant side effects, pharmacologically improved and therapeutically enhanced NO releasing nonsteroidal anti-inflammatory drugs with less side effects are being developed as reviewed in [192]. Moreover, besides the clinical applications of PDE5 inhibitors, they appear to be a good strategy for the treatment of certain CNS disorders and further improve neurogenesis. These drugs have already been shown to be important modulators of the nitricergic system, preventing neurodegeneration and favoring neurogenesis.

In light of these facts, the modulation of the NO system seems to be a good target for the development of strategies to improve brain repair. However, despite all good evidence that drugs that modulate the NO system have given, further studies are necessary. In fact, a full understanding of how inflammation affects neurogenesis is essential to the development of therapeutic strategies that can induce neurogenesis from endogenous neural precursor cells, and further investigation needs to be conducted to better understand the mechanisms underlying the effect of neuroinflammation in cellular regeneration in the diseased brain.

Acknowledgments

This work was supported by the Foundation for Science and Technology, (FCT, Portugal), COMPETE and FEDER (project PTDC/SAU-NEU/102612/2008). B. P. Carreira is supported by FCT (fellowship SFRH/BPD/78901/2011).

References

[1] H. Suh, W. Deng, and F. H. Gage, “Signaling in adult neurogenesis,” Annual Review of Cell and Developmental Biology, vol. 25, pp. 253–275, 2009.
[2] S. Amor, F. Puentes, D. Baker, and P. Van Der Valk, “Inflammation in neurodegenerative diseases,” Immunology, vol. 129, no. 2, pp. 154–169, 2010.
[3] M. L. Monje, H. Toda, and T. D. Palmer, “Inflammatory blockade restores adult hippocampal neurogenesis,” Science, vol. 302, no. 5651, pp. 1760–1765, 2003.
[4] C. T. Ekdahl, J. H. Claasen, S. Bonde, Z. Kokaia, and O. Lindvall, “Inflammation is detrimental for neurogenesis in adult brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 23, pp. 13632–13637, 2003.
[5] S. Moncada and J. P. Bolanos, “Nitric oxide, cell bioenergetics and neurodegeneration,” Journal of Neurochemistry, vol. 97, no. 6, pp. 1676–1689, 2006.
[42] T. Ben-Hur, O. Ben-Menachem, V. Furer, O. Einstein, R. Mizrachi-Kol, and N. Grigoriadis, "Effects of proinflammatory cytokines on the growth, fate, and motility of multipotent neural precursor cells," *Molecular and Cellular Neuroscience*, vol. 24, no. 3, pp. 623–631, 2003.

[43] E. Cacci, J. H. Claassen, and Z. Kokaia, "Microglia-derived tumor necrosis factor-α exaggerates death of newborn hippocampal progenitor cells in vitro," *Journal of Neuroscience Research*, vol. 80, no. 6, pp. 789–797, 2005.

[44] R. E. Josif, C. T. Ekdahl, H. Ahlenius et al., "Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis," *Journal of Neuroscience*, vol. 26, no. 38, pp. 9703–9712, 2006.

[45] J. W. Koo and R. S. Duman, "IL-1β is an essential mediator of the antineuropenic and anhedonic effects of stress," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 2, pp. 751–756, 2008.

[46] L. Vallières, I. L. Campbell, F. H. Gage, and P. E. Sawchenko, "Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6," *Journal of Neuroscience*, vol. 22, no. 2, pp. 486–492, 2002.

[47] B. F. Liu, E. J. Gao, X. Z. Zeng et al., "Proliferation of neural precursors in the subventricular zone after chemical lesions of the nigrostriatal pathway in rat brain," *Brain Research*, vol. 1106, no. 1, pp. 30–39, 2006.

[48] O. Butovsky, Y. Ziv, A. Schwartz et al., "Microglia activated by TNF-α and IFN-γ differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells," *Molecular and Cellular Neuroscience*, vol. 36, no. 3, pp. 343–354, 2007.

[49] B. D. Hoehn, T. D. Palmer, and G. K. Steinberg, "Neurogenesis in rats after focal cerebral ischemia is enhanced by indomethacin," *Stroke*, vol. 36, no. 12, pp. 2718–2724, 2005.

[50] Z. Liu, Y. Fan, S. J. Won et al., "Chronic treatment with minocycline preserves adult new neurons and reduces functional impairment after focal cerebral ischemia," *Stroke*, vol. 38, no. 1, pp. 146–152, 2007.

[51] X. Wang, S. Fu, Y. Wang et al., "Interleukin-1β mediates proliferation and differentiation of multipotent neural precursor cells through the activation of SAPK/JNK pathway," *Molecular and Cellular Neuroscience*, vol. 36, no. 3, pp. 343–354, 2007.

[52] M. Nakamichi, T. Niidome, S. Matsuda, A. Akaike, T. Kihara, and H. Sugimoto, "Microglia-derived interleukin-6 and leukemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells," *European Journal of Neuroscience*, vol. 25, no. 3, pp. 649–658, 2007.

[53] O. Butoyosky, Y. Ziv, A. Schwartz et al., "Microglia activated by IL-4 or IFN-γ differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells," *Molecular and Cellular Neuroscience*, vol. 31, no. 1, pp. 149–160, 2006.

[54] G. Wong, Y. Goldsmith, and A. M. Turnley, "Interferon-γ but not TNFα promotes neuronal differentiation and neurite outgrowth of murine adult neural stem cells," *Experimental Neurology*, vol. 187, no. 1, pp. 171–177, 2004.

[55] J. H. Song, X. W. Chen, D. K. Song, P. Wang, A. Shuaib, and C. Hao, "Interferon γ induces neurite outgrowth by up-regulation of p35 neuron-specific cyclin-dependent kinase 5 activator via activation of ERK1/2 pathway," *Journal of Biological Chemistry*, vol. 280, no. 13, pp. 12896–12901, 2005.

[56] R. Baron, A. Nemirovsky, I. Harpaz, H. Cohen, T. Owens, and A. Monsonego, "IFN-γ enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer’s disease," *FASEB Journal*, vol. 22, no. 8, pp. 2843–2852, 2008.

[57] D. Widner, I. Mikenberg, M. Elvers, C. Kaltschmidt, and B. Kaltschmidt, "Tumor necrosis factor α triggers proliferation of adult neural stem cells via IKK/NF-xb signaling," *BMC Neuroscience*, vol. 7, article 64, 2006.

[58] J. P. Wu, J. S. Kuo, Y. L. Liu, and S. E. Tzeng, "Tumor necrosis factor-alpha modulates the proliferation of neural progenitors in the subventricular/ventricular zone of adult rat brain," *Neuroscience Letters*, vol. 292, no. 3, pp. 203–206, 2000.

[59] R. E. Josif, H. Ahlenius, C. T. Ekdahl et al., "Suppression of stroke-induced progenitor proliferation in adult subventricular zone by tumor necrosis factor receptor 1," *Journal of Cerebral Blood Flow and Metabolism*, vol. 28, no. 9, pp. 1574–1587, 2008.

[60] U. Heldmann, P. Thored, J. H. Claassen, A. Arvidsson, Z. Kokaia, and O. Lindvall, "TNF-α antibody infusion impairs survival of stroke-generated neuroblasts in adult rat brain," *Experimental Neurology*, vol. 196, no. 1, pp. 204–208, 2005.

[61] L. Bernardino, F. Agasse, B. Silva, R. Ferreira, S. Grade, and J. O. Malva, "Tumor necrosis factor-α modulates survival, proliferation, and neuronal differentiation in neonatal subventricular zone cell cultures," *Stem Cells*, vol. 26, no. 9, pp. 2361–2371, 2008.

[62] J. Imitola, K. Raddassi, K. I. Park et al., "Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1a/CX3C chemokine receptor 4 pathway," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 52, pp. 18117–18122, 2004.

[63] H. Peng, R. Kolb, J. E. Kennedy, and J. Zheng, "Differential expression of CXCL12 and CXCR4 during human fetal neural progenitor cell differentiation," *Journal of Neuroimmunology*, vol. 2, no. 3, pp. 251–258, 2007.

[64] A. Arvidsson, T. Collin, D. Kirik, Z. Kokaia, and O. Lindvall, "Neuronal replacement from endogenous precursors in the adult brain after stroke," *Nature Medicine*, vol. 8, no. 9, pp. 963–970, 2002.

[65] H. Nakatomi, T. Kurui, S. Okabe et al., "Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors," *Cell*, vol. 116, no. 4, pp. 429–441, 2002.

[66] P. Thored, A. Arvidsson, E. Cacci et al., "Persistent production of neurons from adult brain stem cells during recovery after stroke," *Stem Cells*, vol. 24, no. 3, pp. 739–747, 2006.

[67] Z. Kokaia, P. Thored, A. Arvidsson, and O. Lindvall, "Regulation of stroke-induced neurogenesis in adult brain—recent scientific progress," *Cerebral Cortex*, vol. 16, supplement 1, pp. i162–i167, 2006.

[68] S. Bonde, C. T. Ekdahl, and O. Lindvall, "Long-term neuronal replacement in adult rat hippocampus after status epilepticus despite chronic inflammation," *European Journal of Neuroscience*, vol. 23, no. 4, pp. 965–974, 2006.

[69] J. Aaram, K. Sandberg, S. L. B. Haeberlein, and M. A. A. Persson, "Migration and differentiation of neural precursor cells can be directed by microglia," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 26, pp. 15983–15988, 2003.

[70] S. C. Morgan, D. L. Taylor, and J. M. Pocock, "Microglia release activators of neuronal proliferation mediated by activation of mitogen-activated protein kinase, phosphatidylinositol-3-kinase/Akt and delta-Notch signalling cascades," *Journal of Neurochemistry*, vol. 90, no. 1, pp. 89–101, 2004.

[71] N. M. Walton, B. M. Sutter, E. D. Laywell et al., "Microglia instruct subventricular zone neurogenesis," *GLIA*, vol. 54, no. 8, pp. 815–825, 2006.

[72] K. Jakubs, S. Bonde, R. E. Josif et al., "Inflammation regulates functional integration of neurons born in adult brain,"
T. M. Dawson and S. H. Snyder, "Gases as biological messengers: nitric oxide and carbon monoxide in the brain," Journal of Neuroscience, vol. 28, no. 47, pp. 12477–12488, 2008.

12 Stem Cells International

B. P. Carreira, M. I. Morte, A. Inacio et al., "Nitric oxide stimulates the proliferation of neural stem cells bypassing the epidermal growth factor receptor," Stem Cells, vol. 28, no. 7, pp. 1219–1230, 2010.

O. Gonzalez-Perez, F. Jauregui-Huerta, and A. Y. Galvez-Contreras, "Immune system modulates the function of adult neural stem cells," Current Immunology Reviews, vol. 6, no. 3, pp. 167–173, 2010.

O. Gonzalez-Perez, A. Quiñones-Hinojosa, and J. M. Garcia-Verdugo, "Immunological control of adult neural stem cells," Journal of Stem Cells, vol. 5, no. 1, pp. 23–31, 2010.

W. K. Alderton, C. E. Cooper, and R. G. Knowles, "Nitric oxide synthases: structure, function and inhibition," Biochemical Journal, vol. 357, no. 3, pp. 593–615, 2001.

J. Garthwaite, S. L. Charles, and R. Chess-Williams, "Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain," Nature, vol. 366, no. 6197, pp. 385–388, 1998.

J. Garthwaite and C. L. Boulton, "Nitric oxide signaling in the central nervous system," Annual Review of Physiology, vol. 57, pp. 683–706, 1995.

F. X. Guix, I. Urribesalgo, M. Coma, and F. J. Muñoz, "The physiology and pathophysiology of nitric oxide in the brain," Progress in Neurobiology, vol. 76, no. 2, pp. 126–152, 2005.

P. Pacher, J. S. Beckman, and L. Liaudet, "Nitric oxide and peroxynitrite in health and disease," Physiological Reviews, vol. 87, no. 1, pp. 315–424, 2007.

R. Sultana, H. F. Poon, J. Cai et al., "Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach," Neurobiology of Disease, vol. 22, no. 1, pp. 76–87, 2006.

R. Sultana, T. Reed, M. Perluigi, R. Coccia, W. M. Pierce, and D. A. Butterfield, "Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: a regional study," Journal of Cellular and Molecular Medicine, vol. 11, no. 4, pp. 839–851, 2007.

D. S. Bredt, "Endogenous nitric oxide synthesis: biological functions and pathophysiology," Free Radical Research, vol. 31, no. 6, pp. 577–596, 1999.

T. M. Dawson and S. H. Snyder, "Gases as biological messengers: nitric oxide and carbon monoxide in the brain," Journal of Neuroscience, vol. 14, no. 9, pp. 5147–5159, 1994.

M. L. Simmons and S. Murphy, "Induction of nitric oxide synthase in glial cells," Journal of Neurochemistry, vol. 59, no. 3, pp. 897–905, 1992.

S. Murphy, "Production of nitric oxide by glial cells: regulation and potential roles in the CNS," GLIA, vol. 29, no. 1, pp. 1–13, 2000.

M. T. Heneka and D. L. Feinstein, "Expression and function of inducible nitric oxide synthase in neurons," Journal of Neuroimmunology, vol. 114, no. 1-2, pp. 8–18, 2001.

M. J. Serou, M. A. DeCoster, and N. G. Bazan, "Interleukin-1 beta activates expression of cyclooxygenase-2 and inducible nitric oxide synthase in primary hippocampal neuronal culture: platelet-activating factor as a preferential mediator of cyclooxygenase-2 expression," Journal of Neuroscience Research, vol. 58, pp. 593–598, 1999.

E. Galea, D. L. Feinstein, and D. J. Reis, "Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 22, pp. 10945–10949, 1992.

S. Murphy, M. L. Simmons, L. Aguillo et al., "Synthesis of nitric oxide in CNS glial cells," Trends in Neurosciences, vol. 16, no. 8, pp. 323–328, 1993.

C. Nathan and Q. W. Xie, "Nitric oxide synthases: roles, tolls, and controls," Cell, vol. 78, no. 6, pp. 915–918, 1994.

J. Schlossmann and F. Hofmann, "cGMP-dependent protein kinases in drug discovery," Drug Discovery Today, vol. 10, no. 9, pp. 627–634, 2005.

K. A. Hanafy, J. S. Krumenacker, and F. Murad, "NO, nitrotyrosine, and cyclic GMP in signal transduction," Medical Science Monitor, vol. 7, no. 4, pp. 801–819, 2001.

H. Prast and A. Philippu, "Nitric oxide as modulator of neuronal function," Progress in Neurobiology, vol. 64, no. 1, pp. 51–68, 2001.

G. C. Brown, "Nitric oxide produced by activated astrocytes rapidly and reversibly inhibits cellular respiration," Neuroscience Letters, vol. 193, no. 3, pp. 201–204, 1995.

V. L. Dawson and T. M. Dawson, "Nitric oxide neurotoxicity," Journal of Chemical Neuroanatomy, vol. 10, no. 3-4, pp. 179–190, 1996.

S. Y. Lee, T. Andoh, D. L. Murphy, and C. C. Chiuhe, "17beta-estradiol activates iC1 182,780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection," The FASEB Journal, vol. 17, no. 8, pp. 947–948, 2003.

G. A. Cunningham, N. H. McClennaghan, P. R. Flatt, and P. Newsholme, "L-alanine induces changes in metabolic and signal transduction gene expression in a clonal rat pancreatic beta-cell line and protects from pro-inflammatory cytokine-induced apoptosis," Clinical Science, vol. 109, no. 5, pp. 447–455, 2005.

P. Mander, V. Borutaite, S. Moncada, and G. C. Brown, "Nitric oxide from inflammatory-activated glia synergizes with hypoxia to induce neuronal death," Journal of Neuroscience Research, vol. 79, no. 1-2, pp. 208–215, 2005.

H. P. Monteiro, R. J. Arai, and L. R. Travassos, "Protein tyrosine phosphorylation and protein tyrosine nitration in redox signaling," Antioxidants and Redox Signaling, vol. 10, no. 5, pp. 843–889, 2008.

V. Calabrese, C. Cornelius, E. Rizzarelli, J. B. Owen, A. T. Dinkova-Kostova, and D. A. Butterfield, "Nitric oxide in cell survival: a Janus molecule," Antioxidants and Redox Signaling, vol. 11, no. 11, pp. 2717–2739, 2009.

R. B. Rock, G. Gekker, S. Hu et al., "Role of microglia in central nervous system infections," Clinical Microbiology Reviews, vol. 17, no. 4, pp. 942–964, 2004.

P. F. Good, P. Werner, A. Hsu, C. W. Olanow, and D. P. Perl, "Evidence for neuronal oxidative damage in Alzheimer’s disease," American Journal of Pathology, vol. 149, no. 1, pp. 21–28, 1996.

P. F. Good, A. Hsu, P. Werner, D. P. Perl, and C. W. Olanow, "Protein nitration in Parkinson’s disease," Journal of Neuropathology and Experimental Neurology, vol. 57, no. 4, pp. 338–342, 1998.

C. Romero-Grimaldi, B. Moreno-López, and C. Estrada, "Age-dependent effect of nitric oxide on subventricular zone and olfactory bulb neural precursor proliferation," Journal of Comparative Neurology, vol. 506, no. 2, pp. 339–346, 2008.
[107] A. Torroglosa, M. Murillo-Carretero, C. Romero-Grimaldi, E. R. Matardeona, A. Campos-Caro, and C. Estrada, “Nitric oxide decreases subventricular zone stem cell proliferation by inhibition of epidermal growth factor receptor and phosphoinositide-3-kinase/Akt pathway,” Stem Cells, vol. 25, no. 1, pp. 88–97, 2007.

[108] S. Fritzen, A. Schmitt, K. Köth, C. Sommer, K. P. Lesch, and A. Reif, “Neuronal nitric oxide synthase (NOS-1) knockout increases the survival rate of neural cells in the hippocampus independently of BDNF,” Molecular and Cellular Neuroscience, vol. 35, no. 2, pp. 261–271, 2007.

[109] E. Ciani, V. Calvanese, C. Crochemore, R. Bartesaghi, and A. Contestabile, “Proliferation of cerebellar precursor cells is negatively regulated by nitric oxide in newborn rat,” Journal of Cell Science, vol. 119, no. 15, pp. 3161–3170, 2006.

[110] E. R. Matardeona, M. Murillo-Carretero, B. Moreno-López, and C. Estrada, “Nitric oxide synthesis inhibition increases proliferation of neural precursors isolated from the postnatal mouse subventricular zone,” Brain Research, vol. 995, no. 2, pp. 274–284, 2004.

[111] A. Cheng, S. Wang, J. Cai, M. S. Rao, and M. P. Mattson, “Nitric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation and differentiation in the mammalian brain,” Developmental Biology, vol. 258, no. 2, pp. 319–333, 2003.

[112] R. Covacu, A. I. Danilov, B. S. Rasmussen et al., “Nitric oxide exposure diverts neural stem cell fate from neurogenesis towards astrogliogenesis,” Stem Cells, vol. 24, no. 12, pp. 2792–2800, 2006.

[113] X. I. Zhu, Y. Hua, J. Jiang et al., “Neuronal nitric oxide synthase-derived nitric oxide inhibits neurogenesis in the adult dentate gyrus by down-regulating cyclic AMP response element binding protein phosphorylation,” Neuroscience, vol. 141, no. 2, pp. 827–836, 2006.

[114] Q. G. Zhou, Y. Hu, Y. Hua et al., “Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis,” Journal of Neurochemistry, vol. 103, no. 5, pp. 1843–1854, 2007.

[115] B. P. Carreira, M. I. Morte, A. S. Lourenco et al., “Differential contribution of the guanylyl cyclase-cyclic GMP-protein kinase g pathway to the proliferation of neural stem cells stimulated by nitric oxide,” Neuronalsins. In press.

[116] C. X. Luo, X. J. Zhu, Q. G. Zhou et al., “Reduced neuronal nitric oxide synthase is involved in ischemia-induced hippocampal neurogenesis by up-regulating inducible nitric oxide synthase expression,” Journal of Neurochemistry, vol. 103, no. 5, pp. 1872–1882, 2007.

[117] Y. Hua, X. Y. Huang, L. Zhou et al., “DETA/NONOate, a nitric oxide donor, produces antidepressant effects by promoting hippocampal neurogenesis,” Psychopharmacology, vol. 200, no. 2, pp. 231–242, 2008.

[118] Z. Kokaia and O. Lindvall, “Neurogenesis after ischaemic brain insults,” Current Opinion in Neurobiology, vol. 13, no. 1, pp. 127–132, 2003.

[119] B. Moreno-López, J. A. Noval, L. G. González-Bonet, and C. Estrada, “Morphological bases for a role of nitric oxide in adult neurogenesis,” Brain Research, vol. 869, no. 1-2, pp. 244–250, 2000.

[120] N. Penanova and G. Enikolopov, “Nitric oxide triggers a switch to growth arrest during differentiation of neuronal cells,” Nature, vol. 375, no. 6526, pp. 68–73, 1995.

[121] W. Poliuha, C. M. Schonhoff, K. S. Harrington et al., “A novel, nerve growth factor-activated pathway involving nitric oxide, p53, and p21(WAF1) regulates neuronal differentiation of PC12 cells,” Journal of Biological Chemistry, vol. 272, no. 38, pp. 24002–24007, 1997.

[122] Y. M. Kim, R. V. Talanian, and T. R. Billiar, “Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms,” Journal of Biological Chemistry, vol. 272, no. 49, pp. 31138–31148, 1997.

[123] C. T. Ekdahl, P. Mohapel, E. Elmér, and O. Lindvall, “Caspase inhibitors increase short-term survival of progenitor-cell progeny in the adult rat dentate gyrus following status epilepticus,” European Journal of Neuroscience, vol. 14, no. 6, pp. 937–945, 2001.

[124] C. Hölscher, “Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity,” Trends in Neurosciences, vol. 20, no. 7, pp. 298–303, 1997.

[125] C. Park, M. Kang, Y. Kim-Kwong, J. Kim, H. Ahn, and Y. Huh, “Inhibition of neuronal nitric oxide synthase increases adrenalectomy-induced granule cell death in the rat dentate gyrus,” Brain Research, vol. 933, no. 1, pp. 81–94, 2002.

[126] Y. Sun, K. Jin, J. T. Childs, L. Xie, X. O. Mao, and D. A. Greenberg, “Neuronal nitric oxide synthase and ischemia-induced neurogenesis,” Journal of Cerebral Blood Flow and Metabolism, vol. 25, no. 4, pp. 485–492, 2005.

[127] M. Murillo-Carretero, A. Torroglosa, C. Castro, A. Villalobo, and C. Estrada, “S-nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity,” Free Radical Biology and Medicine, vol. 46, no. 4, pp. 471–479, 2009.

[128] A. Reif, A. Schmitt, S. Fritzen et al., “Differential effect of endothelial nitric oxide synthase (NOS-III) on the regulation of adult neurogenesis and behaviour,” European Journal of Neuroscience, vol. 20, no. 4, pp. 885–895, 2004.

[129] L. Corsani, E. Bizzoco, F. Pedata, M. Gianfriddo, M. S. Faussone-Pellegrini, and M. G. Vannucchi, “Inducible nitric oxide synthase appears and is co-expressed with the neuronal isoform in interneurons of the rat hippocampus after transient ischemia induced by middle cerebral artery occlusion,” Experimental Neurology, vol. 211, no. 2, pp. 433–440, 2008.

[130] A. Arvidssson, Z. Kokaia, and O. Lindvall, “N-methyl-D-aspartate receptor-mediated increase of neurogenesis in adult rat dentate gyrus following stroke,” European Journal of Neuroscience, vol. 14, no. 1, pp. 10–18, 2001.

[131] A. Cárdenas, M. A. Moro, O. Hurtado et al., “Implication of glutamate in the expression of inducible nitric oxide synthase after oxygen and glucose deprivation in rat forebrain slices,” Journal of Neurochemistry, vol. 74, no. 5, pp. 2041–2048, 2000.

[132] S. Jander, M. Schroeter, and G. Stoll, “Role of NMDA receptor signaling in the regulation of inflammatory gene expression after focal brain ischemia,” Journal of Neuroimmunology, vol. 109, no. 2, pp. 181–187, 2000.

[133] W. Jiang, L. Xiao, J. C. Wang, Y. G. Huang, and X. Zhang, “Effects of nitric oxide on dentate gyrus cell proliferation after seizures induced by pentylentetrazol in the adult rat brain,” Neuroscience Letters, vol. 367, no. 3, pp. 344–348, 2004.

[134] A. Torroglosa, Z. Kokaia, and O. Lindvall, “N-methyl-D-aspartate receptor-mediated increase of neurogenesis in adult rat dentate gyrus following stroke,” European Journal of Neuroscience, vol. 14, no. 1, pp. 10–18, 2001.

[135] A. Cárdenas, M. A. Moro, O. Hurtado et al., “Implication of glutamate in the expression of inducible nitric oxide synthase after oxygen and glucose deprivation in rat forebrain slices,” Journal of Neurochemistry, vol. 74, no. 5, pp. 2041–2048, 2000.
[136] M. A. Tegenge, T. D. Rockel, E. Fritsche, and G. Bicker, “Nitric oxide stimulates human neural progenitor cell migration via cGMP-mediated signal transduction,” Cellular and Molecular Life Sciences, vol. 68, no. 12, pp. 2089–2099, 2011.

[137] L. Shen and J. Zhang, “NMDA receptor and iNOS are involved in the effects of ginsenoside Rgl1 on hippocampal neurogenesis in ischemic gerbils,” Neurological Research, vol. 29, no. 3, pp. 270–273, 2007.

[138] C. X. Luo, X. J. Zhu, A. X. Zhang et al., “Blockade of L-type voltage-gated Ca2+ channel inhibits ischemia-induced neurogenesis by down-regulating iNOS expression in adult mouse,” Journal of Neurochemistry, vol. 94, no. 4, pp. 1077–1086, 2005.

[139] A. Cárdenas, M. A. Moro, O. Hurtado, J. C. Leza, and I. Lizasoain, “Dual role of nitric oxide in adult neurogenesis,” Brain Research Reviews, vol. 50, no. 1, pp. 1–6, 2005.

[140] C. Estrada and M. Murillo-Carretero, “Nitric oxide and adult neurogenesis in health and disease,” Neuroscientist, vol. 11, no. 4, pp. 294–307, 2005.

[141] A. R. Álvaro, J. Martins, I. M. Araújo, J. Rosmaninho-Salgado, A. F. Ambrosio, and C. Cavadas, “Neuropeptide Y stimulates retinal neural cell proliferation—involvement of nitric oxide,” Journal of Neurochemistry, vol. 105, no. 6, pp. 2501–2510, 2008.

[142] R. L. Zhang, Z. G. Zhang, L. Zhang, and M. Chopp, “Proliferation and differentiation of progenitor cells in the cortex and the subventricular zone in the adult rat after focal cerebral ischemia,” Neuroscience, vol. 105, no. 1, pp. 33–41, 2001.

[143] J. L. Burgaud, E. Ongini, and P. Del Soldato, “Nitric oxide-releasing drugs: a novel class of effective and safe therapeutic agents,” Annals of the New York Academy of Sciences, vol. 962, pp. 360–371, 2002.

[144] M. Feelisch and M. Kelm, “Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells,” Biochemical and Biophysical Research Communications, vol. 180, no. 1, pp. 286–293, 1991.

[145] I. L. Megson and D. J. Webb, “Nitric oxide donor drugs: current status and future trends,” Expert Opinion on Investigational Drugs, vol. 11, no. 5, pp. 587–601, 2002.

[146] J. Saraiva, S. S. Marotta-Oliveira, S. A. Cicillini, O. E. Ide, and J. M. Marchetti, “Nanocarriers for nitric oxide delivery,” Journal of Drug Delivery, vol. 2011, Article ID 936438, 16 pages, 2011.

[147] R. Zhang, L. Zhang, Z. Zhang et al., “A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats,” Annals of Neurology, vol. 50, no. 5, pp. 602–611, 2001.

[148] D. Lu, A. Mahmood, R. Zhang, Y. Li, and M. Chopp, “Upregulation of neurogenesis and reduction in functional deficits following administration of DETA/ NONOate, a nitric oxide donor, after traumatic brain injury in rats,” Journal of Neurosurgery, vol. 99, no. 2, pp. 351–361, 2003.

[149] H. Chen, S. M. Zhang, M. A. Hernán et al., “Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease,” Archives of Neurology, vol. 60, no. 8, pp. 1059–1064, 2003.

[150] R. G. Keynes and J. Garthwaite, “Nitric oxide and its role in ischaemic brain injury,” Current Molecular Medicine, vol. 4, no. 2, pp. 179–191, 2004.

[151] P. Pifarre, J. Prado, M. A. Baltrons et al., “Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis,” Acta Neuropathologica, vol. 121, no. 4, pp. 499–508, 2011.

[152] M. A. Tegenge and G. Bicker, “Nitric oxide and cGMP signal transduction positively regulates the motility of human neuronal precursor (NT2) cells,” Journal of Neurochemistry, vol. 110, no. 6, pp. 1828–1841, 2009.

[153] J. E. Keeble and P. K. Moore, “Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs,” British Journal of Pharmacology, vol. 137, no. 3, pp. 295–310, 2002.

[154] P. Geusens, “Naproxinod, a new cycloxygenase-inhibiting nitric oxide donator (CINOD),” Expert Opinion on Biological Therapy, vol. 9, no. 5, pp. 649–657, 2009.

[155] M. A. Ajmone-Cat, E. Cacci, and L. Minghetti, “Nonsteroidal anti-inflammatory drugs and neurogenesis in the adult mammalian brain,” Current Pharmaceutical Design, vol. 14, no. 14, pp. 1435–1442, 2008.

[156] B. Hauss-Wegrzyniak, P. Vranjak, and G. L. Wenk, “The effects of a novel NSAID on chronic neuroinflammation are age dependent,” Neurobiology of Aging, vol. 20, no. 3, pp. 305–313, 1999.

[157] P. T. Jantzen, K. E. Connor, G. DiCarlo et al., “Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice,” Journal of Neuroscience, vol. 22, no. 6, pp. 2246–2254, 2002.

[158] S. Fredduzzi, G. Mariucci, M. Tantucci, P. Del Soldato, and M. V. Ambrosini, “Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat,” Neuroscience Letters, vol. 302, no. 2-3, pp. 121–124, 2001.

[159] S. Fiorucci, E. Antonelli, L. Santucci et al., “Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats,” Gastroenterology, vol. 116, no. 5, pp. 1089–1106, 1999.

[160] J. M. R. Pareppally, H. Mandula, and Q. R. Smith, “Brain uptake of nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen, and indomethacin,” Pharmaceutical Research, vol. 23, no. 5, pp. 873–881, 2006.

[161] W. P. Arnold, C. K. Mittal, S. Katsuki, and F. Murad, “Nitric oxide activates guanylate cyclase and increases guanosine 3’5’-cylic monophosphate levels in various tissue preparations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 74, no. 8, pp. 3203–3207, 1977.

[162] S. Jurado, I. Sánchez-Prieto, and M. Torres, “Expression of cGMP-dependent protein kinases (I and II) and neuronal nitric oxide synthase in the developing rat cerebellum,” Brain Research Bulletin, vol. 65, no. 2, pp. 111–115, 2005.

[163] T. Sardón, M. A. Baltrons, and A. García, “Nitric oxide-dependent and independent down-regulation of NO-sensitive guanylyl cyclase in neural cells,” Toxicology Letters, vol. 149, no. 1–3, pp. 75–83, 2004.

[164] J. S. Krumenacker, K. A. Hanafy, and E. Murad, “Regulation of nitric oxide and soluble guanylyl cyclase,” Brain Research Bulletin, vol. 62, no. 6, pp. 505–515, 2004.

[165] A. L. Burnett, B. Musicki, L. Jin, and T. J. Bivalacqua, “Nitric oxide/redox-based signalling as a therapeutic target for penile disorders,” Expert Opinion on Therapeutic Targets, vol. 10, no. 3, pp. 445–457, 2006.

[166] A. R. Hemmes and H. C. Champion, “Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension,” Expert Review of Cardiovascular Therapy, vol. 4, no. 3, pp. 293–300, 2006.

[167] S. Uthayathas, S. S. Karuppagounder, B. M. Thrash, K. Parameshvaran, V. Suppiramaniam, and M. Dhanasekaran,
“Versatile effects of sildenafil: recent pharmacological applications,” Pharmacological Reports, vol. 59, no. 2, pp. 150–163, 2007.

[168] S. A. Ballard, C. J. Gingell, K. Tang, L. A. Turner, M. E. Price, and A. M. Naylor, “Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes,” Journal of Urology, vol. 159, no. 6, pp. 2164–2171, 1998.

[169] H. Mochida, M. Takagi, H. Inoue et al., “Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor,” European Journal of Pharmacology, vol. 456, no. 1–3, pp. 91–98, 2002.

[170] J. D. Corbin, “Mechanisms of action of PDE5 inhibition in erectile dysfunction,” International Journal of Impotence Research, vol. 16, supplement 1, pp. S4–S7, 2004.

[171] R. C. Rosen and J. B. Kostis, “Overview of phosphodiesterase 5 inhibition in erectile dysfunction,” American Journal of Cardiology, vol. 92, no. 9, pp. 9M–18M, 2003.

[172] G. D. Lewis and M. J. Semigran, “Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension,” Current Heart Failure Reports, vol. 1, no. 4, pp. 183–189, 2004.

[173] M. D. Patel and S. D. Katz, “Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension,” American Journal of Cardiology, vol. 96, no. 12, 2005.

[174] M. K. Steiner, I. R. Preston, R. K. Rünger, and N. S. Hill, “Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides,” Current Opinion in Pharmacology, vol. 5, no. 3, pp. 245–250, 2005.

[175] M. Chalimoniuk and J. B. Strosznajder, “Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum: effects of amyloid β peptide,” Molecular and Chemical Neuropathology, vol. 35, no. 1–3, pp. 77–95, 1998.

[176] U. Gómez-Pinedo, R. Rodrigo, O. Cauli et al., “cGMP modulates stem cells differentiation to neurons in brain in vivo,” Neurosciences, vol. 165, no. 4, pp. 1275–1283, 2010.

[177] K. S. Madhusoodanan and F. Murad, “NO-cGMP signaling and regenerative medicine involving stem cells,” Neurochemical Research, vol. 32, no. 4–5, pp. 681–694, 2007.

[178] C. M. Baratti and M. M. Boccia, “Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice,” Behavioural Pharmacology, vol. 10, no. 8, pp. 731–737, 1999.

[179] B. D. Devan, J. I. Bowker, K. B. Duffy et al., “Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition,” Psychopharmacology, vol. 183, no. 4, pp. 439–445, 2006.

[180] S. Erceg, P. Monfort, M. Hernández-Viadel, R. Rodrigo, C. Montoliu, and V. Felipo, “Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts,” Hepatology, vol. 41, no. 2, pp. 299–306, 2005.

[181] K. Rutten, J. de Vente, A. Şik, M. M. Ittersum, J. Prickaerts, and A. Blokland, “The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP Levels in hippocampal slices,” Behavioural Brain Research, vol. 164, no. 1, pp. 11–16, 2005.

[182] J. Prickaerts, W. C. G. Van Staveren, A. Şik et al., “Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat,” Neuroscience, vol. 113, no. 2, pp. 351–361, 2002.

[183] N. Singh and M. Parle, “Sildenafil improves acquisition and retention of memory in mice,” Indian Journal of Physiology and Pharmacology, vol. 47, no. 3, pp. 318–324, 2003.

[184] B. D. Devan, D. Sierra-Mercado Jr., M. Jimenez et al., “Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats,” Pharmacology Biochemistry and Behavior, vol. 79, no. 4, pp. 691–699, 2004.

[185] R. Zhang, Y. Wang, L. Zhang et al., “Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats,” Stroke, vol. 33, no. 11, pp. 2675–2680, 2002.

[186] R. Zhang, L. Wang, L. Zhang et al., “Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat,” Circulation Research, vol. 92, no. 3, pp. 308–313, 2003.

[187] L. Zhang, Z. Zhang, R. L. Zhang et al., “Tadalafil, a long-acting type 5 phosphodiesterase isoencezyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke,” Brain Research, vol. 1118, no. 1, pp. 192–198, 2006.

[188] L. Zhang, R. L. Zhang, Y. Wang et al., “Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor,” Stroke, vol. 36, no. 4, pp. 847–852, 2005.

[189] R. L. Zhang, Z. Zhang, L. Zhang, Y. Wang, C. Zhang, and M. Chopp, “Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia,” Journal of Neuroscience Research, vol. 83, no. 7, pp. 1213–1219, 2006.

[190] L. Wang, Z. G. Zhang, R. L. Zhang, and M. Chopp, “Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone,” Journal of Cerebral Blood Flow and Metabolism, vol. 25, no. 9, pp. 1150–1158, 2005.

[191] C. Napoli and L. J. Ignarro, “Nitric oxide-releasing drugs,” Annual Review of Pharmacology and Toxicology, vol. 43, pp. 97–123, 2003.

[192] E. Koc and S. G. Kucukguzel, “Medicinal chemistry and anti-inflammatory activity of nitric oxide-releasing NSAI drugs,” Mini-Reviews in Medicinal Chemistry, vol. 9, no. 5, pp. 611–619, 2009.
Review Article

Ethical Implications in the Use of Embryonic and Adult Neural Stem Cells

Rodrigo Ramos-Zúñiga,1 Oscar González-Pérez,1 Ana Macías-Ornelas,1 Vivian Capilla-González,2 and Alfredo Quíñones-Hinojosa2

1 Department of Neurosciences, CUCS, Universidad de Guadalajara, 44630 Guadalajara, JAL, Mexico
2 Department of Neurosurgery, Brain Tumor Stem Cells Laboratory, Johns Hopkins University, Baltimore, MD 4940, USA

Correspondence should be addressed to Rodrigo Ramos-Zúñiga, rodrigor@cencar.udg.mx

Received 1 July 2012; Accepted 7 August 2012

Academic Editor: Sonia Luquin

Copyright © 2012 Rodrigo Ramos-Zúñiga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The advent and growth of technological advances have led to new routes of knowledge. Thereby, we currently face new challenges. We have just started to get a glimpse of the structural and functional role of neural stem cells in differentiation and migration processes, the origin of synaptic networks, and subsequent readjustments in specific circuits. A whole range of treatment possibilities originates from this knowledge that potentially can be used for different neurological diseases in humans. Although this is an encouraging scenario, it implies that the human brain is the object of such study, as well as its potential manipulation and transplantation. It is, therefore, pertinent that ethical principles should be followed in such research to have proper balance between what can be done and what should be done, according to every specific context. Hence, it is wise to consider ethical implications in every research project, along with potential clinical applications, under the principle of causing no harm, following risk and benefit rules in decision making and with respect of the human condition as a priority.

1. Stem Cells

Biotechnology and gene manipulation, as a result of elucidating the human genome, have set new challenges in view of the enormous amount of information in neurosciences area. On one hand, this new knowledge from the last ten years is huge in terms of molecular and genetic information that led to the identification of stem cells. This happened after Thomson [1, 2] proposed the scientific analysis of embryos not used in protocols for in vitro fertilization (IVF). Several cell lines were isolated, compatible with all the different cell phenotypes of the adult. At the time, three features were identified for embryonic stem cells. (a) They derive from embryos in the preimplantation stage. (b) They are preserved as undifferentiated cells for indefinite time in special media. (c) They maintain their pluripotential capacity to generate any line of cells from all embryonic germinal layers [3].

The knowledge around stem cells and their differentiation and maturation processes to correctly make structured tissues is the result of many years of phylogenetic evolution and significant knowledge of the human ontogeny. Currently, we are familiar with many of the variants of pluripotential cells in different types of tissue, as well as advances and different applications of such cells, many of them still under investigation. The greater understanding of the human genome and the normal phenotype evolution gave way to the identification of abnormal phenotype expression in early stages of neurodevelopment disturbances, and also programmed or late stages such as in the case of many degenerative diseases [4–6].

The identification of neural stem cells had a breakthrough associated with studies of animal embryos and subsequently in human beings, and the anatomic and functional confirmation of neuro-ontogeny. When this information was learned, the first debate came about: where do we get tissue from? What is the origin and destination of such tissue?

In a first phase, investigators resorted to embryo studies from miscarriages, but the changes in IVF strategies for the benefit of couples with fertility problems led to the availability of embryos in association with the gestational process.
The question about the origin of such tissue was still unanswered and new questions arose about the care and management of embryos and the final destination of those not selected or successfully implanted, like the ones preserved in the laboratory. This gave way to begin having certain availability of these embryos for scientific research, with variable legal and ethical implications. There are countries that forbid this practice altogether, under the premise that you cannot make decisions about life to propose the cure of certain diseases. In this scenario, the debate about the beginning of life comes up again, as well as the limitations to use embryos in a totally limitless way or the opposite position in countries where embryos are allowed to be created ex profeso for research purposes along with the procurement of stem cells [7].

So far, regulations have been issued as legal standards trying to approach the way in which these processes can follow the same line of respect for human integrity, without limiting the potentialities of science and therapy in embryo studies [8].

Recently, the American Association of Cancer Research (AACR) has promoted new agreements endorsed by the U.S. government to validate the continuity of studies in embryonic stem cells, as a key element to find treatment for nearly 200 diseases linked to the concept of “cancer.” The rationale is that the origin of cancer follows genetic and epigenetic factors which must be studied in order to find a cure for this disease. Consequently, knowing the differences between normal stem cells and cancer stem cells will allow to provide greater therapeutic options in the future. The agreement postulates the prevalence of respect for the human embryo, abiding to the international standard of making use of embryos up to day 14 of the blastocyst stage, but once again emphasizing the pertinence of continuous research of scientific information that cannot be documented otherwise (AACR, 2010) [9].

Aside from the knowledge of embryonic stem cells, other scientific contributions began changing the paradigm in the information and exploration of other exciting scientific territories. The theoretical concept that the adult central nervous system never regenerates [10] changed when scientists finding the neurogenic capacity of the adult brain. Even in human, neural stem cells were found primarily in two region, the subventricular zone of the lateral ventricles and the dentate gyrus of the hippocampus [11–14]. In the case of rodents, newly generated cells are able to migrate, differentiate, mature, and integrate into preexisting circuits, where supply functions as cognition and olfaction [15].

2. Adult Stem Cells and Transplants

It is relevant to analyze the role of neural stem cells because of their potential clinical application in regenerative and repair therapy. It is clear that it is important to have discussions with the purpose of avoiding ethical dilemmas in science and in society, as well as their consequences concerning the procurement of these cells so that investigators can approach the field of applied science, in this case in reference to transplants.

Even though at the present time organ and tissue transplants are a real fact in our everyday life, this was accomplished thanks to a series of collaborations and willingness that led to experimental surgical refinements, the development of microsurgery, as well as the training and skill to perform vascular anastomosis and control rejection responses, just to mention some of the most relevant events

Nevertheless, in the case of neural stem cell transplants experience is barely beginning in the sense of systematization of processes, standardization of sources and origin of stem cells, application methods, controlled directionality of effects, clinical impact, and inherent risks and complications of the surgical procedures [16–20].

Part of this promising expectation was originally based on the concept that the brain was a site with a peculiar structure and functionality which made it “privileged,” thus an organ with certain good features for receiving transplants. All of this was the result of having structures such as the blood–brain barrier and unique conditions in the behavior and tolerance of immune mechanisms [21].

However, these concepts have changed because we now have more information about the blood-brain barrier not being so airtight, and that it allows the passage of certain type of mediator cells of the immune response, and that it changes when there is an intrinsic inflammatory process [22]. The immune response concept itself underwent a change from learning that the microglia are capable of presenting antigens and activating phagocytic features and inducing in situ cytokine activities [23]. Moreover, the brain is currently no longer considered as a “privileged” site but an organ with different immune mechanisms and very peculiar immune response processes. In addition, it has been observed that many pathological and inflammatory conditions significantly affect neurogenic niches. Even more, increasing evidences indicate that chemokines and cytokines play an important role in regulating proliferation, cell fate choices, migration, and survival of neural stem cells under physiological conditions [24].

Even so, the brain is still a site with more favorable conditions for transplantation, compared to other peripheral organs, according to the tolerance experience found in fetal tissues with moderate immune suppression therapy, unlike xenografts, which are rejected. This opened perspectives for transplantation of neural stem cells, presumed to have greater potential in terms of structural and functional regeneration, with reduced risk of immune rejection reaction [25–27].

According to the concepts above, it has been considered that the potential action of these cells, when transplanted to the human nervous system, would have three relevant effects.

(I) Cell Regeneration. Previous studies showed that neural stem cell can differentiate and migrate after transplantation to integrate into the host tissue in models of spinal lesions and stroke [28–32]. This supports and gives hope to the proposed repair therapy. Additionally, active electric connection
mechanisms in the brain cortex have been identified [33], but the functional relevance of this response is still to be established, as well as the reason for the persistence of certain in situ cells as undifferentiated [34].

(II) Neuroprotection. An additional function of neural stem cells is the neuroprotective properties. Transplanted neural stem cells can release specific factors, which promote the survival and prevent cell death in sites where they have been implanted. Some of these released factors that increase their bioavailability are neurotrophic factors [35]. This proposal has led to expectations in case of inflammatory disorder [36], neonatal brain injury [37], and degenerative diseases [38–40]. One of the mechanisms proposed is that the transplanted neurospheres-derived cells have a two way molecular exchange that makes them more sensitive for releasing neurotrophic factors when found in the neuro-glial microenvironment.

(III) Immunomodulation. There is growing evidence about the immune modulating capacity of neural stem cells from in vitro and in vivo studies, in terms of regulating the deleterious inflammatory response and fostering immune conditions for tissue regeneration [41]. This has been shown as a reduced inflammatory response in experimental autoimmune encephalomyelitis, and a reduced proliferation of T-cell derivatives in response to concanavalin A in the oligodendrocytes [42]. Likewise, a reduced inflammatory response has been identified in experimental spinal lesions [43, 44], which would open the way to a new modality in the mechanism of action of transplanted neural stem cells.

3. Potential Applications of Adult Neural Stem Cells

At one point, it was considered that embryonic stem cells were the key for the creation of different potential cell lines with therapeutic purposes, when it became evident that they were available in greater number, easy to identify, and grow in culture. Also, embryonic stem cells grew faster and more easily, compared to adult stem cells, and ultimately they could be more plastic and manageable.

Even so, the use of embryonic stem cells presents legal and ethical limitations, such as the obvious destruction of live embryos to obtain stem cells. Additionally, other technical limitations not previously seen were identified: (a) rejection of embryonic stem cells requiring immunosuppressive treatment, (b) the possibility to induce cells of tumor lineage. All these limitations lead investigators to look for other alternatives.

The search for adult stem cells has become all the more important, getting greater availability to their source of origin and limiting ethical conflicts with the use of embryos [45].

Adult stem cells are found in the brain, pancreas, liver, bone marrow, blood, muscle, skin, and other body tissue. They can be crucial to continue forming and generating tissue which is structurally linked to cell lineages from where they have been phenotypically collected.

Currently, a few scenarios are found in which adult stem cells can have potential application leading to the identification and characterization of adult tissue with germinal properties such as the case of the hematopoietic tissue and the skin. Olfactory tissue stem cells have also been proposed as an alternative to be studied and transplanted to repair vascular brain lesions or traumatic spinal cord lesions [30]. A unique feature of adult neural stem cells is that they have been well identified and characterized in the adult brain, particularly in the subventricular zone and the dentate gyrus of the hippocampus [15], where neural stem cells show a potential differentiation to glial and neuronal cells aside from being compatible with radial migration [46, 47].

This sort of application has the potential advantage of implanting predifferentiated cells to certain glial or neuronal cell lineage, as a step forward in the therapy to repair pathologic processes, for example, ischemia, multiple sclerosis, spinal cord injury, or degenerative processes such as Alzheimer, Huntington, or Parkinson’s disease [48–51].

4. Risks with Ethical Implications

Risks involved in the clinical application of adult neural stem cells have not been totally evaluated, nor have long-term followup, so it is still necessary to be cautious and alert. Not only because of the ethical implications that can be anticipated in terms to what is morally and socially accepted in each community, but also because of the technical implications and risks to the patient’s health.

These risks are basically found within the following possibilities:

(A) Risk of Tumors. This possibility has been considered a real one, according to reports of teratomas in the striate cortex in experimental Parkinson models. A previous report mentioned 20% of new onset tumors in an experimental sample, when undifferentiated stem cells were used [52]. The possibility of using viral vectors or genetic manipulations from regulator genes, trying to guide differentiation and efficacy in dopaminergic neurons, also involves the risk of viral transmission out of control and out of target, plus the risk of mutagenesis. The stem cells themselves pose an additional unknown risk. The longer cells are grown in culture, the more likely they are to acquire genetic and epigenetic changes, in agreement with the previous experience with embryonic stem cells [53–55].

(B) Inadequate Migration. The risk of migration defects gives rise to heterotopias in the white matter, sub-ependymal region, and the cortical gray substance if there is no control in the migration process toward a lesion in a specific area. There might be an out of target aberrant migration, giving rise to potential heterotopias with the ensuing clinical complications such as difficult to control epilepsy (refractory) or other neuropathological conditions. Being able to get greater
differentiation in adult neural stem cells and the necessary refinement in target migration is still a challenge [27, 56].

(C) Transplant Rejection. Immune rejection conditions will always be found in adult neural stem cell transplants. Although there is now greater experience with embryonic mesencephalic stem cells and management of the need to give constant immunosuppression (cyclosporine), not only to avoid rejection, but also to maintain clinical response in adult neural stem cells the experience is not the same. Theoretically, since cells are more differentiated in adult tissues and more antigenic they might require greater use of immunosuppressive drugs with the inherent additional risks such as liver and renal toxicity, hypertension and immunodeficiency [57].

(D) Surgical Risks. In spite that most of the brain cell tissue transplants are done with stereotactic method, with specific mapping and accurate coordinates, the procedure is not devoid of risk. An average of 3% surgical risk has been reported associated to bleedings or infection. Even though the risk involved is less compared to deep brain stimulation procedures, where a foreign body is placed, this condition must be carefully looked into for risk-benefit analysis [34].

(E) Infections. This is a constant risk in every cell transplant process in which pathogens may be transmitted from the donor to the recipient, such as hepatitis B or C, lymphphotropism virus, HIV/Aids, cytomegalovirus, and herpes simplex virus. In addition, there is also the risk of infection in the culture media and in handling the samples, either from bacteria (Staphylococcus, Streptococci, E. coli), yeasts, spores, and prion diseases [58].

5. Neuroethics and Neural Stem Cells

In view of the response from society to these unforeseen topics resulting from scientific and technological advances applied to medical science, it was necessary to have ethical support from certain deontological criteria and universal concepts (not specific to medical science), such as the UN Declaration of Universal Human Rights [59].

Subsequently, a more specific form is described with the advent of bioethics [60], applied in greater association with life science and survival. The latter school of thought is prevalent mainly in western culture and postulates respect of basic principles of human behavior in interaction with other individuals. This is the reason why every human action, even nonmedical, may be subjected to these precepts.

In more recent times, neuroethics has come to respond to the great demand of topics that neurosciences have put forth in dealing with traditional ethics. It has been necessary to establish more specific study lines, as a result of a great amount of information, research, and potential treatment applications with ethical implications, but more specific and dealt by experts who have deep knowledge of dilemmas prevailing in basic and clinical neuroscience.

Table 1: Ethical considerations in the use of neural stem cells. Ethical considerations related to the origin and source of neural stem cells and the potential clinical applications.

| Ethical considerations                                                                 | Origin                                                                            | Applications                                                                 |
|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Embryos from miscarriages and abortions, IVF embryos, ex profeso                       | Basic research, characterization, biological behavior, differentiation, migration, neurodevelopment. |
| embryos, cultures, cadavers, tissues and somatic cells. Care and preservation of progenitor cells. | Transplants, diseases of neurodevelopment, trauma, stroke, neurodegenerative diseases. Regenerative therapy. Risks, long term results. Public health impact. Patents and accessibility |

Neuroethics is not proposed with the reductionist view of a single organ, but rather redefining the important role of neuroscience as the object of study in every variant, and the unique condition that it is the human brain itself that ponderous, discusses and decides about its own object of study.

Today, there are two points of interest in the field of stem cells proposed by neuroethics: on the one hand, the origin of stem cells and the way in which they are obtained, studied, protected, and preserved. On the other hand, everything around the application of neural stem cells, from feasibility to viability, risk and benefit, the transplant process itself, complications, outcome, public health impact, and also potential deviations [61–63].

At this point, I will particularly refer to the second segment, since there is a great deal of literature about the management and regulation of the origin of embryonic stem cells particularly referring to regulations of human embryos for research, where the dilemma of the difference between zygote, embryo, fetus, and the moment when life starts is still debated. However, in terms of ethical dilemmas from the application of stem cells to neurologic diseases, we do not have the same amount of information (Table 1).

At the present time, it is relevant to promote and motivate the use of adult neural stem cells for three main reasons: (a) to reorient the strategy to a more successful outcome considering cell lineage in the most differentiated possible way, in order to have better certainty about the functional implications of mature cells in the recipient tissue; (b) when the same tissue origin is considered, there would be greater likelihood to reach the therapeutic target, with less risk of variables involved in migration and functional errors, once the rejection reaction is under control; (c) adult neural stem cells involve less ethical objections, as compared to embryonic stem cells [64, 65].

For these specific potential cases for research and transplants, and the challenges and dilemmas they involve, it is wise to once again resort to the pragmatic ethics in bioethical research, that rules its actions within a framework of respect for the subjects of research, particularly groups of sick and vulnerable subjects.
Thus, it is considered healthy that proposals of fully justified new research that produces scientific knowledge, improves public health as well as the quality of medical care, must, above everything else, protect the patients and avoid creating damage. Also, such research must be totally compatible not only with legal regulations but also with precepts of moral and behavior values and virtues that identify a defined social context [66, 67].

Following these concepts, in the case of adult neural stem cell transplants, the same criteria used for transplants in general are applied in which a bioethical triangle is formed.

On one hand, we find the donor line in which there is total freedom, knowledge, informed consent to give, by means of an altruistic action, the tissue, and cells for a transplant. No extraordinary risks for the life or health of the donor are involved, without conflicts of interest or submission to scientific postures. In every case, a reasonable risk-benefit position must prevail, taking into account potential help for control or cure of a disease and the value of contributions to scientific knowledge.

On the other hand, we find the recipient line which would be assumed to be the main potential beneficiary, with the same rights, with informed consent and ethically validated in terms of selection and assignment criteria and with clear information about the expectations of the procedure, without any conflict of interest from secondary compensations. The donor makes the decision according to the established risk-benefit, considering that what is technically viable must also be ethically acceptable.

Finally, at the base of the triangle, we find the line of the human and professional team, participating in the scientific research, the harvesting of cells, cultures, transplant procurement, the transplantation itself, and subsequent followup and control. As any human activity, it is not free of risks and byas. That is the reason why everyone must do their work with self-respect, and respect for the team and obviously everyone involved in the transplantation process; following the principles of professional behavior of technical training, ethically acknowledged and supported.

This rational balance in the bioethical triangle must be totally compatible with principles of truthfulness, justice, equality, autonomy, welfare, and confidentiality, postulated by bioethics and that now neuroethics adopts as fundamental premises to deal with these new dilemmas that science has brought about neural stem cells [68].

This is where neuroethics attempts to create awareness among neuroscientists, geneticists, neurosurgeons, and all the professionals involved in this process about the responsibility of anticipating to the debate due to the use and abuse of these procedures and research. The neuroethicists have a social responsibility to see that the advent of technological advances which have increased our ability and power to carry out new experiments be maintained within the risk-benefit regulatory criteria, with respect for life and within morally and socially accepted strategies [69] (Figure 1).

One of the current and future challenges that has also been settled with specific actions in this scenario has to do with justice and access to this type of therapy as a standard treatment for given diseases in the future. One of the ways to deal with this matter has been to discourage development and approval of restrictive patents in this area, in order for this knowledge to prevail as heritage of humanity, and that viability and feasibility can be guaranteed everywhere in the world following the simplest reproducibility strategies with an ethical point of view [70].

6. Conclusions

Extensive and constant discussion is required about the role of biotechnology and its ethical implications in the scenario of neural stem cells. If we can have a balanced position, we shall be able to do scientific work with a tool that has great potential to solve health problems in different stages of life, such as in the case of neural stem cells, with no limitations. But it should certainly prevail in a position of respect for human beings and society that are the main beneficiaries of this promising proposal.

References

[1] J. A. Thomson, J. Itskovitz-Eldor, S. S. Shapiro et al., “Embryonic stem cell lines derived from human blastocysts,” Science, vol. 282, no. 5391, pp. 1145–1147, 1998.
[2] J. A. Thomson and J. S. Odorico, “Human embryonic stem cell and embryonic germ cell lines,” Trends in Biotechnology, vol. 18, no. 2, pp. 53–57, 2000.
[3] R. Pérez, Ars Médica Mexicana. I. Temas De Ética Médica, El Colegio Nacional, México, Mexico, 2011.
[4] M. Rosner, K. Schipany, B. Shanmugasundaram et al., “Amniotic fluid stem cells: future perspectives,” Stem Cells International, vol. 2012, Article ID 741810, 6 pages, 2012.
[5] G. M. Tomás Y Garrido and N. López Moratalla, “From the totipotence of the zygote to mature stem cells and reserve cells,” Cuadernos de Bioética, vol. 20, no. 70, pp. 317–331, 2009.
[6] C. M. Kelly, O. J. Handley, and A. E. Rosser, “Human trials for neurodegenerative disease,” Methods in Molecular Biology, vol. 549, pp. 33–47, 2009.

[7] A. McCall and M. Revel, The Use of Embryonic Stem Cells in Therapeutic Research: Division of Human Sciences, Philosophy and Ethics of Sciences and Technology, Paris, France, 2001, http://unescodoc.unesco.org/images/0013/001322/132287e.pdf.

[8] H. Niknejad, T. Dehimi, A. Ahmadiani et al., “Permanent expression of midbrain dopaminergic neurons traits in differentiated amniotic epithelial cells,” Neuroscience Letters, vol. 506, no. 1, pp. 22–27, 2012.

[9] M. Foti, “AACR Testimony on Stem Cell Research: American association for Cancer Research,” 2010, http://www.aacr.org/home/public-media/science-policy-government-affairs/testimony/2010-aacr-testimony-on-stem-cell-research.aspx.

[10] S. Ramon y Cajal, Degeneration and Regeneration of the Nervous System, Oxford University Press, London, UK, 1928.

[11] P. S. Eriksson, E. Perfilieva, T. Björk-Eriksson et al., “Neurogenesis in the adult human hippocampus,” Nature Medicine, vol. 4, no. 11, pp. 1313–1317, 1998.

[12] A. Alvarez-Buylla and D. A. Lim, “For the long run: maintaining germinal niches in the adult brain,” Neuron, vol. 41, no. 5, pp. 683–686, 2004.

[13] A. Quiñones-Hinojosa, N. Sanai, M. Soriano-Navarro et al., “Cellular composition and cytoarchitecture of the adult human subventricular zone: a niche of neural stem cells,” Journal of Comparative Neurology, vol. 494, no. 3, pp. 415–434, 2006.

[14] H. Sanai, A. D. Tramontin, A. Quiñones-Hinojosa et al., “Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration,” Nature, vol. 427, no. 6976, pp. 740–744, 2004.

[15] V. Capilla-Gonzalez, S. Gil-Perotin, A. Ferragud et al., “Exposure to N-ethyl-N-nitrosourea in adult mice alters structural and functional integrity of neurogenic sites,” PLoS ONE, vol. 7, no. 1, Article ID e29891, 2012.

[16] E. Nivet, M. Vignes, S. D. Girard et al., “Engraftment of human neural stem/progenitor cells as a promising candidates for regenerative therapy in spinal cord injury,” Stem Cells, vol. 27, no. 8, pp. 2032–2043, 2009.

[17] R. S. N. Tewarie, A. Hurtado, R. H. Bartels, A. Grottenhuis, and M. Oudega, “Stem cell-based therapies for spinal cord injury,” Journal of Spinal Cord Medicine, vol. 32, no. 2, pp. 105–114, 2009.

[18] O. Tsuji, K. Miura, K. Fujiiyoshi et al., “Cell therapy for spinal cord injury by neural stem/progenitor cells derived from IPS/ES cells,” Neurotherapeutics, vol. 8, no. 4, pp. 668–676, 2011.

[19] R. R. Andres, R. Choi, G. K. Steinberg, and R. Guzman, “Potential of adult neural stem cells in stroke therapy,” Regenerative Medicine, vol. 3, no. 6, pp. 893–905, 2008.

[20] K. I. Park, Y. D. Teng, and E. Y. Snyder, “The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue,” Nature Biotechnology, vol. 20, no. 11, pp. 1111–1117, 2002.

[21] V. Bonnemain, I. Neveu, and P. Naveilhan, “Neural stem/progenitor cells as a promising candidates for regenerative therapy of the central nervous system,” Frontiers in Cellular Neurosciences, vol. 6, no. 1, pp. 1–8, 2012.

[22] B. Carletti, F. Piemonte, and F. Rossi, “Neuroprotection: the emerging concept of restorative neural stem cell biology for the treatment of neurodegenerative diseases,” Current Neuropharmacology, vol. 9, no. 2, pp. 313–317, 2011.

[23] S. Pluchino, L. Zanotti, E. Brini, S. Ferrari, and G. Martino, “Regeneration and repair in multiple sclerosis: the role of cell transplantation,” Neuroscience Letters, vol. 456, no. 3, pp. 101–106, 2009.

[24] Z. Luan W. P. Liu, S. Q. Qu et al., “Treatment of newborns with severe injured brain with transplantation of human neural precursor cells,” Zhonghua Er Ke Za Zhi, vol. 49, no. 6, pp. 445–449, 2011.

[25] H. Okano, “Strategies toward CNS-regeneration using induced pluripotent stem cells,” Genome Informatics, vol. 23, no. 1, pp. 217–220, 2009.

[26] P. B. Kuegler, B. Zimmer, T. Waldmann et al., “Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing,” ALTEX, vol. 27, no. 1, pp. 17–42, 2010.

[27] Z. Master, M. McLeod, and I. Mendez, “Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson’s disease,” Journal of Medical Ethics, vol. 33, no. 3, pp. 169–173, 2007.

[28] E. Y. Snyder, C. Yoon, J. D. Flax, and J. D. Macklis, “Multipotent neural precursors can differentiate toward replacement of neurons undergoing targeted apoptotic degeneration in adult mouse neocortex,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 21, pp. 11663–11668, 1997.

[29] O. Arias-Carrión and T. F. Yuan, “Autologous neural stem cells but lacks chain migration, ” Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration,” Nature, vol. 427, no. 6976, pp. 740–744, 2004.

[30] O. Tsuji, K. Miura, K. Fujiiyoshi et al., “Cell therapy for spinal cord injury by neural stem/progenitor cells derived from IPS/ES cells,” Neurotherapeutics, vol. 8, no. 4, pp. 668–676, 2011.

[31] R. R. Andres, R. Choi, G. K. Steinberg, and R. Guzman, “Potential of adult neural stem cells in stroke therapy,” Regenerative Medicine, vol. 3, no. 6, pp. 893–905, 2008.

[32] K. I. Park, Y. D. Teng, and E. Y. Snyder, “The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue,” Nature Biotechnology, vol. 20, no. 11, pp. 1111–1117, 2002.

[33] V. Bonnemain, I. Neveu, and P. Naveilhan, “Neural stem/progenitor cells as a promising candidates for regenerative therapy of the central nervous system,” Frontiers in Cellular Neurosciences, vol. 6, no. 1, pp. 1–8, 2012.

[34] B. Carletti, F. Piemonte, and F. Rossi, “Neuroprotection: the emerging concept of restorative neural stem cell biology for the treatment of neurodegenerative diseases,” Current Neuropharmacology, vol. 9, no. 2, pp. 313–317, 2011.

[35] S. Pluchino, L. Zanotti, E. Brini, S. Ferrari, and G. Martino, “Regeneration and repair in multiple sclerosis: the role of cell transplantation,” Neuroscience Letters, vol. 456, no. 3, pp. 101–106, 2009.

[36] Z. Luan W. P. Liu, S. Q. Qu et al., “Treatment of newborns with severe injured brain with transplantation of human neural precursor cells,” Zhonghua Er Ke Za Zhi, vol. 49, no. 6, pp. 445–449, 2011.

[37] H. R. Martinez, M. T. Gonzalez-Garza, J. E. Moreno-Cuevas, E. Caro, E. Gutierrez-Jimenez, and J. J. Segura, “Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients,” Cytotherapy, vol. 11, no. 1, pp. 26–34, 2009.

[38] J. Zhao and Q. Xu, “Emerging restorative treatments for Parkinson’s disease: manipulation and induction of
N. Sanai, A. Alvarez-Buylla, and M. S. Berger, “Mechanisms of P. G. Hess, “Risk of tumorigenesis in first-in-human trials of P. Karpowicz, C. B. Cohen, and D. Van Der Kooy, “Developing L. M. Björklund, R. Sanchez-Pernaute, S. Chung et al., G. Lilienthal, “Pros and cons of stem cell research- ethical concerns, " V. Enzmann, E. Yolcu, H. J. Kaplan, and S. T. Ildstad, “Stem S. W. Lee, G. D. Clemenson, and F. H. Gage, “New neurons in M. Cusimano, D. Biziato, E. Brambilla et al., “Transplanted Y. Mu and F. H. Gage, “Adult hippocampal neurogenesis and its role in Alzheimer’s disease,” Molecular Neurodegeneration,” 2006, no. 5, pp. 497–507, 2012. S. V. Anisimov, “Cell therapy for Parkinson’s disease: III. Neonatal, fetal and embryonic stem cell-based applications,” Advances in Gerontology,” vol. 22, no. 2, pp. 296–315, 2009. S. V. Anisimov, “Cell-based therapeutic approaches for Parkinson’s disease: progress and perspectives,” Reviews in the Neurosciences,” vol. 20, no. 5–6, pp. 347–381, 2009. L. M. Björklund, R. Sanchez-Pernaute, S. Chung et al., “Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model,” Proceedings of the National Academy of Sciences of the United States of America,” vol. 99, no. 4, pp. 2344–2349, 2002. P. Karpowicz, C. B. Cohen, and D. Van Der Kooy, “Developing human-nonhuman chimeras in human stem cell research: ethical issues and boundaries,” Kennedy Institute of Ethics Journal,” vol. 15, no. 2, pp. 107–134, 2005. P. G. Hess, “Risk of tumorigenesis in first-in-human trials of embryonic stem cell neural derivatives: ethics in the face of long-term uncertainty,” Accountability in Research,” vol. 16, no. 4, pp. 175–198, 2009. N. Sanai, A. Alvarez-Buylla, and M. S. Berger, “Mechanisms of disease: neural stem cells and the origin of gliomas,” New England Journal of Medicine,” vol. 353, no. 8, pp. 811–822, 2005. J. S. Grisolia, “Stem cell grafting for epilepsy: clinical promise and ethical concerns,” Epilepsy and Behavior,” vol. 2, no. 4, pp. 318–323, 2001.
Review Article

The Insulin Regulatory Network in Adult Hippocampus and Pancreatic Endocrine System

Masanao Machida, Shin Fujimaki, Ryo Hidaka, Makoto Asashima, and Tomoko Kuwabara

Research Center for Stem Cell Engineering, National Institute of Advanced Industrial Science and Technology (AIST), Central 4, 1-1-4 Higashi, Tsukuba Science City 305-8562, Japan

Correspondence should be addressed to Tomoko Kuwabara, t.warashina@aist.go.jp

Received 13 June 2012; Revised 6 August 2012; Accepted 9 August 2012

1. Introduction

Insulin is a hormone that helps cells store sugars and fats as energy sources, and a variety of problems develop in the circulatory organs including heart when its synthesis and secretion become impaired [1–4]. The fact that insulin is also essential to maintaining brain function is important [5–8], and in addition to the retinopathy and peripheral neuropathy that are known complications of diabetes, changes in insulin signals in the brain of diabetic patients have a pronounced impact on neuropathy in the central nervous system (CNS), especially in the hippocampus [9]. Actually, not only are diabetic patients at increased risk of contracting neurodegenerative diseases and psychiatric disorders such as Alzheimer’s disease, Parkinson’s disease, depression, and Huntington’s disease, but diabetes has also been experimentally shown to have a great effect on the functions of the neural circuits in the hippocampal region [9–13].

The hormone insulin is secreted by the β cells that compose the pancreatic endocrine tissue in response to the environment and conditions in which the individual and the organs and tissues find themselves, and its metabolic mechanisms are strictly regulated [1–6]. Insulin also plays a major role in the stage that controls differentiation, especially by tissue stem cells, into almost all of the cells that compose the organ or the body. Under conditions in which the amount of insulin levels is reduced, the proliferative and maintenance functions of undifferentiated stem cells themselves (self-renewal capacity) are often consistently suppressed, even in different lineages. On the other hand, based on research reports in recent years it is now clear that insulin-activated signal transduction mechanisms play a major role in regulating their differentiation pathways at the stem cell differentiation induction stage in the various tissues [5–9].

2. Neural Stem Cells and Insulin

Stem cells retain pluripotency, which is the source of their ability to differentiate into various cell types that compose tissues and to fulfill their functions. When organs are formed during embryonic stage, organogenesis is achieved by
vigorou renewal by embryonic stem cells, which have very high proliferative capacity, and by orderly differentiation of tissue cell groups for the patterning. Stem cells can renew themselves almost indefinitely and differentiate into the cells that compose tissues. Asymmetric cell division allows stem cells to self-renew and produce another cell that undergoes differentiation. Stem cells are broadly classified into two types: stem cells in the embryo stage and adult stem cells, which are present in the tissues of adults. Neural stem cells, which are responsible for neurogenesis, are present not only during embryonic and perinatal stages but also in the adulthood stage.

In recent years, it has been shown that neural stem cells are present in adult mammalian brain. They self-renew by continually dividing, as well as differentiate into functional neurons and glial cells (astrocytes, oligodendrocytes) (Figure 1). The property of neural stem cells, such as self-renewal and the multipotency, is finely modulated by both cell-intrinsic and cell-extrinsic factors. It is well known that dietary restriction and exercise (mild running, etc.) enhance adult neurogenesis. On the other hand, severe stresses, brain inflammation, and the aging impair the rate of neurogenesis significantly. High-fat diets and obesity pose serious health problems as well as the decline of adult neurogenesis. To control the coordinate energy intake and expenditure, insulin signaling is utilized. Insulin is an important neuromodulator, contributing to neurobiological processes, in particular energy homeostasis and the cognitive function. Adult neural stem cells sense and respond to changes in energy homeostasis occurring locally in the brain and systemically in the mammalian organism. The regulatory system from an undifferentiated neural stem cell to a differentiated neuron, astrocyte, or oligodendrocyte is associated with various transcriptional changes, including numerous genes associated with metabolism and energy sensing such as insulin signal transduction pathways and insulin receptors (Figure 1). Understanding the hormonal aspects of how adult neurogenesis is regulated may lead new strategies for treating neurodegenerative disorders.

3. Diabetes and Hippocampal Neurons

As a result of high-calorie diets and sedentary lifestyles, diabetes is rapidly becoming more prevalent and appears to negatively impact the brain, increasing the risk of depression and dementia. The diabetes patients of type-1 (caused by insulin deficiency) or type-2 (mediated by insulin resistance) exhibit impaired cognitive function compared to age [14]. The incidence of Alzheimer’s disease is almost twice that in a nondiabetic population [10]. Diabetes-related cognitive dysfunction has been controversial as to its underlying cause, whether it is the result of both microvascular and macrovascular cerebral diseases, hypoglycemic episodes with subsequent neuronal loss, the direct neuronal damage caused by chronically elevated intracellular glucose concentration in hyperglycemia, or the decline of neurogenesis. Recent studies suggest that diabetes produces a variety of neurochemical, neuroanatomical and behavioral changes that are indicative of accelerated brain aging in the hippocampus, including morphological changes [15], accumulation of oxidative stress markers [16], electrophysiological changes [17], neuroendocrine changes [18], and cellular molecular changes [19]. Diabetes rats exhibit dendritic atrophy of hippocampal pyramidal neurons, decreases in spine density, synaptic reorganization in the dentate gyrus (DG), increased neuronal vulnerability and reductions in cell proliferation and neurogenesis [20–22]. Since insulin replacement inhibits or reverses these neurological deficits in diabetes animals [23, 24], these results support the emerging and expanding hypotheses regarding the important role of insulin in the CNS, especially for hippocampal neurons.

4. NeuroD1 Gene for the Insulin Expression in Both Pancreas and Hippocampus

As an example of control in the hippocampal nervous system in the brain, insulin increases the tolerance of mature neurons to toxicity and has a protective function that keeps the network functions of the neurons in an active state [25, 26] (Figure 1). Insulin also exercises control of the fate-determining mechanism (cell fate choice) of adult neural stem cells, that is, it newly promotes induction of undifferentiated neural stem cells to differentiate into oligodendrocytes [27], which have the function of protecting neurons. Moreover, insulin promotes the function of fibroblast growth factor 2 (FGF2), which has an important role in maintaining neural stem cells in the undifferentiated state, and it also plays a major role in the stem cell self-renewal stage, that is, it strongly activates stem cell proliferation [28–32].

The hippocampus is one of the parts of the brain in which severe damage occurs in both diabetic patients and patients with neurological diseases, including Alzheimer’s disease [9–13]. The hippocampus governs human memory and learning functions, and all throughout life new neurons are generated daily by the neural stem cells located in the DG region, which is the region of the hippocampus where adult neurogenesis occurs [33–39]. The newly generated neurons construct new neural circuits with existing neurons, and a variety of extracellular factors, intracerebral neurohormones, and neurotransmitters whose function is to transmit information between neurons are synthesized and secreted, and they support the functions of the neural circuits. Not only a decrease in the neural activity of information transmission in these neurons but also a decrease in the phenomenon of neurogenesis by neural stem cells occurs due to the insulin deficiency in diabetic patients, and as a result there is a large decline in learning and memory capacity, which is governed by the hippocampus [5–13].

Research on the molecular mechanisms that control neurogenesis by the adult neural stem cells in the hippocampus has been vigorously pursued [36, 40, 41]. The paracrine factor Wnt3 is synthesized by astrocytes [42–44], which are a neurogenesis niche environment in the hippocampus. Neuronal differentiation is initiated when the NeuroD1 gene is activated by the Wnt3 factor produced by the glia [42–44].
Figure 1: Schematic representation of the signals and transcription factors regulating adult neurogenesis. Undifferentiated adult neural stem cells express Sox2 transcription factor for the self-renewal function. FGF-2 promotes the proliferation of neural stem cells and insulin and IGF-1, and IGF-2 support the process. Astrocyte-secreted Wnt3 promotes the neuronal differentiation from neural stem cells by the activation of NeuroD1 transcription factor in the neuronal progenitor cell. The NeuroD1 transcription factor triggers the expression of insulin gene. Insulin, IGF-1, and IGF-2 promote the oligodendrocyte differentiation from neural stem cells. They also promote neuronal survival and possess the protection ability of mature neurons by preventing their natural cell death.

NeuroD1 is also a transcriptional factor that directly activates the insulin gene [45–47]. NeuroD1-gene-deficient mice lack the DG region, which is the site of neurogenesis in the hippocampus, and that causes a fatal functional impairment of the nervous system [47, 48]. NeuroD1-deficiency in mice causes severe diabetes and perinatal lethality because NeuroD1 is required for insulin gene expression [45, 46]. Rubio-Cabezas et al. investigated human subjects and sequenced the NeuroD1 gene in 44 unrelated patients with permanent neonatal diabetes, result in that homozygous mutations in NeuroD1 were identified in diabetes patients [49]. The study shows that diabetes, neurological abnormalities including cerebellar hypoplasia, learning difficulties, sensorineural deafness and visual impairment result from the loss of function mutations in NeuroD1. These reports indicate the critical role of NeuroD1 in both the endocrine pancreas and the CNS not only in animal models (rodents) but also in humans.

5. Insulin Expressions in CNS

Neuronal synthesis of insulin has been debated for long time. De novo insulin synthesis in mammalian brain has been supported by the detection of preproinsulin I and II mRNA in rat fetal brain and cultured neurons and also by insulin immunoreactivity in neuronal endoplasmic reticulum, axon, dendrites, and synapses [50–56]. Singh et al. reported that insulin is expressed in cultured rat hippocampal neurons but is not expressed in peripheral sympathetic neuronal cells [57]. Devaskar et al. reported that rabbit hippocampus expressed insulin mRNA apparently by using RNase protection assays and in situ hybridization analysis [58]. High performance liquid chromatography, radioimmunoassay, and [35S]cysteine metabolic labeling of cultured neuronal and glial cells indicated extracellular secretion of immunoprecipitable insulin by neurons only [58]. Further studies provided clear evidence that insulin synthesis occurs in mammalian brain CNS, where it may reach high levels [57, 59–61]. Consistent with these studies, we also reported that de novo insulin synthesis was performed in adult neural stem cell culture in vitro and in newborn neurons in the rat and mouse hippocampus in vivo [62].

Importantly, the mentioned NeuroD1 transcriptional factor is essential for expression of target insulin gene in CNS. Wnt3 stimulates their activation as stem cell niches-secreting paracrine factor in hippocampal DG [42–44]. The localization of insulin-expressing neurons involves olfactory bulb and higher order association which are rich in dopaminergic norepinephrine innervation [57, 62]. These same areas express insulin receptors [63], suggesting autocrine or paracrine action of the insulin in adult hippocampus. Since hippocampal neurogenesis is coupled with expression of NeuroD1 [43, 46–48, 64], the expression (and the secretion) of insulin in newborn neurons via the NeuroD1 transcription factor may be upregulated in a treatment that promotes adult neurogenesis in diabetes patients.
6. Regenerative Therapy for Diabetes Using Adult Neural Stem Cells

Transplantation of pancreatic islets (islets of Langerhans) from the pancreas of a different donor is an effective treatment method for type-1 diabetes. However, the problem of shortage of human donors for pancreatic islet transplantation is extremely serious. As described previously, adult neurons existing in our brain neurogenic area, such as hippocampus, have the intrinsic capacity to produce insulin, implying that adult neural stem cells have a potential as a cell source for the stem cell-based transplantation therapy of diabetes (Figure 2). Adult neural stem cells can be established and cultured by collection from the olfactory bulb [65–68], which is easier location to collect multipotent neural stem cells than the hippocampus. It has been confirmed that when adult neural stem cells are collected from diabetic rats, established as cultures, and transplanted into the pancreases of diabetic rats once a state of ready insulin production has been achieved, a decreased blood glucose level can be maintained [62]. In addition, when the transplanted neural stem cells were removed from the alleviated diabetic rats, the blood glucose level again increased [62]. Since the strategy is based on autologous transplantation of cells (adult stem cells from patient’s olfactory bulb: endoscopic collection of neural stem cells from the olfactory bulb is preferable to collection of intracerebral neural stem cells by means of difficult surgery), there are no donor issues and no concerns about the adverse effects of immunosuppressive agents. The insulin-producing cells are continuously replenished by adult neural stem cells and therapeutic efficacy is thus maintained. Another advantage is that the treatment has a low carcinogenesis risk and is considerably safe because the procedure involves no gene transfer.

However, to make it closer to reality of the treatment using adult neural stem cells for diabetes, there are several challenges and issues to be overcome. It is important to evaluate the method using adult neural stem cells derived from large model animals more close to human, such as monkeys and pigs. During the time-period that adult neural stem cells are extracted from the CNS, such as olfactory bulb, and expanded to transplant to the pancreas of the patients, the improvement of the technology and methodology to activate the neural stem cells with high quality to express the insulin is also required. Increasing the insulin expression capability by ex vivo culture with recombinant Wnt3 protein (activator of NeuroD1 expression) and antibody against IGFBP-4 (inhibitor of Wnt signaling) is essential for the scheme that was examined in rodent study [62] (Figure 2). This step can be further improved by the various types of drug screening and/or also for order-made cell screening system for the personalized therapy. The screening system unites adult neural stem cells that assume drug discovery for diabetes patients with neurological diseases is considered to be available, in conjunction with a pharmaceutical company with chemical compound libraries. If declined ability of the CNS and the neural stem cell function could be improved by the medication, the synergistic effect of diabetes treatment with combined transplantation therapy would be expected.

In terms of stem cell-based regenerative medicine, it is more elegant to activate the adult stem cells present in the patient’s body safely, and in a way that is closer to that which occurs naturally without stressful surgeries in future. Monitoring of patient’s insulin production ability on the olfactory bulb-derived adult neural stem cells would be also useful in both diabetes treatments and neurological diseases caused by low-insulin levels.

7. Similarity between Adult CNS and Pancreatic Endocrine System

A basic mechanism of expression of a certain absolutely essential biological factor, insulin, that has correlative similarities has been demonstrated in very different tissues that are far apart from each other in the body: the pancreas and the hippocampus. Because the nervous system is the source of insulin production in invertebrates, such as the fly [69, 70], it is very interesting that in maintaining the function of both the CNS and the pancreatic endocrine system the insulin regulatory system plays a major role in the mechanism that controls stem cell differentiation in both tissues and has been preserved during evolution. Comparisons and analyses of the functions of neural circuits in the CNS and hormone metabolic system in the pancreatic endocrine system are expected to provide new clues to understanding and analyses based on new approaches in the field of research on the control mechanisms of neuronal circuits. For example, is not there a possibility that the insulin control network, that is, proliferation and differentiation of stem cells and protection of neurons in the CNS (Figure 1) functions similarly in the cells that build up pancreatic endocrine tissue (α cells, β cells, δ cells, and γ cells)?

Actually, niche environment correlations are observed. An astrocyte marker in CNS, GFAP, is expressed in a similar manner in the α cells of the pancreas together with glucagon [61, 71, 72]. Another astrocytic gene, S100beta, is also expressed in pancreatic GFAP-positive cells [73]. Pancreatic δ cells may be regulated under gene control in the similar way in part as interneurons at hilus region in the hippocampus, since they share same expression somatostatin as typical marker of the cell population [74]. Somatostatin is a multifunctional peptide with variety of functions, and it has been associated with disease progression, such as neurological disorders including Alzheimer’s disease and multiple endocrine neoplasia [75, 76]. The understanding of the regulatory system of differentiation of each lineage from adult neural stem cells may contribute to develop new tools of the therapy of diseases affecting both pancreatic endocrine system and CNS.

8. Sensor Cell Populations That Control the Cell Fate Choice of the Stem Cells-Wnt3 and Insulin

Astrocytes function as the neural stem cell niche in the hippocampus, and they not only have important functions that maintain neuron functions and support neural activity,
albeit through two disparate signaling cascades [78]. Insulin and Wnt both negatively regulate GSK3, activated by Wnt3/Wnt3a, beta-catenin is the substrate for the phosphorylation. In the canonical Wnt signaling that is constitutively inhibits glycogen synthesis by a variety of transcription factors [79]. Insulin receptors are target genes contain insulin response elements, which bind GSK3. 

Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed serine/threonine kinase controlling stem cell behavior. Glycogen synthase kinase 3 (GSK3) is a ubiquitously expressed serine/threonine kinase that is central to insulin and Wnt signaling [77]. In insulin-signaling, GSK3 constitutively inhibits glycogen synthesis by the phosphorylation. In the canonical Wnt signaling that is activated by Wnt3/Wnt3a, beta-catenin is the substrate for the GSK3. Wnt and insulin both negatively regulate GSK3, albeit through two disparate signaling cascades [78]. Insulin target genes contain insulin response elements, which bind a variety of transcription factors [79]. Insulin receptors are abundant in neurons in cell bodies and synapses and less abundant in glia [80–84]. Wnts can signal through several different types of receptors, but the most widely recognized Wnt receptors are Frizzled proteins (Fzd). Fzd receptor subtypes and related signaling molecules are expressed in the adult hippocampus, where they play roles in the survival, function, and plasticity of neurons. In mice lacking Wnt3a, the hippocampal formation is disrupted, suggesting Wnt3a-mediated signaling is crucial for the normal growth of the hippocampus [85].

Astrocytes have been found to retain sensor function that produces the environmental signals to the stem cells, by producing the paracrine factor Wnt3 in response to the circumstances [42–44]. The frequency of neurogenesis declines with age, and it varies with the environment in which individuals find themselves, such as stress or disease, suggesting that neurogenesis in the hippocampus is regulated by molecular mechanisms that are capable of readily changing in response to external stimuli [44, 86]. Some “external stimuli,” for example, exercise and an enriched environment, increase the formation of the network of new neurons in the hippocampus, while others, for example, stress, disease, and aging, reduce it, and the patterns of expression of large numbers of gene groups change in a variety of ways.

9. Developing New Strategy to Treat Diabetes and Neurological Diseases

When we observe the homology between the pancreas and hippocampus by comparing them against each other, very interesting questions arose as to whether there might also be a cell population that has a sensor function in the pancreatic endocrine system. Hardly anything has yet been learned about the behavior according to the stage of disease progression or biological information, such as age, of the α cells in pancreatic endocrine tissue, which correspond to the Wnt3 factor producing ability of the hippocampal astrocytes, and future research is being awaited. If it were possible to control the Wnt3 producing ability of hippocampal astrocytes and pancreatic α cell niches, it might lead to improvement of the tissue stem cells whose function is reduced in the diabetic state as well as to progress in new research and development that will be useful in medical care and drug discovery.

In this paper, we described the insulin control network of both the neural stem cells in the brain and the endocrine cells in the pancreas based on their involvement with diabetic patients, and the accumulating academic information linked to overcoming the diminished functions of stem cells whose functions have deteriorated will be very useful. In the future, it appears that it might also be possible to contribute to elucidating the pathology not only of diabetes but also of neuropsychiatric diseases whose risk increases as the pathology of diabetes progresses or to the search for new therapeutic reagents for the treatment of human neuropsychiatric diseases and to the development of treatment techniques.

Acknowledgments

The original work described in the present paper was supported, in part, by the National Institute of Advanced Industrial Science and Technology (to M. Machida, S. Fujimaki, R. Hidaka, M. Asashima and T. Kuwabara),
References

[1] Y. Terauchi and T. Kadowaki, “Insights into molecular pathogenesis of type 2 diabetes from knockout mouse models,” Endocrine Journal, vol. 49, no. 3, pp. 247–263, 2002.

[2] T. Kadowaki, K. Hara, T. Yamauchi, Y. Terauchi, K. Tobe, and R. Nagai, “Molecular mechanism of insulin resistance and obesity,” Experimental Biology and Medicine, vol. 228, no. 10, pp. 1111–1117, 2003.

[3] M. Naito, J. Fujikura, K. Ebihara et al., “Therapeutic impact of leptin on diabetes, diabetic complications, and longevity in insulin-deficient diabetic mice,” Diabetes, vol. 60, no. 9, pp. 2265–2273, 2011.

[4] T. Kadowaki, “Obesity: progress in diagnosis and treatment; Topics, III. Obesity and its complications; 1. Obesity and diabetes,” Nihon Naika Gakkai Zasshi, vol. 100, no. 4, pp. 939–944, 2011.

[5] I. Wickelgren, “Tracking insulin to the mind,” Science, vol. 280, no. 5363, pp. 517–519, 1998.

[6] S. Hoyer, N. Henneberg, S. Knapp, H. Lannert, and E. Martin, “Brain glucose metabolism is controlled by amplification and desensitization of the neuronal insulin receptor,” Annals of the New York Academy of Sciences, vol. 777, pp. 374–379, 1996.

[7] E. C. McNay, “Insulin and ghrelin: peripheral hormones modulating memory and hippocampal function,” Current Opinion in Pharmacology, vol. 7, no. 6, pp. 628–632, 2007.

[8] V. A. Rafalski and A. Brunet, “Energy metabolism in adult neural stem cell fate,” Progress in Neurobiology, vol. 93, no. 2, pp. 182–203, 2010.

[9] A. M. Stranahan, T. V. Arumugam, R. G. Cutler, K. Lee, J. M. Egan, and M. P. Mattson, “Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons,” Nature Neuroscience, vol. 11, no. 3, pp. 309–317, 2008.

[10] A. Ott, R. P. Stolk, F. Van Harskamp, H. A. P. Pols, A. Hofman, and M. M. B. Breteler, “Diabetes mellitus and the risk of dementia: the Rotterdam Study,” Neurology, vol. 53, no. 9, pp. 919–1942, 1999.

[11] T. Brismar, L. Maurex, G. Cooray et al., “Predictors of cognitive impairment in type 1 diabetes,” Psychoneuroendocrinology, vol. 32, no. 8–10, pp. 1041–1051, 2007.

[12] J. Guo, C. Yu, H. Li et al., “Impaired neural stem/progenitor cell proliferation in streptozotocin-induced and spontaneous diabetic mice,” Neuroscience Research, vol. 68, no. 4, pp. 329–336, 2010.

[13] S. Craft and Y. Christen, Eds., Diabetes, Insulin and Alzheimer’s Disease: Research and Perspectives in Alzheimer’s Disease, Springer, 2010.

[14] G. J. Biessels, A. C. Kappelle, B. Bravenboer, D. W. Erkelens, and W. H. Gispen, “Cerebral function in diabetes mellitus,” Diabetologia, vol. 37, no. 7, pp. 645–650, 1994.

[15] A. M. Magarinos and B. S. McEwen, “Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 11056–11061, 2000.

[16] C. A. Grillo, G. G. Pirola, D. R. Rosell, E. K. Hoskin, B. S. McEwen, and L. P. Reagan, “Region specific increases in oxidative stress and superoxide dismutase in the hippocampus of diabetic rats subjected to stress,” Neuroscience, vol. 121, no. 1, pp. 133–140, 2003.

[17] J. G. Biessels, A. Kamal, G. M. Ramakers et al., “Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats,” Diabetes, vol. 45, no. 9, pp. 1259–1266, 1996.

[18] L. J. Leedom, W. P. Meehan, and A. Zeidler, “Avoidance responding in mice with diabetes mellitus,” Physiology and Behavior, vol. 40, no. 4, pp. 447–451, 1987.

[19] L. P. Reagan, “Glucose, stress, and hippocampal neuronal vulnerability,” International Review of Neurobiology, vol. 51, pp. 289–324, 2002.

[20] E. O. Alvarez, J. Beauquis, Y. Revis et al., “Cognitive dysfunction and hippocampal changes in experimental type 1 diabetes,” Behavioural Brain Research, vol. 198, no. 1, pp. 224–230, 2009.

[21] J. Beauquis, P. Roig, F. Homo-Delarche, A. De Nicola, and F. Saravia, “Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocin-induced diabetic mice: reversion by antidepressant treatment,” European Journal of Neuroscience, vol. 23, no. 6, pp. 1539–1546, 2006.

[22] H. B. Kim, M. H. Jang, M. C. Shin et al., “Treadmill exercise increases cell proliferation in dentate gyrus of rats with streptozotocin-induced diabetes,” Journal of Diabetes and Its Complications, vol. 17, no. 1, pp. 29–33, 2003.

[23] G. J. Biessels, A. Kamal, I. J. A. Urban, B. M. Spruijt, D. W. Erkelens, and W. H. Gispen, “Water maze learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: effects of insulin treatment,” Brain Research, vol. 800, no. 1, pp. 125–135, 1998.

[24] A. M. Magarinos, K. Jain, E. D. Blount, L. Reagan, B. H. Smith, and B. S. McEwen, “Peritoneal implantation of macroencapsulated porcine pancreatic islets in diabetic rats ameliorates severe hyperglycemia and prevents retraction and simplification of hippocampal dendrites,” Brain Research, vol. 902, no. 2, pp. 282–287, 2001.

[25] S. Doré, S. Kar, and R. Quirion, “Insulin-like growth factor I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4772–4777, 1997.

[26] B. Cheng and M. P. Mattson, “IGF-I and IGF-II protect cultured hippocampal and septal neurons against calcium-mediated hypoglycemic damage,” Journal of Neuroscience, vol. 12, no. 4, pp. 1558–1566, 1992.

[27] J. Hsieh, J. B. Aimone, B. K. Kaspar, T. Kuwabara, K. Nakashima, and F. H. Gage, “IGF-I instructs multipotent adult neural progenitor cells to become oligodendrocytes,” Journal of Cell Biology, vol. 164, no. 1, pp. 111–122, 2004.

[28] K. D. Beck, L. Powell-Braxton, H. R. Widmer, J. Valverde, and W. Erkelens, “Water maze learning and hippocampal changes in experimental type 1 diabetes,” Neurology, vol. 42, no. 4, pp. 717–730, 1995.

[29] M. J. Carson, R. R. Behringer, R. L. Brinster, and F. A. McMorris, “Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice,” Neuron, vol. 10, no. 4, pp. 729–740, 1993.

[30] M. A. I. Æberg, N. D. Æberg, H. Hedbäck, J. Oscarsson, and P. S. Eriksson, “Peripheral infusion of IGF-I selectively
induces neurogenesis in the adult rat hippocampus,” *Journal of Neuroscience*, vol. 20, no. 8, pp. 2896–2903, 2000.

[31] Y. Arsenijevic, S. Weiss, B. Schneider, and P. Aeberscher, “Insulin-like growth factor-1 is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2,” *Journal of Neuroscience*, vol. 21, no. 8, pp. 7194–7202, 2001.

[32] M. A. L. Åberg, N. D. Åberg, T. D. Palmer et al., “IGF-I has a direct proliferative effect in adult hippocampal progenitor cells,” *Molecular and Cellular Neuroscience*, vol. 24, no. 1, pp. 23–40, 2003.

[33] F. H. Gage, J. Ray, and L. J. Fisher, “Isolation, characterization, and use of stem cells from the CNS,” *Annual Review of Neuroscience*, vol. 18, pp. 159–192, 1995.

[34] F. H. Gage, “Mammalian neural stem cells,” *Science*, vol. 287, no. 5457, pp. 1433–1438, 2000.

[35] H. Okano, “Neural stem cells: progression of basic research and perspective for clinical application,” *Keio Journal of Medicine*, vol. 51, no. 3, pp. 115–128, 2002.

[36] D. K. Ma, M. C. Marchetto, J. U. Guo, G. L. Ming, F. H. Gage, and H. Song, “Epigenetic choreographers of neurogenesis in the adult mammalian brain,” *Nature Neuroscience*, vol. 13, no. 11, pp. 1338–1344, 2010.

[37] K. A. D’Amour and F. H. Gage, “Genetic and functional differences between multipotent neural and pluripotent embryonic stem cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 1, pp. 11866–11872, 2003.

[38] H. Suh, A. Consiglio, J. Ray, T. Sawai, K. A. D’Amour, and F. Gage, “In vivo fate analysis reveals the multipotent and self-renewal capacities of Sox2” neural stem cells in the adult hippocampus,” *Cell Stem Cell*, vol. 1, no. 5, pp. 515–528, 2007.

[39] G. Kempermann and F. H. Gage, “Neurogenesis in the adult hippocampus,” *Novartis Foundation Symposium*, vol. 231, pp. 220–235, 2000.

[40] J. Hsieh, “Orchestrating transcriptional control of adult neurogenesis,” *Genes and Development*, vol. 26, no. 10, pp. 1010–1021, 2012.

[41] Y. Mu, S. W. Lee, and F. H. Gage, “Signaling in adult neurogenesis,” *Current Opinion in Neurobiology*, vol. 20, no. 4, pp. 416–423, 2010.

[42] D. C. Lie, S. A. Colamarino, H. J. Song et al., “Wnt signalling regulates adult hippocampal neurogenesis,” *Nature*, vol. 437, no. 7063, pp. 1370–1375, 2005.

[43] T. Kuwabara, J. Hsieh, A. Mostru et al., “Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis,” *Nature Neuroscience*, vol. 12, no. 9, pp. 1097–1105, 2009.

[44] M. Okamoto, K. Inoue, H. Iwamura et al., “Reduction in paracrine Wnt3 factors during aging causes impaired adult neurogenesis,” *The FASEB Journal*, vol. 25, no. 10, pp. 3570–3582, 2011.

[45] F. J. Naya, C. M. M. Stellrecht, and M. J. Tsai, “Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor,” *Genes and Development*, vol. 9, no. 8, pp. 1009–1019, 1995.

[46] F. J. Naya, H. P. Huang, Y. Qiu et al., “Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/NeuroD-deficient mice,” *Genes and Development*, vol. 11, no. 18, pp. 2323–2334, 1997.

[47] M. Liu, S. J. Pleasure, A. E. Collins et al., “Loss of BETA2/NeuroD leads to malformation of the dentate gyrus and epilepsy,” vol. 97, no. 2, pp. 865–870, 2000.

[48] T. Miyata, T. Maeda, and J. E. Lee, “NeuroD is required for differentiation of the granule cells in the cerebellum and hippocampus,” *Genes and Development*, vol. 13, no. 13, pp. 1647–1652, 1999.

[49] O. Rubio-Cabezás, J. A. L. Minton, I. Kantor, D. Williams, S. Ellard, and A. T. Hattersley, “Homozygous mutations in NEUROD1 are responsible for a novel syndrome of permanent neonatal diabetes and neurological abnormalities,” *Diabetes*, vol. 59, no. 9, pp. 3236–3231, 2010.

[50] W. Zhao, H. Chen, H. Xu et al., “Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats,” *The Journal of Biological Chemistry*, vol. 274, no. 49, pp. 34893–34902, 1999.

[51] R. Schechter, T. Yanovitch, M. Abboud, G. Johnson, and J. Gaskins, “Effects of brain endogenous insulin on neurofilament and MAPK in fetal rat neuron cell cultures,” *Brain Research*, vol. 808, no. 2, pp. 270–278, 1998.

[52] S. Craft, J. Newcomer, S. Kanne et al., “Memory improvement following induced hyperinsulinemia in Alzheimer’s disease,” *Neurobiology of Aging*, vol. 17, no. 1, pp. 123–130, 1996.

[53] R. Schechter, D. Beju, T. Gaffney, F. Schaefer, and L. Whetzel, “Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system,” *Brain Research*, vol. 736, no. 1-2, pp. 16–27, 1996.

[54] R. Schechter, H. F. Sadiq, and S. U. Devaskar, “Insulin and insulin mRNA are detected in neuronal cell cultures maintained in an insulin-free-serum-free medium,” *Journal of Histochemistry and Cytochemistry*, vol. 38, no. 6, pp. 829–836, 1990.

[55] M. Adamo, M. K. Raizada, and D. LeRoith, “Insulin and insulin-like growth factor receptors in the nervous system,” *Molecular Neurobiology*, vol. 3, no. 1-2, pp. 71–100, 1989.

[56] R. Schechter, L. Holtzclaw, F. Sadiq, A. Kahn, and S. Devaskar, “Insulin synthesis by isolated rabbit neurons,” *Endocrinology*, vol. 123, no. 1, pp. 503–513, 1988.

[57] B. S. Singh, P. A. Rajakumar, E. M. Eves, M. R. Rosner, B. H. Wainer, and S. U. Devaskar, “Insulin gene expression in immortalized rat hippocampal and pheochromocytoma-12 cell lines,” *Regulatory Peptides*, vol. 69, no. 1, pp. 7–14, 1997.

[58] S. U. Devaskar, S. J. Giddings, P. A. Rajakumar, L. R. Carnaghi, R. K. Menon, and D. S. Zahn, “Insulin gene expression and insulin synthesis in mammalian neuronal cells,” *The Journal of Biological Chemistry*, vol. 269, no. 11, pp. 8445–8454, 1994.

[59] R. U. Margolis and N. Altszuler, “Insulin in the cerebrospinal fluid,” *Nature*, vol. 215, pp. 5108, pp. 1375–1376, 1967.

[60] R. Schechter, J. Whitmire, L. Holtzclaw, M. George, R. Harlow, and S. U. Devaskar, “Developmental regulation of insulin in the mammalian central nervous system,” *Brain Research*, vol. 582, no. 1, pp. 27–37, 1992.

[61] D. LeRoith, “CNS regulation of carbohydrate metabolism,” in *Advances In Metabolic Disorders*, A. Szabo, Ed., vol. 10, pp. 304–340, Academic Press, 1983.

[62] T. Kuwabara, M. N. Kagalwala, Y. Onuma et al., “Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb,” *EMBO Molecular Medicine*, vol. 3, no. 12, pp. 742–754, 2011.

[63] J. L. Marks, D. Porte, W. L. Stahl, and D. G. Baskin, “Localization of insulin receptor mRNA in rat brain by in situ hybridization,” *Endocrinology*, vol. 127, no. 6, pp. 3234–3236, 1990.
[64] Z. Gao, K. Ure, J. L. Ables et al., “Neurod1 is essential for the survival and maturation of adult-born neurons,” Nature Neuroscience, vol. 12, no. 9, pp. 1090–1092, 2009.

[65] S. F. Pagano, F. Impagnatiello, M. Girelli et al., “Isolation and characterization of neural stem cells from the adult human olfactory bulb,” Stem Cells, vol. 18, no. 4, pp. 295–300, 2000.

[66] X. Zhang, K. M. Klueber, Z. Guo, C. Lu, and F. J. Roisen, “Adult human olfactory neural progenitors cultured in defined medium,” Experimental Neurology, vol. 186, no. 2, pp. 112–123, 2004.

[67] Z. Liu and L. J. Martin, “Olfactory bulb core is a rich source of neural progenitor and stem cells in adult rodent and human,” Journal of Comparative Neurology, vol. 459, no. 4, pp. 368–391, 2003.

[68] M. A. Curtis, M. Kam, U. Nannmark et al., “Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension,” Science, vol. 315, no. 5816, pp. 1243–1249, 2007.

[69] E. Bertelli, M. Regoli, D. Orazioli, R. Gerli, and E. Bertelli, “Glial fibrillary acidic protein (GFAP)-like immunoreactivity in rat endocrine pancreas,” Journal of Histochemistry and Cytochemistry, vol. 48, no. 2, pp. 259–265, 2000.

[70] E. Bertelli, M. Regoli, F. Gambelli, M. Lucattelli, G. Lungarella, and A. Bastianini, “GFAP is expressed as a major soluble pool associated with glucagon secretory granules in α-cells of mouse pancreas,” Journal of Histochemistry and Cytochemistry, vol. 48, no. 9, pp. 1233–1242, 2000.

[71] S. Winer, H. Tsui, A. Lau et al., “Autoimmune islet destruction in spontaneous type 1 diabetes is not β-cell exclusive,” Nature Medicine, vol. 9, no. 2, pp. 198–205, 2003.

[72] S. Billova, A. S. Galanopoulou, N. G. Seidah, X. Qiu, and U. Kumar, “Immunohistochemical expression and colocalization of somatostatin, carboxypeptidase-E and prohormone convertases 1 and 2 in rat brain,” Neuroscience, vol. 147, no. 2, pp. 403–416, 2007.

[73] S. Burn, B. H. Edil, “Neuroendocrine pancreatic tumors: guidelines for management and update,” Current Treatment Options in Oncology, vol. 13, no. 1, pp. 24–34, 2012.

[74] J. Epelbaum, J. L. Guillou, F. Gastambide, D. Hoyer, E. Duron, and C. Viollet, “Somatostatin, Alzheimer’s disease and cognition: an old story coming of age?” Progress in Neurobiology, vol. 89, no. 2, pp. 153–161, 2009.

[75] E. J. McManus, K. Sakamoto, L. J. Armit et al., “Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis,” The EMBO Journal, vol. 24, no. 8, pp. 1571–1583, 2005.

[76] C. Hooper, R. Killick, C. Fernandes, D. Sugden, and S. Lovestone, “Transcriptomic profiles of Wnt3a and insulin in primary cultured rat cortical neurones,” Journal of Neurochemistry, vol. 118, no. 4, pp. 512–520, 2011.

[77] R. M. O’Brien, R. S. Streeper, J. E. Ayala, B. T. Stadelmaier, and L. A. Hornbuckle, “Insulin-regulated gene expression,” Biochemical Society Transactions, vol. 29, no. 4, pp. 552–558, 2001.

[78] D. G. Baskin, A. J. Sipols, M. W. Schwartz, and M. F. White, “Immunocytochemical detection of insulin receptor substrate-1 (IRS-1) in rat brain: colocalization with phosphotyrosine,” Regulatory Peptides, vol. 48, no. 1-2, pp. 257–266, 1993.

[79] S. M. K. Lee, S. Tole, E. Grove, and A. P. McMahon, “A local Wnt-3a signal is required for development of the mammalian hippocampus,” Development, vol. 127, no. 3, pp. 457–467, 2000.

[80] T. Kuwabara and M. Asashima, “Regenerative medicine using adult neural stem cells: potentials for diabetes therapy and other pharmaceutical applications,” Journal of Molecular Cell Biology, vol. 4, no. 3, pp. 133–139, 2012.